CINXE.COM

<!DOCTYPE html> <html lang="en"> <head id="Head1"><meta name="viewport" content="width=device-width, initial-scale=1.0" /><meta http-equiv="X-UA-Compatible" content="IE=edge" /><title> Annual Meeting - Nov. 8-10 - SITC 2024 </title><meta name='audience' content='ALL' /><meta name='rating' content='General' /><meta name='distribution' content='Global, Worldwide' /><meta name='copyright' content='Higher Logic, LLC' /><meta name='content-language' content='EN' /><meta name='referrer' content='strict-origin-when-cross-origin' /><meta name="apple-itunes-app" content="app-id=1555408470, app-argument=http://www.sitcancer.org/2024/schedule/sitc24-annualmeeting"><link rel='SHORTCUT ICON' href='//higherlogicdownload.s3.amazonaws.com/SITCANCER/e16ea3ed-ca86-452e-b5e9-18d717c3857f/UploadedImages/AMPCP_2024/SITC24_Favicon.png' type='image/png' /><link href='https://d2x5ku95bkycr3.cloudfront.net/HigherLogic/Font-Awesome/6.4.2-pro/css/all.min.css' type='text/css' rel='stylesheet' /><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/prism/1.24.1/themes/prism.min.css" integrity="sha512-tN7Ec6zAFaVSG3TpNAKtk4DOHNpSwKHxxrsiw4GHKESGPs5njn/0sMCUMl2svV4wo4BK/rCP7juYz+zx+l6oeQ==" crossorigin="anonymous" referrerpolicy="no-referrer" /><link href='https://d2x5ku95bkycr3.cloudfront.net/HigherLogic/bootstrap/3.4.1/css/bootstrap.min.css' rel='stylesheet' /><link type='text/css' rel='stylesheet' href='https://d3uf7shreuzboy.cloudfront.net/WebRoot/stable/Desktop/Bundles/Desktop_bundle.min.d7804150d2a3d23b0f7bd53234959d21d94a14f1.hash.css'/><link href='https://ajax.googleapis.com/ajax/libs/jqueryui/1.10.1/themes/base/jquery-ui.css' type='text/css' rel='stylesheet' /><link href='https://d132x6oi8ychic.cloudfront.net/higherlogic/microsite/generatecss/2b495af7-ef43-40d3-8f8d-d42fc2073d1a/c4603878-5e01-4a39-8159-01899f20c254/638681333986830000/34' type='text/css' rel='stylesheet' /><link type='text/css' rel='stylesheet' href='https://cdn.jsdelivr.net/npm/instantsearch.css@8.0.0/themes/satellite-min.css' /><link type='text/css' rel='stylesheet' href='https://maxcdn.bootstrapcdn.com/font-awesome/4.5.0/css/font-awesome.min.css' /><link type='text/css' rel='stylesheet' href='https://fonts.googleapis.com/css?family=Dosis:500,700' /><link type='text/css' rel='stylesheet' href='https://fonts.googleapis.com/css?family=Open+Sans:400,700' /><link type='text/css' rel='stylesheet' href='https://cdn.jsdelivr.net/jquery.slick/1.6.0/slick.css' /><link type='text/css' rel='stylesheet' href='https://cdn.jsdelivr.net/jquery.slick/1.6.0/slick-theme.css' /><link type='text/css' rel='stylesheet' href='https://use.typekit.net/cqp4ikw.css' /><link type='text/css' rel='stylesheet' href='https://use.typekit.net/zyl7cfs.css' /><script type='text/javascript' src='https://d2x5ku95bkycr3.cloudfront.net/HigherLogic/JavaScript/promise-fetch-polyfill.js'></script><script type='text/javascript' src='https://d2x5ku95bkycr3.cloudfront.net/HigherLogic/JavaScript/systemjs/3.1.6/system.min.js'></script><script type='systemjs-importmap' src='/HigherLogic/JavaScript/importmapping-cdn.json?638682707383915372'></script><script type='text/javascript' src='https://d3gliviwslgzfo.cloudfront.net/WebRoot/stable/Bundles/hlq-2024-05-08.js'></script><script src='https://d3gliviwslgzfo.cloudfront.net/WebRoot/stable/Bundles/hlqmigrate-2024-05-08.js'></script><script type='text/javascript' src='https://d3gliviwslgzfo.cloudfront.net/WebRoot/stable/Bundles/hlqui-2024-05-08.js'></script><script src='https://d2x5ku95bkycr3.cloudfront.net/HigherLogic/bootstrap/3.4.1/js/bootstrap.min.js'></script><script type='text/javascript'>var higherlogic_crestApi_origin = 'https://api.connectedcommunity.org'</script><script type='text/javascript' src='/HigherLogic/CORS/easyXDM/easyXDM.Min.js'></script><script src="https://cdnjs.cloudflare.com/ajax/libs/prism/1.24.1/prism.min.js" integrity="sha512-axJX7DJduStuBB8ePC8ryGzacZPr3rdLaIDZitiEgWWk2gsXxEFlm4UW0iNzj2h3wp5mOylgHAzBzM4nRSvTZA==" crossorigin="anonymous" referrerpolicy="no-referrer"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/prism/1.24.1/plugins/autoloader/prism-autoloader.min.js" integrity="sha512-xCfKr8zIONbip3Q1XG/u5x40hoJ0/DtP1bxyMEi0GWzUFoUffE+Dfw1Br8j55RRt9qG7bGKsh+4tSb1CvFHPSA==" crossorigin="anonymous" referrerpolicy="no-referrer"></script><script type='text/javascript' src='https://d3uf7shreuzboy.cloudfront.net/WebRoot/stable/Desktop/Bundles/Desktop_bundle.min.a15963cc8802bf5ef87ffb22f53b2f3528e2cc6f.hash.js'></script><script type='text/javascript' src='https://cdnjs.cloudflare.com/ajax/libs/html2pdf.js/0.9.2/html2pdf.bundle.min.js'></script><script type='text/javascript' src='https://cdn.jsdelivr.net/npm/instantsearch.js@4.56.11/dist/instantsearch.production.min.js'></script><script type='text/javascript' src='https://cdn.jsdelivr.net/npm/algoliasearch@4.20.0/dist/algoliasearch-lite.umd.js'></script><script type='text/javascript' src='https://use.typekit.net/fho7nrh.js'></script><script type='text/javascript' src='https://use.fortawesome.com/7f3536d6.js'></script><script type='text/javascript' src='https://cdn.jsdelivr.net/jquery.slick/1.6.0/slick.min.js'></script><script type='text/javascript' src='https://cdnjs.cloudflare.com/ajax/libs/jspdf/1.3.2/jspdf.debug.js'></script><script type='text/javascript' src='https://unpkg.com/jspdf-autotable'></script><script type='text/javascript' src='https://use.fortawesome.com/39cff8dc.js'></script><meta property="og:type" content="website"><meta property="og:title" content="SITC 2024 Annual Meeting Schedule"><meta property="og:image" content="https://higherlogicdownload.s3.amazonaws.com/SITCANCER/e16ea3ed-ca86-452e-b5e9-18d717c3857f/UploadedImages/AMPCP_2024/SITC2024-logo-dates_forweb.png "><script>window.CDN_PATH = 'https://d3uf7shreuzboy.cloudfront.net'</script><script>var filestackUrl = 'https://static.filestackapi.com/filestack-js/3.28.0/filestack.min.js'; var filestackUrlIE11 = 'https://d2x5ku95bkycr3.cloudfront.net/HigherLogic/JavaScript/filestack.ie11.min.js';</script><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='//www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-M6VQVS2');</script><meta name="description" content="View the SITC 2024 Annual Meeting schedule" /></head> <body class="bodyBackground sitc24-annualmeeting interior "> <noscript><iframe src="//www.googletagmanager.com/ns.html?id=GTM-M6VQVS2" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript> <div id="MPOuterMost" class="container full"> <form method="post" action="./sitc24-annualmeeting" onsubmit="javascript:return WebForm_OnSubmit();" id="MasterPageForm" class="form"> <div class="aspNetHidden"> <input type="hidden" name="ScriptManager1_TSM" id="ScriptManager1_TSM" value="" /> <input type="hidden" name="StyleSheetManager1_TSSM" id="StyleSheetManager1_TSSM" value="" /> <input type="hidden" name="__EVENTTARGET" id="__EVENTTARGET" value="" /> <input type="hidden" name="__EVENTARGUMENT" id="__EVENTARGUMENT" value="" /> <input type="hidden" name="__VIEWSTATE" id="__VIEWSTATE" value="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" /> </div> <script type="text/javascript"> //<![CDATA[ var theForm = document.forms['MasterPageForm']; if (!theForm) { theForm = document.MasterPageForm; } function __doPostBack(eventTarget, eventArgument) { if (!theForm.onsubmit || (theForm.onsubmit() != false)) { theForm.__EVENTTARGET.value = eventTarget; theForm.__EVENTARGUMENT.value = eventArgument; theForm.submit(); } } //]]> </script> <script src="https://ajax.aspnetcdn.com/ajax/4.6/1/WebForms.js" type="text/javascript"></script> <script type="text/javascript"> //<![CDATA[ window.WebForm_PostBackOptions||document.write('<script type="text/javascript" src="/WebResource.axd?d=pynGkmcFUV13He1Qd6_TZDy7_GOIpjJ0Ev_gCdQYqqHk_ZWFLV5XISDcYendLTMgPoYek08VT5y3fOFST6xT6Q2&t=638628063619783110"><\/script>');//]]> </script> <script src="https://ajax.aspnetcdn.com/ajax/4.6/1/MicrosoftAjax.js" type="text/javascript"></script> <script type="text/javascript"> //<![CDATA[ (window.Sys && Sys._Application && Sys.Observer)||document.write('<script type="text/javascript" src="/ScriptResource.axd?d=uHIkleVeDJf4xS50Krz-yKqyI6ItVec4s3idbjHVhZG9J4GiEigPlJ1Pr7dbHMCyIOf7kxfX3Nb7yVtUXhwQ7AOu-iPRjdC_l5vxB_gc6Z3Dxd5tRPLJv-GNFNwaN0H-W3X3hfs6Qrai_oPPvnAUre8zbJUdf1a1YJ0rNRsMv-o1&t=2a9d95e3"><\/script>');//]]> </script> <script src="https://ajax.aspnetcdn.com/ajax/4.6/1/MicrosoftAjaxWebForms.js" type="text/javascript"></script> <script type="text/javascript"> //<![CDATA[ (window.Sys && Sys.WebForms)||document.write('<script type="text/javascript" src="/ScriptResource.axd?d=Jw6tUGWnA15YEa3ai3FadCxOzjXo7DUqjVdZ-ppUm_hmRsjByokg8vJsbXd_vty5sSD7cLjWah6CFay_-VEpx11xzWP5I0beGdwJH7ICkEzqKBZp0aF_WH7BGPayHXieN2_FVY_LynI6wS_6mDtAk2iKQomHaPnn3KkQQDR1LTw1&t=2a9d95e3"><\/script>');function WebForm_OnSubmit() { null; return true; } //]]> </script> <div class="aspNetHidden"> <input type="hidden" name="__VIEWSTATEGENERATOR" id="__VIEWSTATEGENERATOR" value="738F2F5A" /> <input type="hidden" name="__EVENTVALIDATION" id="__EVENTVALIDATION" value="CfDJ8GYwqx9YzLZGmPQ2hZZF70JQCi3/uoN0Ru6MJAQ7c10z4Kc8cZaMXBwd0IJYzChnanCGBcQG0anLsjNaJXoBIp7jh4gP/QDSZwcaecBbBXldyT4yutfWp2HBfL4mRrwG0aySQoxma4QBtXn72eH/SnwzzwRbWw41jPAOJRV1az+IhSwku1PzfdRL1eSFVk0bmEU4dHbmJUUF3kLoV7PDqrI=" /> </div> <input name="__HL-RequestVerificationToken" type="hidden" value="CfDJ8GYwqx9YzLZGmPQ2hZZF70LIOpaZ7QDdaJSxPpaEJTbcH1w-6kVD8PPrjf_SjBWLkPotw89v2xH-m8fAPIXnggKpkMEbdjPs2w95XthC7-dIYZ1IT6ni3qu6CrpRV60cfgoqZZ_awgB1CAicFCYmT5k1" /> <div id="GlobalMain"> <script type="text/javascript"> //<![CDATA[ Sys.WebForms.PageRequestManager._initialize('ctl00$ScriptManager1', 'MasterPageForm', [], [], [], 90, 'ctl00'); //]]> </script> </div> <div id="GlobalMessageContainer"> <div id="GlobalMessageContent" > <img ID="GlobalMsg_Img" alt="Message Image" src=""/>   <span id="GlobalMsg_Text"></span><br /><br /> </div> </div> <div id="react-setup" style="height:0"> <script> var formTokenElement = document.getElementsByName('__HL-RequestVerificationToken')[0]; var formToken = formTokenElement? formTokenElement.value : ''; window.fetchOCApi = function(url, params) { return fetch(url, { method: 'POST', body: JSON.stringify(params), headers: { RequestVerificationFormToken: formToken, 'Content-Type': 'application/json' } }).then(function(response) { return response.json(); }).then(function(body) { return body.data }); } </script> <div id="__hl-activity-trace" traceId="80bc93062aa0688d9f399fc725989eab" spanId="33e4d260509341f1" tenantCode="SITCANCER" micrositeKey="e16ea3ed-ca86-452e-b5e9-18d717c3857f" navigationKey="0e784297-948f-401b-97ed-9de9708127dc" navigationName="sitc24-annualmeeting" viewedByContactKey="00000000-0000-0000-0000-000000000000" pageOrigin="http://www.sitcancer.org" pagePath="/2024/schedule/sitc24-annualmeeting" referrerUrl="" userHostAddress="8.222.208.146 " userAgent="Mozilla/4.0 (compatible; MSIE 7.0; Windows NT 6.0; SLCC1; .NET CLR 2.0.50727; .NET CLR 3.0.04506; .NET CLR 3.5.21022; .NET CLR 1.0.3705; .NET CLR 1.1.4322)" ></div> <div id="page-react-root"></div> <script id="hlReactRootLegacyRemote" defer src="https://d3uf7shreuzboy.cloudfront.net/WebRoot/stable/ReactRootLegacy/ReactRootLegacy~hlReactRootLegacyRemote.bundle.e3e14a157800b68e8ff0.hash.js"></script> <script>window.reactroot_webpackPublicPath = 'https://d3uf7shreuzboy.cloudfront.net/WebRoot/stable/ReactRoot/'</script> <script defer src="https://d3uf7shreuzboy.cloudfront.net/WebRoot/stable/ReactRoot/ReactRoot~runtime~main.bundle.e7f477778cba7f022a3d.hash.js"></script> <script defer src="https://d3uf7shreuzboy.cloudfront.net/WebRoot/stable/ReactRoot/ReactRoot~react-_yarn_cache_react-npm-18_2_0-1eae08fee2-b9214a9bd7_zip_node_modules_react_index_js.bundle.012593f3ef708f027ac2.hash.js"></script><script defer src="https://d3uf7shreuzboy.cloudfront.net/WebRoot/stable/ReactRoot/ReactRoot~vendor-_yarn___virtual___react-dom-virtual-05f150c4a1_0_cache_react-dom-npm-18_2_0-dd675bca1c-65c11b.bundle.8b02460446e4027ef67f.hash.js"></script><script defer src="https://d3uf7shreuzboy.cloudfront.net/WebRoot/stable/ReactRoot/ReactRoot~vendor-_yarn___virtual___react-dom-virtual-05f150c4a1_0_cache_react-dom-npm-18_2_0-dd675bca1c-17e4a5.bundle.1dbb26f4013744b692d1.hash.js"></script><script defer src="https://d3uf7shreuzboy.cloudfront.net/WebRoot/stable/ReactRoot/ReactRoot~vendor-_yarn_cache_lodash-npm-4_17_21-6382451519-c08619c038_zip_node_modules_lodash_lodash_js.bundle.8d689d0e26f432a3f17d.hash.js"></script><script defer src="https://d3uf7shreuzboy.cloudfront.net/WebRoot/stable/ReactRoot/ReactRoot~main.bundle.d9c6907ad1d4db1ca2e8.hash.js"></script> <script> window.hl_tinyMceIncludePaths = { cssIncludes: 'https://d2x5ku95bkycr3.cloudfront.net/HigherLogic/Font-Awesome/6.4.2-pro/css/all.min.css|https://cdnjs.cloudflare.com/ajax/libs/prism/1.24.1/themes/prism.min.css|https://d2x5ku95bkycr3.cloudfront.net/HigherLogic/bootstrap/3.4.1/css/bootstrap.min.css|https://d3uf7shreuzboy.cloudfront.net/WebRoot/stable/Desktop/Bundles/Desktop_bundle.min.d7804150d2a3d23b0f7bd53234959d21d94a14f1.hash.css|https://ajax.googleapis.com/ajax/libs/jqueryui/1.10.1/themes/base/jquery-ui.css|https://d132x6oi8ychic.cloudfront.net/higherlogic/microsite/generatecss/2b495af7-ef43-40d3-8f8d-d42fc2073d1a/c4603878-5e01-4a39-8159-01899f20c254/638681333986830000/34|https://cdn.jsdelivr.net/npm/instantsearch.css@8.0.0/themes/satellite-min.css|https://maxcdn.bootstrapcdn.com/font-awesome/4.5.0/css/font-awesome.min.css|https://fonts.googleapis.com/css?family=Dosis:500,700|https://fonts.googleapis.com/css?family=Open+Sans:400,700|https://cdn.jsdelivr.net/jquery.slick/1.6.0/slick.css|https://cdn.jsdelivr.net/jquery.slick/1.6.0/slick-theme.css|https://use.typekit.net/cqp4ikw.css|https://use.typekit.net/zyl7cfs.css', tinymcejs: 'https://d3uf7shreuzboy.cloudfront.net/WebRoot/stable/Desktop/JS/Common/hl_common_ui_tinymce.bc594acd1c86ca782a5f0446e0276d20202ffaf9.hash.js', hashmentionjs: 'https://d3uf7shreuzboy.cloudfront.net/WebRoot/stable/Desktop/JS/Common/hl_common_ui_tinymce_hashmention.94b265db0d98038d20e17308f50c5d23682bf370.hash.js', mentionjs: 'https://d3uf7shreuzboy.cloudfront.net/WebRoot/stable/Desktop/JS/Common/hl_common_ui_tinymce_mention.a35f893e40ce48b298979135724cd9e6ad18dde1.hash.js', hashtagjs: 'https://d3uf7shreuzboy.cloudfront.net/WebRoot/stable/Desktop/JS/Common/hl_common_ui_tinymce_hashtag.5579d26160cf6c00ace1fde0afcb2aacaf5baceb.hash.js' }; </script> <script> window.addEventListener('DOMContentLoaded', function (){ window.renderReactRoot( [], 'page-react-root', {"tenant":{"name":"Society for Immunotherapy of Cancer","logoPath":"https://higherlogicdownload.s3.amazonaws.com/SITCANCER/e16ea3ed-ca86-452e-b5e9-18d717c3857f/UploadedImages/AMPCP_2024/SITC2024-logo-dates_forweb.png","contactSummary":"<address> 555 East Wells Street, Suite 1100<br />Milwaukee WI 53202-3823<br />United States<br />Phone: +1 414-271-2456<br /></address>"},"communityKey":"00000000-0000-0000-0000-000000000000","micrositeKey":"e16ea3ed-ca86-452e-b5e9-18d717c3857f","canUserEditPage":false,"isUserAuthenticated":false,"isUserSuperAdmin":false,"isUserCommunityAdmin":false,"isUserSiteAdmin":false,"isUserCommunityModerator":false,"currentUserContactKey":"00000000-0000-0000-0000-000000000000","isTopicCommunity":false,"isSelfModerationCommunity":false,"loginUrl":"https://sitc.execinc.com/HigherLogic/HLLoginRedirect.aspx?Redirect=","colorPickerDefaults":{"primaryColor":"#FF00FF","textOnPrimary":"#FFFF99","secondaryColor":"#66FFFF","textOnSecondary":null,"linkColor":null,"linkHoverColor":null,"footerBackgroundColor":null,"footerTextColor":null}} ) }); </script> <svg aria-hidden="true" style="height: 0px;"> <defs> <linearGradient id="skeleton-svg-gradient" x1="0" x2="1" y1="0" y2="1"> <stop offset="0%" stop-color="rgba(239, 239, 239, 0.25)"> <animate attributeName="stop-color" values="rgba(239, 239, 239, 0.25); rgba(68, 72, 85, 0.2); rgba(239, 239, 239, 0.25);" dur="3s" repeatCount="indefinite"></animate> </stop> <stop offset="100%" stop-color="rgba(68, 72, 85, 0.2)"> <animate attributeName="stop-color" values="rgba(68, 72, 85, 0.2); rgba(239, 239, 239, 0.25); rgba(68, 72, 85, 0.2);" dur="3s" repeatCount="indefinite"></animate> </stop> </linearGradient> </defs> </svg> </div> <div id="MPOuterHeader" class="row siteFrame"> <div class="col-md-12"> <div id="HEADER" class="row"> <div class="col-md-12"> <div class="ContentUserControl"> <script charset="utf-8" src="https://cdn.jsdelivr.net/gh/eConverse-Media/code-snippets@latest/js-for-FOUC.min.js"></script> </div><div class="ContentUserControl"> <script charset="utf-8">$(function () { handlePageTitles(); handleSearch() handleHeadline(); handlekeynoteSpeakers(); handlePanel(); handleCTAs(); handleNavRegisterBtn(); if ($('.HLWelcome .imgButton').length) { $('body').addClass('logged-in'); } }); function handlePageTitles() { handleBgImage(".interior-page-title", "#PageTitleH1"); } function handleSearch() { $('#NAV .navbar-nav').append( '<li class="search-btn-top"><button type="button" onclick="toggleSearch();"><i class="fal fa-search"></i></button></li>' ); $('.search-bar-top').prependTo('#MPOuterHeader'); $('.search-bar-top .form-control').attr('placeholder', 'Type search terms here...'); $('#searchColumn .form-control').attr('placeholder', 'Type search terms here...'); $(document).click(function (e) { var searchBar = $('.search-bar-top'), searchButton = $('.search-btn-top'), target = e.target; if (!$(target).is(searchBar) && !$(target).is(searchButton) && !$(target).closest('.search-bar-top').html() && !$(target).closest('.search-btn-top').html() ) { closeSearch(); } }); } function toggleSearch() { if ($('.search-bar-top').hasClass('open')) { closeSearch(); } else { openSearch(); } } function closeSearch() { $('.search-bar-top').removeClass('open'); $('.search-btn-top').removeClass('open'); } function openSearch() { $('.search-bar-top').addClass('open'); $('.search-btn-top').addClass('open'); $('.search-bar-top .form-control').focus(); } function handleHeadline() { $('.headline-text').wrapAll('<div class="headlines" />'); $('.headline-text').wrapAll('<div class="headline-slider slider-for slick-dotted" />'); $(".headline-slider").slick({ dots: false, arrows: true, infinite: true, slidesToShow: 1, slidesToScroll: 1, autoplay: false, autoplaySpeed: 7000, nextArrow: '<button type="button" class="slick-arrow next-arrow"><i class="fas fa-caret-right"></i></button>', prevArrow: '<button type="button" class="slick-arrow prev-arrow"><i class="fas fa-caret-left"></i></button>', responsive: [{ breakpoint: 500, settings: { slidesToShow: 1, arrows: false, autoplay: true, } }] }); } function handlekeynoteSpeakers() { $('.keynote-speaker .HtmlContent').each(function () { $(this).wrapInner('<div class="text-container" />'); $(this).prepend('<div class="img-container" />'); handleBgImage($(this), $(this).find('.img-container')); }); } function handlePanel() { $('.resource-panel').wrapAll('<div class="resource-wrapper" />'); $('.resource-menu').prependTo('.resource-wrapper'); $('.resource-menu .HtmlContent ul li:first-of-type').addClass('active') $('.resource-panel .HtmlContent').each(function () { var klass = $(this).find('h6').text().toLowerCase(); klass = klass.replace(/\s+/g, '-'); klass = klass.replace(/,/g, ''); klass = klass.replace(/[{()}]/g, ''); klass = klass.replace(/&/g, 'and'); klass = klass.replace(/\*/g, ''); $(this).parent().addClass(klass) $(this).wrapInner('<div class="text-container" />'); $(this).prepend('<div class="img-container" />'); handleBgImage($(this), $(this).find('.img-container')); }); $('.resource-menu .HtmlContent ul li a').each(function () { $(this).contents().unwrap().wrap('<button type="button" />') }); $('.resource-menu .HtmlContent ul li button').each(function () { var klass = $(this).text().toLowerCase(); klass = klass.replace(/\s+/g, '-'); klass = klass.replace(/,/g, ''); klass = klass.replace(/[{()}]/g, ''); klass = klass.replace(/&/g, 'and'); klass = klass.replace(/\*/g, ''); $(this).attr('onClick', 'openPanel(".' + klass + '")'); $(this).addClass(klass); }); $('.resource-menu .HtmlContent ul li button').click(function () { $('.resource-menu .HtmlContent ul li ').removeClass('active'); $(this).parent().addClass('active'); }) } function openPanel(klass) { $('.resource-panel').hide(); $('.resource-panel' + klass).show(); } function handleCTAs() { $('.large-cta .HtmlContent').each(function () { $(this).wrapInner('<div class="text-container" />'); $(this).append('<div class="img-container" />'); handleBgImage($(this), $(this).find('.img-container')); }); } function handleNavRegisterBtn() { $('#NAV .navbar-nav').append($('.register-button')); $('.register-button').wrap('<li><li>') }</script> </div><div class="ContentUserControl"> <script charset="utf-8" src="https://cdn.jsdelivr.net/gh/eConverse-Media/code-snippets/background-images.js"></script> </div><div class="ContentItemHtml search-btn-top"> <div class="HtmlContent"><link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/font-awesome/4.5.0/css/font-awesome.min.css"> <i class="fa fa-search fa-lg"></i></div><div class="HtmlFooter"></div></div><div class="ContentUserControl search-bar-top"> <script type="text/javascript"> System.import('Common/SearchBox.js').then(function () { $('#AddlContentHeaderTop_ctl08_SearchButton').click(function () { $('#AddlContentHeaderTop_ctl08_hiddenSearchButton').click(); }); $('#AddlContentHeaderTop_ctl08_SearchOptions').click(function (e) { e.stopPropagation(); }); if ('False' == 'True') { $('#AddlContentHeaderTop_ctl08_SearchTerm').click(function (e) { $('#AddlContentHeaderTop_ctl08_SearchBoxToggle').addClass('open'); e.stopPropagation(); }); $('#AddlContentHeaderTop_ctl08_SearchTerm').focus(function (e) { $('#AddlContentHeaderTop_ctl08_SearchBoxToggle').addClass('open'); e.stopPropagation(); }); $('#AddlContentHeaderTop_ctl08_EndDate').hide(); $('#AddlContentHeaderTop_ctl08_StartDate').hide(); $('#AddlContentHeaderTop_ctl08_SearchTerm').focus(function () { $('#AddlContentHeaderTop_ctl08_SearchOptions').show(); }); $('#AddlContentHeaderTop_ctl08_DateRangeDDL').change(function () { if ($('#AddlContentHeaderTop_ctl08_DateRangeDDL').find(":selected").text() == 'on this day') { $('#AddlContentHeaderTop_ctl08_StartDate').show(); $('#AddlContentHeaderTop_ctl08_EndDate').hide(); $('#AddlContentHeaderTop_ctl08_EndDate').val(""); } else if ($('#AddlContentHeaderTop_ctl08_DateRangeDDL').find(":selected").text() == 'All') { $('#AddlContentHeaderTop_ctl08_EndDate').hide(); $('#AddlContentHeaderTop_ctl08_StartDate').hide(); } else { $('#AddlContentHeaderTop_ctl08_StartDate').show(); $('#AddlContentHeaderTop_ctl08_EndDate').show(); } }); } $('#AddlContentHeaderTop_ctl08_SearchInputs') .hl_ui_common_searchBox({ controlId: 'AddlContentHeaderTop_ctl08_SearchInputs', inputId: 'AddlContentHeaderTop_ctl08_SearchTerm', buttonId: 'AddlContentHeaderTop_ctl08_hiddenSearchButton' }); }); </script> <button id="SearchToggleIcon" type="button" class="btn btn-default" style="display: none;" role="button" aria-label="searchToggle"> <span class="glyphicon glyphicon-search" style="vertical-align: middle"></span> </button> <div id="AddlContentHeaderTop_ctl08_newSearchBox"> <div id="AddlContentHeaderTop_ctl08_SearchInputs" class="SearchInputs"> <div id="AddlContentHeaderTop_ctl08_WholeSearch" onkeypress="javascript:return WebForm_FireDefaultButton(event, 'AddlContentHeaderTop_ctl08_hiddenSearchButton')"> <div class="input-group" style="vertical-align: middle"> <input name="ctl00$AddlContentHeaderTop$ctl08$SearchTerm" type="text" id="AddlContentHeaderTop_ctl08_SearchTerm" class="form-control" autocomplete="off" qa-id="search-term" aria-label="search box" placeholder="search" Title="search" style="font-weight: normal;" /> <div id="AddlContentHeaderTop_ctl08_SearchBoxToggle" class="input-group-btn search-box-toggle"> <button id="AddlContentHeaderTop_ctl08_OptionsButton" type="button" style="display: none;" class="btn btn-default dropdown-toggle" data-toggle="dropdown" aria-label="search options"> <span class="caret"></span> <span class="sr-only">Search Options</span> </button> <button id="AddlContentHeaderTop_ctl08_SearchButton" type="button" class="btn btn-default " role="button" aria-label="search"> <span class="glyphicon glyphicon-search" style="vertical-align: middle"></span> </button> <ul class="dropdown-menu pull-right" role="menu"> <li> </li> </ul> </div> <input type="submit" name="ctl00$AddlContentHeaderTop$ctl08$hiddenSearchButton" value="" onclick="javascript:WebForm_DoPostBackWithOptions(new WebForm_PostBackOptions("ctl00$AddlContentHeaderTop$ctl08$hiddenSearchButton", "", true, "", "", false, false))" id="AddlContentHeaderTop_ctl08_hiddenSearchButton" style="display: none;" /> </div> </div> </div> </div> </div><div class="ContentUserControl"> <script charset="utf-8"></script> <script src="https://use.fortawesome.com/7f3536d6.js"></script> <script></script> </div><div class="ContentUserControl"> <script charset="utf-8">$( document ).ready(function() { $('.img-crop img').wrap('<span></span>'); $('.team.bottom').hide(); $(".team.top").each(function(index) { $(this).next(".team.bottom").andSelf().wrapAll("<div class='team-wrap' />") }); $('.team.top').on('click', function() { $parent_box = $(this).closest('.team-wrap'); $parent_box.siblings().find('.team.bottom').slideUp(); $parent_box.find('.team.bottom').slideToggle(300, 'swing'); }); });</script> </div><div class="ContentUserControl"> <script charset="utf-8">$(function() { if (window.location.href.indexOf('#tab') > -1) { var url = window.location.href; str = url.split('#').pop(); // console.log(str[str.length - 1]); tabNum = '.tab-content.page-' + str[str.length - 1]; console.log(tabNum); $('.tab-content').hide(); $(tabNum).show(); } else { $('.tab-links li:first-child').addClass('active') $('.tab-content').hide(); $('.tab-content.page-1').show(); } $('.tab-content').wrapAll('<div class="tab-content-wrap"></div>'); $('.tab-links li').click(function() { var elem = $(this).context, link = $(elem).find('a'), elementId = link.attr('id'); $('.tab-links li').removeClass('active'); $(this).addClass('active'); showTabContent(elementId); }); $('.tab-links li:first-child').addClass('active') }); function showTabContent(tabClass) { $('.tab-content').each(function() { var self = $(this), classes = self.attr('class'); if (classes.indexOf(tabClass) >= 0 || tabClass === 'all') { self.show(); } else { self.hide(); } }); }</script> </div><div class="ContentUserControl"> <script charset="utf-8" src="https://cdnjs.cloudflare.com/ajax/libs/jspdf/2.5.1/jspdf.umd.min.js"></script> </div><div class="ContentUserControl"> <script charset="utf-8">$(function() { $(".accordion-heading").each(function() { $(this).next(".accordion-text").andSelf().wrapAll("<div class='accordion-wrap' />"); }); $('.accordion-heading').on('click', function() { var items = []; $('.accordion-wrap').each(function (i, item) { items.push(item); }); $parent_box = $(this).closest('.accordion-wrap'); $parent_box.find('.accordion-text').slideToggle(600, 'swing'); $parent_box.toggleClass('open'); }); });</script> </div><div class="ContentUserControl"> <script charset="utf-8">function topOfPage() { $('body,html').animate({scrollTop: 0}, 500); } function scrollToLocation(val) { var headerHeight = !!($('#MPOuterHeader').hasClass('stickyNav') || $('#NAV').hasClass('stickyNav')) ? $('#MPOuterHeader').outerHeight() : 0; var location = $(val).offset().top - headerHeight; $('body,html').animate({scrollTop: location}, 500); }</script> </div><div class="ContentItemHtml"> <div class="HtmlContent"> <script> !function(e,t,n,s,u,a){e.twq||(s=e.twq=function(){s.exe?s.exe.apply(s,arguments):s.queue.push(arguments); },s.version='1.1',s.queue=[],u=t.createElement(n),u.async=!0,u.src='//static.ads-twitter.com/uwt.js', a=t.getElementsByTagName(n)[0],a.parentNode.insertBefore(u,a))}(window,document,'script'); // Insert Twitter Pixel ID and Standard Event data below twq('init','o4hgv'); twq('track','PageView'); </script> </div><div class="HtmlFooter"></div></div><div class="ContentUserControl"> <script charset="utf-8"><script type="text/javascript"> (function(c,l,a,r,i,t,y){ c[a]=c[a]||function(){(c[a].q=c[a].q||[]).push(arguments)}; t=l.createElement(r);t.async=1;t.src="https://www.clarity.ms/tag/"+i; y=l.getElementsByTagName(r)[0];y.parentNode.insertBefore(t,y); })(window, document, "clarity", "script", "g9lhesjwph");</script></script> </div><div class="ContentUserControl"> <script charset="utf-8">$(function () { $('.tab-content').show(); if (window.location.href.indexOf("#tab2") > -1 || (window.location.href.indexOf("#session-2") > -1)) { $('.tab-links li').removeClass('active') $('.tab-links li a#page-2').parent().addClass('active') $('.tab-content:not(.page-2)').hide(); } else if (window.location.href.indexOf("#tab3") > -1 || (window.location.href.indexOf("#session-3") > -1)) { $('.tab-links li').removeClass('active') $('.tab-links li a#page-3').parent().addClass('active') $('.tab-content:not(.page-3)').hide(); } else if (window.location.href.indexOf("sitc24-preconference#tils") > -1 || window.location.href.indexOf("sitc24-preconference#industry") > -1) { $('.tab-links li').removeClass('active') $('.tab-links li a#page-1').parent().addClass('active'); $('.tab-content:not(.page-1)').hide(); } else if (window.location.href.indexOf("sitc24-preconference") > -1) { $('.tab-links li').removeClass('active') $('.tab-links li a#page-2').parent().addClass('active') $('.tab-content:not(.page-2)').hide(); } else { $('.tab-content:not(.page-1)').hide(); } })</script> </div><div class="ContentUserControl"> <script charset="utf-8"><script>(function(w,d,t,r,u){var f,n,i;w[u]=w[u]||[],f=function(){var o={ti:"187123435", enableAutoSpaTracking: true};o.q=w[u],w[u]=new UET(o),w[u].push("pageLoad")},n=d.createElement(t),n.src=r,n.async=1,n.onload=n.onreadystatechange=function(){var s=this.readyState;s&&s!=="loaded"&&s!=="complete"||(f(),n.onload=n.onreadystatechange=null)},i=d.getElementsByTagName(t)[0],i.parentNode.insertBefore(n,i)})(window,document,"script","//bat.bing.com/bat.js","uetq");</script></script> </div><div class="ContentItemHtml"><div class="HtmlContent"><p> <script data-cfasync="false">(function(w,i,s,e){window[w]=window[w]||function(){(window[w].q=window[w].q||[]).push(arguments)};window[w].l=Date.now();s=document.createElement('script');e=document.getElementsByTagName('script')[0];s.defer=1;s.src=i;e.parentNode.insertBefore(s, e)})('wisepops', 'https://wisepops.net/loader.js?v=3&h=P5FPJSHQxh');</script> </p></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml"> <div class="HtmlContent"></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml interior-page-title hidden"> <div class="HtmlContent"><img src="https://higherlogicdownload.s3.amazonaws.com/SITCANCER/e16ea3ed-ca86-452e-b5e9-18d717c3857f/UploadedImages/SITC-2022/heading-background.jpeg" alt="heading-background.jpeg" caption="false" class="img-responsive" /></div><div class="HtmlFooter"></div></div> <div id="MPimage" class="MPimage"> <div id="mainskiplinkholder" class="skiplinkholder"><a id="skiplink" href="#MPContentArea">Skip to main content (Press Enter).</a></div> <div id="MPheader" class="MPheader"> <div class="row"> <div class="col-md-12"> <div class="pull-right"> <div class="inline"> <div class='HLWelcome HLWelcomeHeader'> <script type="text/javascript"> $(document).ready(function () { $('.Picture_Profile').tipTip({ delay: 200 }); }); function toggleHelp() { if ($("ul#CompleteBarHelpContainer").is(":visible")) { $("ul#CompleteBarHelpContainer").hide(); } else { $("ul#CompleteBarHelpContainer").show(); } } // Added as onClick for logoutLink on back end if opted in // On logout, removes the CREST API cookie that was added on login, whose value is a token used to authenticate to the API function removeApiToken(tenantKey, token) { hl_webapi_remove_cookie(tenantKey, token, tenantKey, "HLApiPassThrough"); window.location = ""; return false; } $(document).on('click', "span.CompleteBarClose", function (e) { e.stopPropagation(); toggleHelp(); $(".btn-group").find('button#BtnShowProfile').dropdown('toggle'); }); </script> <div class="EndDiv"> </div> <div id="Welcome_NotLoggedIn" class="Login"> <a id="Welcome_LoginLink" class="btn btn-primary" qa-id="login-link" href="https://sitc.execinc.com/HigherLogic/HLLoginRedirect.aspx?Redirect=https%3a%2f%2fwww.sitcancer.org%2f2024%2fschedule%2fsitc24-annualmeeting">Login</a> </div> </div> </div> </div> <div class="pull-right"> <div id="auxskiplinkholder" class="skiplinkholder"> <a id="auxskiplink" href="#Logo">Skip auxiliary navigation (Press Enter).</a> </div> <div id="MPAuxNav" class="inline vertical-align-middle"> </div> </div> </div> </div> <div id="Logo" class="row" role="banner"> <div class="col-md-12"> <div id="DesktopLogoDiv" class="LogoImg inline"> <a href='https://www.sitcancer.org/2024/home' style=''> <img src='https://higherlogicdownload.s3.amazonaws.com/SITCANCER/e16ea3ed-ca86-452e-b5e9-18d717c3857f/UploadedImages/AMPCP_2024/SITC2024-logo-dates_forweb.png' alt="SITC 2024 logo. This will take you to the homepage" /></a> </div> <div id="PhoneLogoDiv" class="LogoImg inline"> <a href='' style='display: none'> <img src='' alt="SITC 2024 logo. This will take you to the homepage" /></a> </div> <div id="SloganText" class="SloganText inline"></div> </div> </div> </div> </div> <div style="clear: both"></div> </div> </div> <div id="NAV" class="row traditional-nav"> <div class="col-md-12"> <div id="navskiplinkholder" class="skiplinkholder"><a id="navskiplink" href="#MPContentArea">Skip main navigation (Press Enter).</a></div> <div id="MPButtonBar"> <nav class="navbar navbar-default"> <div class="navbar-header"> <button type="button" class="navbar-toggle" data-toggle="collapse" data-target=".navbar-ex1-collapse, .icon-bar-start"> <span class="sr-only">Toggle navigation</span> <span class="icon-bar-start"></span> <span class="icon-bar"></span> <span class="icon-bar"></span> <span class="icon-bar"></span> </button> </div> <div class="collapse navbar-collapse navbar-ex1-collapse"> <div class="row"> <div class="col-md-12 "> <ul class="nav navbar-nav"> <li class='dropdown'><a href='/2024/attendee-resources' class='dropdown-toggle' data-toggle='dropdown'><span>Attendee Resources</span> <strong class='caret'></strong></a><ul class='dropdown-menu'><li ><a href='/2024/attendee-resources/faq' >Frequently Asked Questions</a></li><li ><a href='/2024/attendee-resources/registration' >Registration Rates</a></li><li ><a href='/2024/attendee-resources/sitc24-housing' >Housing</a></li><li ><a href='/2024/attendee-resources/visa-info' >Visa Information</a></li><li ><a href='/2024/attendee-resources/sitc24-ce' >Continuing Education</a></li><li ><a href='/2024/attendee-resources/enduring-materials' >Enduring Materials</a></li><li ><a href='/2024/attendee-resources/career-connections' >Career Connections</a></li><li ><a href='/2024/attendee-resources/membership' >Membership</a></li></ul></li><li class='dropdown'><a href='/2024/schedule' class='dropdown-toggle' data-toggle='dropdown'><span>Schedule</span> <strong class='caret'></strong></a><ul class='dropdown-menu'><li class='dropdown-submenu'><a href='/2024/schedule/sitc24-preconference' >Pre-Conference Programs - Nov. 6-7 <strong class='caret'></strong></a><ul class='dropdown-submenu'><li ><a href='/2024/schedule/sitc24-preconference/combination-workshop' >Beyond Checkpoint Inhibitors: New Immuno-oncology Modalities and Approaches</a></li><li ><a href='/2024/schedule/sitc24-preconference/primer-2024' >Primer on Tumor Immunology and Cancer Immunotherapy™</a></li><li ><a href='/2024/schedule/sitc24-preconference/tils' >Tumor Infiltrating Lymphocytes (TIL) Symposium</a></li><li ><a href='/2024/schedule/sitc24-preconference/sitc2024-workshop' >Immune Engineering Workshop</a></li><li ><a href='/2024/schedule/sitc24-preconference/expert-lunch' >Meet-the-Expert Lunch</a></li><li ><a href='/2024/schedule/sitc24-preconference/sitc24-gww' >Grant Writing Workshop</a></li></ul></li><li class='dropdown-submenu'><a href='/2024/schedule/sitc24-annualmeeting' >Annual Meeting - Nov. 8-10 <strong class='caret'></strong></a><ul class='dropdown-submenu'><li ><a href='/2024/schedule/sitc24-annualmeeting/sitc24-friday' >Friday, Nov. 8</a></li><li ><a href='/2024/schedule/sitc24-annualmeeting/sitc24-saturday' >Saturday, Nov. 9</a></li><li ><a href='/2024/schedule/sitc24-annualmeeting/sitc24-sunday' >Sunday, Nov. 10</a></li></ul></li><li class='dropdown-submenu'><a href='/2024/schedule/early-career' >Early Career Scientist Activities - Nov. 7 <strong class='caret'></strong></a><ul class='dropdown-submenu'><li ><a href='/2024/schedule/early-career/speed-mentoring' >Early Career Scientist Speed Mentoring Event</a></li><li ><a href='/2024/schedule/early-career/ecs-networking' >Early Career Scientist Networking Reception</a></li></ul></li><li ><a href='/2024/schedule/sitc24-awards' >Awards</a></li><li ><a href='/2024/schedule/sponsored-symposia' >Sponsored Symposia</a></li><li ><a href='/2024/schedule/sitc24-checkpoints' >The CheckPoints Party</a></li><li ><a href='/2024/schedule/sitc24-business-meeting' >SITC Business Meeting</a></li><li ><a href='/2024/schedule/urg-stem' >URG Undergrads in STEM Program</a></li><li ><a href='/2024/schedule/fun-run' >SITC Fun Run</a></li></ul></li><li class='dropdown'><a href='/2024/abstracts' class='dropdown-toggle' data-toggle='dropdown'><span>Abstracts</span> <strong class='caret'></strong></a><ul class='dropdown-menu'><li class='dropdown-submenu'><a href='/2024/abstracts/abstract-submission' >Abstract Submission <strong class='caret'></strong></a><ul class='dropdown-submenu'><li ><a href='/2024/abstracts/abstract-submission/abstract-dates' >Important Dates</a></li><li ><a href='/2024/abstracts/abstract-submission/abstract-guidelines' >Submission Guidelines</a></li><li ><a href='/2024/abstracts/abstract-submission/abstract-selection' >Selection Process</a></li><li ><a href='/2024/abstracts/abstract-submission/abstractpolicies' >Policies</a></li><li ><a href='/2024/abstracts/abstract-submission/abstracts-yia' >Young Investigator Award Abstracts</a></li><li ><a href='/2024/abstracts/abstract-submission/abstract-lba' >Late-Breaking Abstracts</a></li><li ><a href='/2024/abstracts/abstract-submission/abstract-categories' >Abstract Categories</a></li></ul></li><li class='dropdown-submenu'><a href='/2024/abstracts/abstract-presentation' >Presenter Information <strong class='caret'></strong></a><ul class='dropdown-submenu'><li ><a href='/2024/abstracts/abstract-presentation/sitc24-presentation-guidelines' >Oral Abstract Presentation Guidelines</a></li><li ><a href='/2024/abstracts/abstract-presentation/sitc24-presenter-guidelines' >Poster Presenter Guidelines</a></li></ul></li><li ><a href='/2024/abstracts/titles-and-publications' >Titles and Publications</a></li><li ><a href='/2024/abstracts/faq' >Frequently Asked Questions</a></li></ul></li><li class='dropdown'><a href='/2024/support' class='dropdown-toggle' data-toggle='dropdown'><span>Exhibit & Support</span> <strong class='caret'></strong></a><ul class='dropdown-menu'><li ><a href='/2024/support/sitc-2024-exhibitors' target='_blank'>SITC 2024 Exhibitors and Floor Plan</a></li><li ><a href='/2024/support/2024-supporters' >SITC 2024 Supporters</a></li><li ><a href='/2024/support/sponsorship' >General Information</a></li><li ><a href='/2024/support/exhibitor-information' >Exhibit</a></li><li ><a href='/2024/support/reserve-booth' target='_blank'>Reserve a Booth</a></li><li ><a href='/2024/support/sponsorship-advertising2024' >Sponsorship and Advertising</a></li><li ><a href='/2024/support/ancillary-policy' >Ancillary Event</a></li><li ><a href='/2024/support/sponsored-symposia' >Sponsored Symposia</a></li><li ><a href='/2024/support/sitc24-career' >Career Connections</a></li></ul></li><li class='dropdown'><a href='/2024/press' class='dropdown-toggle' data-toggle='dropdown'><span>Press</span> <strong class='caret'></strong></a><ul class='dropdown-menu'><li ><a href='/2024/press/information' >Press Information</a></li><li ><a href='/2024/press/press-registration' >Press Registration Form</a></li><li ><a href='/2024/press/media-policy' >Media Policy</a></li></ul></li> </ul> </div> </div> </div> </nav> </div> <div class="MenuBarUnderline"> </div> </div> </div> </div> </div> <div id="MPOuter" class="row siteFrame "> <div id="ContentColumn" class="col-md-12">  <div id="BreadCrumb" class="BreadCrumb"> </div> <div id="MPContentArea" class="MPContentArea" role="main"> <h1 id="PageTitleH1" qa-attribute="PageTitleH1" style="display: none;" aria-hidden="true"> Annual Meeting - Nov. 8-10 </h1> <input type="hidden" name="ctl00$DefaultMasterHdnCommunityKey" id="DefaultMasterHdnCommunityKey" value="00000000-0000-0000-0000-000000000000" /> <div id="FlashMessageContainer"> </div> <div id="MainCopy_ContentWrapper" class="schedule"> <div class="row row-full schedule-hero hero-text "><div class="col-md-12 section1"><div class="ContentItemHtml"> <div class="HtmlContent"><style> .schedule-anchor { display: block; position: relative; top: -18vh; visibility: hidden; } </style> <h1 style="text-align: center;"><strong>SITC 2024 Annual Meeting Schedule</strong></h1> <h3><strong>Friday, Nov. 8–Sunday, Nov. 10<br></strong></h3> <p style="text-align: center;"><strong>Welcome to our 39<sup>th</sup> Annual Meeting. You can view the entire Annual Meeting schedule below.</strong></p></div><div class="HtmlFooter"></div></div></div></div><div class="row row-full "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section2"><div class="ContentItemHtml tab-links"> <div class="HtmlContent"><ul class="tab-links" style="padding: 2px 0px;"> <li><a id="page-1" href="#tab1"><strong>Annual Meeting</strong>Fri., Nov. 8</a></li> <li><a id="page-2" href="#tab2"><strong>Annual Meeting</strong>sat., Nov. 9</a></li> <li><a id="page-3" href="#tab3"><strong>Annual Meeting</strong>sun., Nov. 10</a></li> </ul></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml"><div class="HtmlContent"><p style="text-align: right; margin-bottom: none;"><button id="button" type="button" style="text-size: 12px;" class="button-gray">Download Schedule PDF</button></p></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-1 tab-content bg-white-shadow "><div class="col-md-12 section3"><div class="ContentItemHtml"> <div class="HtmlContent"><h2 style="text-align: center;"><strong>Friday, Nov. 8, 2024</strong></h2> <h3 style="text-align: center;">39<sup>th</sup> Annual Meeting | George R. Brown Convention Center | 7:45 a.m.–7 p.m. CST</h3> <p style="text-align: center;"><em>Exhibit Hall open from 9 a.m.–7 p.m. Times and program schedules subject to change.</em></p></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix page-1 tab-content bg-white-shadow session-100 "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section4"><div class="ContentItemHtml session-100"> <div class="HtmlContent"><hr style="height: 2px; border-width: 0; color: #fba61c; background-color: #fba61c; max-width: 130px; margin-left: 0px;"> <h3><a id="session-100"></a><b>Session 100: Presidential Welcome</b></h3> <h4>7:45-7:50 a.m. CST | George R. Brown Convention Center - Level 3 - Hall A3</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-4 section5"><div class="ContentItemHtml"> <div class="HtmlContent"><h4><strong>Chair: </strong></h4> <p><strong>Leisha Emens, MD, PhD<br></strong><span style="font-size: 12pt;"><em><span style="font-family: Calibri, sans-serif;">Kaiser Permanente</span></em></span><br><span style="font-size: 12pt;"></span></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-8 section6"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>View Full Session Schedule</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 50px; width: 100%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 50px;"> <td style="width: 15.5941%; height: 50px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>7:45 a.m.</strong></span></td> <td style="width: 84.4059%; height: 50px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Presidential Welcome<br></strong>Leisha Emens, MD, PhD</span></td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>Session Description</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p>SITC President Leisha Emens, MD, PhD will welcome attendees for the official start of the 39<sup>th</sup> Annual Meeting.</p></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-1 tab-content bg-white-shadow "><div class="col-md-12 section7"><div class="ContentItemHtml session-100"> <div class="HtmlContent"><hr style="height: 2px; border-width: 0; color: #fba61c; background-color: #fba61c; max-width: 130px; margin-left: 0px;"> <h3><strong>Remembrance of Dr. Jeffrey Weber</strong></h3> <h4>7:50-7:55 a.m. CST | George R. Brown Convention Center - Level 3 - Hall A3</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix page-1 tab-content bg-white-shadow session-100 "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section8"><div class="ContentItemHtml session-100"> <div class="HtmlContent"><hr style="height: 2px; border-width: 0; color: #fba61c; background-color: #fba61c; max-width: 130px; margin-left: 0px;"> <div id="session-101"> <h3><b>Session 101: Awards Ceremony 1<br></b></h3> </div> <h4>7:55-8:20 a.m. CST | George R. Brown Convention Center - Level 3 - Hall A3</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-4 section9"><div class="ContentItemHtml"> <div class="HtmlContent"><h4><strong>Chair: </strong></h4> <p><strong>Leisha Emens, MD, PhD<br></strong><span style="font-size: 12pt;"><em><span style="font-family: Calibri, sans-serif;">Kaiser Permanente</span></em></span><br><span style="font-size: 12pt;"></span></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-8 section10"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>View Full Session Schedule</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 112.5px; width: 100%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 62.9062px;"> <td style="width: 15.5941%; height: 62.9062px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>7:50 a.m.</strong></span></td> <td style="width: 84.4059%; height: 62.9062px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Introduction<br></strong>Leisha Emens, MD, PhD<br></span></td> </tr> <tr style="height: 49.594px;"> <td style="width: 15.5941%; vertical-align: top; height: 49.594px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>7:55 a.m.</strong></span></td> <td style="width: 84.4059%; vertical-align: top; height: 49.594px;"> <p><strong><span style="font-family: calibri, arial, helvetica, sans-serif;">Award Recognition</span></strong></p> <p><strong><span style="font-family: calibri, arial, helvetica, sans-serif;">• 2024 Fellows of the Academy of Immuno-Oncology Recognition<br></span></strong></p> <p><strong><span style="font-family: calibri, arial, helvetica, sans-serif;">• 2024 SITC Lifetime Achievement Award</span></strong><strong><span style="font-family: calibri, arial, helvetica, sans-serif;"></span></strong></p> <p><strong><span style="font-family: calibri, arial, helvetica, sans-serif;">• 2024 Tara Withington Public Service Award<br></span></strong></p> <p><strong><span style="font-family: calibri, arial, helvetica, sans-serif;">• 2024 Pedro J. Romero Service to JITC Award<br></span></strong></p> <p><strong><span style="font-family: calibri, arial, helvetica, sans-serif;">• 2024 Steven A. Rosenberg Scholar Award</span></strong></p> </td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>Session Description</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p>The Awards Ceremony will recognize annual award recipients, presented by SITC President Leisha Emens, MD, PhD.</p></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-1 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section11"><div class="ContentItemHtml session-0-smalley"> <div class="HtmlContent"><div class="schedule-anchor" id="session-102"></div> <hr style="height: 2px; border-width: 0; color: #fba61c; background-color: #fba61c; max-width: 130px; margin-left: 0px;"> <h3><b>Session 102: Keynote Address – "What is T Cell Exhaustion?"<br></b>Rafi Ahmed, PhD, FAIO - <em>Emory University School of Medicine</em><b><br></b></h3> <h4>8:20-9:10 a.m. CST | George R. Brown Convention Center - Level 3 - Hall A3</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-4 section12"><div class="ContentItemHtml"> <div class="HtmlContent"><h4><strong>Chair: </strong></h4> <p><strong>Leisha Emens, MD, PhD<br></strong><span style="font-size: 12pt;"><em><span style="font-family: Calibri, sans-serif;">Kaiser Permanente</span></em></span><br><span style="font-size: 12pt;"></span></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-8 section13"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>View Full Session Schedule</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 123.5px; width: 100%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 62.9062px;"> <td style="width: 15.5941%; height: 62.9062px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt; color: rgb(0, 0, 0);"><strong>8:20 a.m.</strong></span></td> <td style="width: 84.4059%; height: 62.9062px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt; color: rgb(0, 0, 0);"><strong>Introduction<br></strong>Leisha Emens, MD, PhD <br></span></td> </tr> <tr style="height: 60.594px;"> <td style="width: 15.5941%; vertical-align: top; height: 60.594px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt; color: rgb(0, 0, 0);"><strong>8:25 a.m.</strong></span></td> <td style="width: 84.4059%; vertical-align: top; height: 60.594px;"><strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">What is T Cell Exhaustion?</span></strong><br> <div class="ewa-rteLine"><span style="font-size: 12pt; color: rgb(0, 0, 0);"><span style="font-family: Calibri;" fontscheme="2">Rafi Ahmed, PhD, FAIO -</span><em fontscheme="2" style="font-family: Calibri;"> Emory University School of Medicine</em></span></div> </td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>Session Description</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-fareast-font-family: Aptos; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;">The 39th Annual Meeting Keynote Address will be given by Rafi Ahmed, PhD, FAIO from Emory University School of Medicine. Dr. Ahmed’s presentation on T Cell Exhaustion will be followed by time for questions from the audience.</span></p></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-1 tab-content bg-gray-shadow "><div class="col-md-12 section14"><div class="ContentItemHtml"> <div class="HtmlContent"><h3 style="text-align: center;"><strong>Break</strong></h3> <h4 style="text-align: center;">9:10–9:40 a.m. CST </h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix page-1 tab-content bg-white-shadow session-100 "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section15"><div class="ContentItemHtml session-100"> <div class="HtmlContent"><div class="schedule-anchor" id="session-103"></div> <hr style="height: 2px; border-width: 0; color: #fba61c; background-color: #fba61c; max-width: 130px; margin-left: 0px;"> <h3><b>Session 103: Pre-malignancy Biology Driving Precision Prevention and Interception Immunotherapy<br></b></h3> <h4>9:40–11:45 a.m. CST | George R. Brown Convention Center -Level 3 - Hall A3</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-4 section16"><div class="ContentItemHtml"> <div class="HtmlContent"><h4><strong>Co-Chairs: </strong></h4> <p><span style="font-size: 12pt;"><strong>Olivera Finn, PhD, FAIO<br></strong><em>University of Pittsburgh</em></span></p> <p><span style="font-size: 12pt;"><strong>Elizabeth Jaffee, MD, FAIO, FAACR, FACP, FAAAS</strong></span><br><span style="font-size: 12pt;"><em>Sidney Kimmel Cancer Center, Johns Hopkins University</em></span><span style="font-size: 12pt;"></span></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-8 section17"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>View Full Session Schedule</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 415.2px; width: 100%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 70.4333px;"> <td style="width: 15.5797%; height: 70.4333px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>9:40 a.m.</strong></span></td> <td style="width: 84.4203%; height: 70.4333px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Introduction<br></strong>Co-Chair <br></span></td> </tr> <tr style="height: 71.1px;"> <td style="width: 15.5797%; height: 71.1px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>9:50 a.m.</strong></span></td> <td style="width: 84.4203%; height: 71.1px; vertical-align: top;"> <div class="ewa-rteLine"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Germline Mediated Immunoediting Dictates Tumor Subtypes and Clinical Outcomes</strong></span></div> <span style="font-size: 12pt;"><span style="font-family: calibri, arial, helvetica, sans-serif;">Christina Curtis, PhD, MSc – <em>Stanford Universit</em></span><em>y</em></span></td> </tr> <tr style="height: 75.4333px;"> <td style="width: 15.5797%; height: 75.4333px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>10:15 a.m.</strong></span></td> <td style="width: 84.4203%; height: 75.4333px; vertical-align: top;"> <div class="ewa-rteLine"><strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Mapping Tumor-Immune Interactions Using 3D Spatial Profiling</span></strong></div> <span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong></strong>Peter Sorger, PhD - <em>Harvard Medical School</em><br></span></td> </tr> <tr style="height: 71.1px;"> <td style="width: 15.5797%; height: 71.1px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>10:40 a.m.</strong></span></td> <td style="width: 84.4203%; height: 71.1px; vertical-align: top;"> <div class="ewa-rteLine"><strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Preventive Vaccines </span></strong></div> <span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong></strong>Napoor Raje, MD - <em>Massachusetts General Hospital</em><br></span></td> </tr> <tr style="height: 64px;"> <td style="width: 15.5797%; height: 64px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>11:05 a.m.</strong></span></td> <td style="width: 84.4203%; height: 64px; vertical-align: top;"> <div class="ewa-rteLine"> <div class="ewa-rteLine"><strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Immune Contexture of Premalignant Lesions</span></strong></div> </div> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><span style="color: rgb(0, 0, 0); font-family: Calibri;" fontscheme="2">Jerome Galon, PhD -<em> </em></span><em><span style="color: rgb(0, 0, 0); font-family: Calibri;">INSERM, Sorbonne Universites Paris </span></em></span><span style="font-family: calibri, arial, helvetica, sans-serif;"><span style="font-size: 16px;"></span></span></p> </td> </tr> <tr style="height: 63.1333px;"> <td style="width: 15.5797%; height: 63.1333px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>11:30 a.m.</strong></span></td> <td style="width: 84.4203%; height: 63.1333px; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.1350"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(1350) Dissecting immune surveillance and escape in lynch syndrome patients</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif;">Robert Samstein, MD, PhD –<em> Icahn School of Medicine at Mount Sinai Tisch Cancer Institute</em></span></p> </td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>Session Description</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p>Many important discoveries in immunology over the last several decades have been applied to the cancer problem with the goal of making immune rejection of cancer more effective. This knowledge has resulted in the development of highly effective cancer immunotherapies for patients with advanced disease. Relatively little of this knowledge has translated into efforts to strengthen cancer immunosurvellance to prevent or intercept cancer development. Vaccines have successfully prevented virus-associated cancers including cervical and hepatocellular carcinomas. At this time of rising cancer rates in young adults, vaccines targeting the earliest changes in premalignacy are urgently needed. This session will highlight research leading us in this new direction. </p></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-1 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section18"><div class="ContentItemHtml"> <div class="HtmlContent"><div class="schedule-anchor" id="session-104"></div> <hr style="height: 2px; border-width: 0; color: #fba61c; background-color: #fba61c; max-width: 130px; margin-left: 0px;"> <h3><strong>Session 104: <span data-olk-copy-source="MessageBody">Clinical </span>Late-Breaking Abstract Session </strong></h3> <p><strong><span style="font-family: helvetica;"><span style="font-size: 11pt;">The LBA Session will feature Late-Breaking Abstracts – Clinical Only (LBAs) for</span><span style="font-size: 11pt;"> <span lang="EN-GB">abstracts with late-breaking data from interventional clinical trials in humans. For more information about LBAs, click <a href="https://www.sitcancer.org/2024/abstracts/abstract-submission/abstract-lba" target="_blank" rel="noopener">here</a>.</span></span></span></strong></p> <h4>11:45 a.m.–12:15 p.m. CST | George R. Brown Convention Center -Level 3 - Hall A3</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-4 section19"><div class="ContentItemHtml"> <div class="HtmlContent"><h4><strong>Chair: </strong></h4> <p><span style="font-size: 12pt;"><strong>Alfred L. Garfall, MD<br></strong><em>Perelman School of Medicine, University of Pennsylvania</em><br></span></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-8 section20"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>View Full Session Schedule</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 215.312px; width: 100%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 108.812px;"> <td style="width: 15.6337%; height: 108.812px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>11:45 a.m.</strong></span></td> <td style="width: 84.3663%; height: 108.812px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.1463">(1463) <span>Coformulated vibostolimab/pembrolizumab plus chemotherapy as first-line therapy vs atezolizumab plus chemotherapy for extensive-stage small-cell lung cancer (ES-SCLC): Randomized, phase 3 KEYVIBE-008</span></a><br></strong>Jacob Sands, MD - <em>Dana-Farber Cancer Institue</em></span></td> </tr> <tr style="height: 106.5px;"> <td style="width: 15.6337%; vertical-align: top; height: 106.5px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>12 p.m.</strong></span></td> <td style="width: 84.3663%; vertical-align: top; height: 106.5px;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.1492"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(1492) Telomere-Targeting agent THIO in sequence with cemiplimab demonstrates long-term therapeutic<br>benefits beyond treatment cessation - a phase 2 THIO-101 trial in advanced ICI resistant NSCLC patients</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Victor Zaporojan, MD – <em>MAIA Biotechnology, Inc</em></span></p> </td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>Session Description</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p>This 30-minute session will highlight two selected Late-breaking Abstracts who will each showcase their work in a 15-minute oral presentation. </p></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-1 tab-content bg-gray-shadow "><div class="col-md-12 section21"><div class="ContentItemHtml"> <div class="HtmlContent"><h3 style="text-align: center;"><strong>Lunch and Poster Viewing</strong></h3> <h4 style="text-align: center;">12:15–1:45 p.m. CST | George R. Brown Convention Center -Level 1 -Exhibit Halls AB</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix page-1 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section22"><div class="ContentItemHtml"> <div class="HtmlContent"><div class="schedule-anchor" id="session-105a"></div> <hr style="height: 2px; border-width: 0; color: #fba61c; background-color: #fba61c; max-width: 130px; margin-left: 0px;"> <h3><strong>Concurrent Session 105a: Rapid Oral Abstract-Basic</strong></h3> <h4>12:30–1:30 p.m. CST | George R. Brown Convention Center - Level 3 - Grand Ballroom B</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-4 section23"><div class="ContentItemHtml"> <div class="HtmlContent"><h4><strong>Co-Chairs: </strong></h4> <p><strong>Sarah B. Gitto, PhD</strong><b><br></b><em>University of Pennsylvania</em><span style="font-size: 12pt;"></span></p> <p><b>Geoffrey Markowitz, PhD<br></b><em>Weill Cornell Medicine</em><b><br></b></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-8 section24"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>View Full Session Schedule</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 76px; width: 100%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 76px;"> <td style="width: 15.6337%; height: 76px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>12:30 p.m.</strong></span></td> <td style="width: 84.3663%; height: 76px; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0264"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(264) Development of an off-the-shelf, MICA/B-targeted CAR T cell to overcome a pan-tumor escape mechanism for solid tumors</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif;">Alex J. Garcia, PhD – <em>Fate Therapeutics</em></span></p> </td> </tr> <tr> <td style="width: 15.6337%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>12:38 p.m.</strong></span></td> <td style="width: 84.3663%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0318"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(318) Developing a preclinical toxicity model to predict and prevent clinical CAR T cell toxicity in prostate cancer</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Nour Shobaki, PharmD, PhD – <em>Perelman School of Medicine at the University of Pennsylvania</em></span></p> </td> </tr> <tr> <td style="width: 15.6337%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>12:46 p.m.</strong></span></td> <td style="width: 84.3663%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0978"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(978) Cancer-associated fibroblast-derived Dickkopf-1 impairs anti-tumor immunity in breast cancer by suppressing NK cell-mediated cytotoxicity</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Seunghyun Lee, PhD – <em>Washington University School of Medicine</em></span></p> </td> </tr> <tr> <td style="width: 15.6337%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>12:54 p.m.</strong></span></td> <td style="width: 84.3663%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Q&A</strong></span></td> </tr> <tr> <td style="width: 15.6337%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>1 p.m.</strong></span></td> <td style="width: 84.3663%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.1015"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(1015) Androgen loss weakens anti-tumor immunity and accelerates brain tumor growth</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Juyeun Lee, PhD – <em>Cleveland Clinic, Lerner Research Institute</em></span></p> </td> </tr> <tr> <td style="width: 15.6337%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>1:08 p.m.</strong></span></td> <td style="width: 84.3663%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.1149"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(1149) A novel tunable proteomimetic nanoplatform enables simultaneous delivery of antigens with 2’3’-cGAMP via formation of stable electrostatic complexes</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Max Wang – <em>Northwestern University</em></span></p> </td> </tr> <tr> <td style="width: 15.6337%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>1:16 p.m.</strong></span></td> <td style="width: 84.3663%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.1309"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(1309) A STUB1-CHIC2 complex decreases IL-27Rα expression on CD8+ T cells to restrain tumor immunity</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Martin LaFleur, PhD – <em>Harvard Medical School</em></span></p> </td> </tr> <tr> <td style="width: 15.6337%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>1:24 p.m.</strong></span></td> <td style="width: 84.3663%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Q&A</strong></span></td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>Session Description</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p>This fast-paced session will feature six oral presentations from select basic science abstracts with time for Q&A. </p></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-1 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section25"><div class="ContentItemHtml"> <div class="HtmlContent"><hr style="height: 2px; border-width: 0; color: #f4d301; background-color: #f4d301; max-width: 255px; margin-left: 0px;"> <h3><strong>Concurrent Session 105b: Rapid Oral Abstracts - Clinical</strong></h3> <h4>12:30–1:30 p.m. CST | George R. Brown Convention Center - Level 3 - Grand Ballroom C</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-4 section26"><div class="ContentItemHtml"> <div class="HtmlContent"><h4><strong>Co-Chairs: </strong></h4> <p><strong>Zachary A. Cooper, PhD</strong><br><em>AstraZeneca</em></p> <p><strong>Robyn Gartrell, MD</strong><br><em>Johns Hopkins School of Medicine</em></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-8 section27"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>View Full Session Schedule</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 85.317px; width: 100%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 85.317px;"> <td style="width: 15.6337%; height: 85.317px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>12:30 p.m.</strong></span></td> <td style="width: 84.3663%; height: 85.317px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0409"><strong>(409) Multimodal single-cell sequencing analysis reveals putative tumor reactive population in lifileucel TIL products</strong></a><br>Joseph Dean, PhD – Iovance<br></span></td> </tr> <tr> <td style="width: 15.6337%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>12:38 p.m.</strong></span></td> <td style="width: 84.3663%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0649"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(649) A phase 1 dose-escalation and expansion study of CUE-101 as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Christine Chung, MD – <em>H. Lee Moffitt Cancer Center and Research Institute</em></span></p> </td> </tr> <tr> <td style="width: 15.6337%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>12:46 p.m.</strong></span></td> <td style="width: 84.3663%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0711"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(711) Final overall survival from PERLA, a phase II randomized double-blind trial of dostarlimab + chemotherapy (CT) vs pembrolizumab + CT in metastatic non-squamous non-small cell lung cancer (NSCLC)</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Solange Peters, MD, PhD – <em>Lausanne University Hospital</em></span></p> </td> </tr> <tr> <td style="width: 15.6337%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>12:54 p.m.</strong></span></td> <td style="width: 84.3663%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Q&A</strong></span></td> </tr> <tr> <td style="width: 15.6337%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>1 p.m.</strong></span></td> <td style="width: 84.3663%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.1037"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(1037) SARS-COV-2 mRNA vaccines are associated with Type I interferon signaling and improved clinical responses to immune checkpoint inhibition</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Adam J. Grippin – <em>The University of Texas MD Anderson Cancer Center</em></span></p> </td> </tr> <tr> <td style="width: 15.6337%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>1:08 p.m.</strong></span></td> <td style="width: 84.3663%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.1413"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(1413) An integrated tumor, immune and genetic landscape of pleural mesothelioma to unleash effective immunotherapy avenues</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Katarzyna Tomczak, PhD – <em>The University of Texas MD Anderson Cancer Center</em></span></p> </td> </tr> <tr> <td style="width: 15.6337%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>1:16 p.m.</strong></span></td> <td style="width: 84.3663%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0615"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(615) Intratumoral Fc-engineered agonistic CD40 antibody induces tumor rejection and systemic antitumor immunity in metastatic cancer patients. A bench-to-bedside and back approach</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Juan C. Osorio, MD – <em>Memorial Sloan Kettering Cancer Center</em></span></p> </td> </tr> <tr> <td style="width: 15.6337%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>1:24 p.m.</strong></span></td> <td style="width: 84.3663%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Q&A</strong></span></td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>Session Description</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p>This fast-paced session will feature six oral presentations from select clinical abstracts with time for Q&A. </p></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-1 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section28"><div class="ContentItemHtml session-106a"> <div class="HtmlContent"><div id="session-106a"></div> <hr style="height: 2px; border-width: 0; color: #f4d301; background-color: #f4d301; max-width: 255px; margin-left: 0px;"> <h3><strong>Concurrent Session 106a: Leveraging B Cells for Anti-Tumor Immunity <br></strong></h3> <h4>1:45–3:20 p.m. CST | George R. Brown Convention Center - Level 3 - Hall A3</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-4 section29"><div class="ContentItemHtml"> <div class="HtmlContent"><h4><strong>Co-Chairs: </strong></h4> <p><span style="font-size: 12pt;"><strong>Tullia Bruno, PhD</strong></span><br><span style="font-size: 12pt;"><em>University of Pittsburgh</em></span><br><span style="font-size: 12pt;"></span></p> <p><span style="font-size: 12pt;"><strong>Daniel Hollern, PhD</strong> <br><em><span style="font-size: 12pt;">Salk Institute </span><br></em></span></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-8 section30"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>View Full Session Schedule</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 402.183px; width: 100%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 62.9px;"> <td style="width: 15.6337%; height: 62.9px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>1:45 p.m.</strong></span></td> <td style="width: 84.3663%; height: 62.9px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Intro to B Cells: Inside and Outside of Tertiary Lymphoid Structures </strong><em><br></em>Tullia Bruno, PhD<em> -</em> <em>University of Pittsburgh, <span data-ved="2ahUKEwiR24yfg6yHAxW2g4kEHTn8A30Q2kooAnoECCwQCA">Pennsylvania</span><br></em></span></td> </tr> <tr style="height: 63.4px;"> <td style="width: 15.6337%; height: 63.4px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>1:55 p.m.</strong></span></td> <td style="width: 84.3663%; height: 63.4px; vertical-align: top;"><strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Extrafollicular B Cell Activation Drives Robust Anti-tumor Immune Responses in Triple Negative Breast Cancer</span></strong><br> <div class="ewa-rteLine"><span style="font-size: 12pt;"><span style="color: rgb(0, 0, 0); font-family: Calibri;">Daniel Hollern, PhD - </span><em style="color: rgb(0, 0, 0); font-family: Calibri;">Salk Institute</em></span></div> </td> </tr> <tr style="height: 63.8px;"> <td style="width: 15.6337%; height: 63.8px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>2:20 p.m.</strong></span></td> <td style="width: 84.3663%; height: 63.8px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong></strong></span><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Determinants of B Cell Function in Cancer</strong></span><br><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Yuliya Pylayeva-Gupta, PhD - <em>UNC Lineberger Comprehensive Cancer Center</em></span><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><br></span></td> </tr> <tr style="height: 63.4px;"> <td style="width: 15.6337%; height: 63.4px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>2:45 p.m.</strong></span></td> <td style="width: 84.3663%; height: 63.4px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong></strong></span><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Temporal Single Cell Profiling Identifies B-Cell Specific Checkpoint Molecules that Regulate Anti-Tumor Immunity</strong></span><br><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Lloyd Bod, PhD - <em>Massachusetts General Cancer Center</em></span><br><span style="font-family: calibri, arial, helvetica, sans-serif;"><span style="font-size: 16px;"></span></span></td> </tr> <tr style="height: 83.5px;"> <td style="width: 15.6337%; height: 83.5px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>3:10 p.m.</strong></span></td> <td style="width: 84.3663%; height: 83.5px; vertical-align: top;"><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0364"><strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">(364) Th17 cells harmonize with host B cells for long-lived tumor immunity</span></strong></a><br><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Anna C. Cole, BA – <em>Emory University</em></span></td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>Session Description</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p class="MsoNormal">Among the cells of the immune system is a highly dynamic composition of lymphocytes known as B cells. To maintain tissue homeostasis, B cells leverage contextual information to mature towards diverse phenotypes and functions that include immune suppression and eliciting immune mediated cytotoxicity. Indeed, B cells can form regulatory B cells which engage T cells and other immune cells with molecular messages to protect tissues from autoimmunity and suppress cytotoxic responses. Yet, under other molecular signals, B cells can be induced to ignite and amplify effector immune responses when functioning as organizers of cytotoxic immune cell aggregates where they engage in molecular exchange and antigen presentation. Likewise, B cells are well appreciated for their differentiation into antibody secreting cells to elicit local and systemic immunity. In line with these diverse and critical functions, B cell heterogeneity, activation, and function is being shown to be critical to tumor progression, cancer patient survival, and responses to chemo and immune therapy. Together, this contemporary research on B cells has made it clear that there are abundant opportunities to improve immunotherapy by control of B cell function. In this session, we emphasize (1) the therapeutic utility of B cells, (2) showcase new strategies to mechanistically ignite B cell anti-tumor functions, and (3) discuss how B cells can be modulated within and outside cellular neighborhoods i.e. tertiary lymphoid structures. <span style="mso-spacerun: yes;"> </span><o:p></o:p></p></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-1 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section31"><div class="ContentItemHtml"> <div class="HtmlContent"><div class="schedule-anchor" id="session-106b"></div> <hr style="height: 2px; border-width: 0; color: #f4d301; background-color: #f4d301; max-width: 255px; margin-left: 0px;"> <h3><strong>Concurrent Session 106b: Microbiome: Ready for Prime Time?<br></strong></h3> <h4>1:45–3:20 p.m. CST | George R. Brown Convention Center - Level 3 - General Assembly Theater</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-4 section32"><div class="ContentItemHtml"> <div class="HtmlContent"><h4><strong>Co-Chairs: </strong></h4> <p><span style="font-size: 12pt;"><strong>Bertrand Routy, MD, PhD</strong></span><br><span style="font-size: 12pt;"><em>CHUM Research Centre </em></span><br><span style="font-size: 12pt;"></span></p> <p><span style="font-size: 12pt;"><strong>Jennifer Wargo, MD, MMSC</strong><br><em>The University of Texas MD Anderson Cancer Center</em><br></span></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-8 section33"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>View Full Session Schedule</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 639.766px; width: 100%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 82.1562px;"> <td style="width: 12.9909%; height: 82.1562px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>1:45 p.m.</strong></span></td> <td style="width: 87.0091%; height: 82.1562px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Introduction<br></strong>Co-Chair<br></span></td> </tr> <tr style="height: 82.6875px;"> <td style="width: 12.9909%; height: 82.6875px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>1:47 p.m.</strong></span></td> <td style="width: 87.0091%; height: 82.6875px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong><span style="font-size: 12pt;"><strong style="font-family: calibri, arial, helvetica, sans-serif;">Microbiome Disruption in Cancer Immunotherapy and Transplantation</strong></span></strong></span><br><span style="font-family: calibri, arial, helvetica, sans-serif;"><span style="font-size: 16px;">Jonathan Peled, MD, PhD</span></span><em><span style="font-family: calibri, arial, helvetica, sans-serif;"><span style="font-size: 16px;"> - Memorial Sloan Kettering Cancer Center<br></span></span></em></td> </tr> <tr style="height: 82.6875px;"> <td style="width: 12.9909%; height: 82.6875px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>2:02 p.m.</strong></span></td> <td style="width: 87.0091%; height: 82.6875px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Microbial Cell Therapies: Challenges and Opportunities for Bugs as Drugs</strong></span><br><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Christopher Johnston, PhD </span><em><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">- The University of Texas MD Anderson Cancer Center<br></span></em></td> </tr> <tr style="height: 93.75px;"> <td style="width: 12.9909%; height: 93.75px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>2:17 p.m.</strong></span></td> <td style="width: 87.0091%; height: 93.75px; vertical-align: top;"> <p><strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Profiling and Modulating the Microbiome in Cancer</span> </strong><br><span style="font-family: calibri, arial, helvetica, sans-serif;"><span style="font-size: 16px;">Lisa Derosa, </span><span style="font-size: 16px;"><span style="color: windowtext; font-size: 11pt; font-family: Calibri, sans-serif; line-height: 18px;" data-contrast="auto" class="TextRun BCX2 SCXO98404697" xml:lang="EN-US" lang="EN-US"><span class="NormalTextRun BCX2 SCXO98404697" style="background-color: inherit;">MD, PhD</span></span></span></span><em><span style="font-family: calibri, arial, helvetica, sans-serif;"><span style="font-size: 16px;">- Gustave Roussy</span></span></em></p> </td> </tr> <tr style="height: 84.453px;"> <td style="width: 12.9909%; height: 84.453px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>2:32 p.m.</strong></span></td> <td style="width: 87.0091%; height: 84.453px; vertical-align: top;"> <p style="padding-top: 5px; padding-right: 5px; padding-bottom: 5px; text-align: left;"><span style="font-size: 12pt;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Phase II Clinical Trial of Fecal Microbiota Transplantation in Combination with Immunotherapy in Patients with Lung Cancer and Melanoma (FMT-LUMINate)</strong></span></span></p> <p style="padding-top: 5px; padding-right: 5px; padding-bottom: 5px; text-align: left;"><span style="font-size: 12pt;"><span style="font-family: calibri, arial, helvetica, sans-serif;"><span style="font-size: 16px;">Arielle Elkrief, MD, FRCPC -</span></span><em><span style="font-family: calibri, arial, helvetica, sans-serif;"><span style="font-size: 16px;"> University of Montréal Research Center</span></span></em><em><span style="font-family: calibri, arial, helvetica, sans-serif;"></span></em></span></p> </td> </tr> <tr style="height: 84.8438px;"> <td style="width: 12.9909%; height: 84.8438px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif;"><span style="font-size: 16px;"><b>2:47 p.m.</b></span></span></td> <td style="width: 87.0091%; height: 84.8438px; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0562"><span style="font-size: 12pt; font-family: calibri, arial, helvetica, sans-serif;"><strong>(562) Bile acids circumvent gut dysbiosis-induced resistance to anti-PD-1</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif;">Anne-Laure Mallard de La Varende, MS – <em>Gustave Roussy</em></span></p> </td> </tr> <tr style="height: 69.8438px;"> <td style="width: 12.9909%; vertical-align: top; height: 69.8438px;"><span style="font-family: calibri, arial, helvetica, sans-serif;"><span style="font-size: 16px;"><b>2:57 p.m.</b></span></span></td> <td style="width: 87.0091%; vertical-align: top; height: 69.8438px;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0602"><span style="font-size: 12pt; font-family: calibri, arial, helvetica, sans-serif;"><strong>(602) High fiber dietary intervention in plasma cell disorders improves microbiome and immune biomarkers and delays progression to myeloma</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif;">Urvi A. Shah, MD, MS – <em>Memorial Sloan Kettering Cancer Center</em></span></p> </td> </tr> <tr style="height: 59.3438px;"> <td style="width: 12.9909%; vertical-align: top; height: 59.3438px;"><span style="font-family: calibri, arial, helvetica, sans-serif;"><span style="font-size: 16px;"><b>3:07 p.m.</b></span></span></td> <td style="width: 87.0091%; vertical-align: top; height: 59.3438px;"><span style="font-size: 12pt;"><strong style="font-family: calibri, arial, helvetica, sans-serif;">Panel Discussion and Q&A <br></strong></span></td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>Session Description</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p>In less than a decade, several discoveries propelled the gut microbiome from the dark matter to one of the “hallmarks of cancer”. Recent studies revealed that the baseline microbiome composition correlated with the anti-cancer response, the risk of immune-related toxicities and the development of graft-versus-host disease (GVHD). This intricate relationship is linked through several mechanisms including microbiome-associated molecular patterns, cross-reactive antigens, bacterial metabolites and immune checkpoint expression.</p> <p>Furthermore, harnessing the microbiome using fecal microbiota transplantation, probiotics and prebiotics demonstrated that shifting the microbiome composition can enhance immune checkpoint inhibitors (ICI) response and improve GVHD. In this session, we will focus on the development of user-friendly strategies to profile microbiome composition as a novel biomarker. We will review the ongoing strategies to improve the microbiome composition for patients amenable to ICI treatment or allogeneic stem cell transplantation. In sum, the aim of this session is to understand and review the mechanisms by which bugs can become new cancer drugs.</p></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-1 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section34"><div class="ContentItemHtml"> <div class="HtmlContent"><div class="schedule-anchor" id="session-107d"></div> <hr style="height: 2px; border-width: 0; color: #f4d301; background-color: #f4d301; max-width: 255px; margin-left: 0px;"> <h3><strong>Concurrent Session 106c: Oral Abstract Session</strong></h3> <h4>1:45–3:20 p.m. CST | George R. Brown Convention Center - Level 3 - Grand Ballroom A</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-4 section35"><div class="ContentItemHtml"> <div class="HtmlContent"><h4><strong>Co-Chairs: </strong></h4> <p><span style="font-size: 12pt;"><strong>Roberta Zappasodi, PhD</strong><em><br>Weill Cornell Medicine<br><br></em><strong>Tanaya Shree, MD, PhD</strong><em><br>Oregon Health and Sciences University<br></em></span></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-8 section36"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>View Full Session Schedule</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 405.219px; width: 100%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 56px;"> <td style="width: 15.6337%; height: 56px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>1:45 p.m.</strong></span></td> <td style="width: 84.3663%; height: 56px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Introduction</strong><br></span></td> </tr> <tr style="height: 106.5px;"> <td style="width: 15.6337%; vertical-align: top; height: 106.5px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>1:49 p.m.</strong></span></td> <td style="width: 84.3663%; vertical-align: top; height: 106.5px;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0210"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(210) Metacellular networks and proteomic ecotypes predict survival outcomes in HNSCC treated with post-operative radiation therapy and durvalumab</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Siddharth Sheth, DO, MPH – <em>University of North Carolina School of Medicine</em></span></p> </td> </tr> <tr style="height: 40.4531px;"> <td style="width: 15.6337%; vertical-align: top; height: 40.4531px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>2:04 p.m.</strong></span></td> <td style="width: 84.3663%; vertical-align: top; height: 40.4531px;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0230"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(230) Mannose supplementation: A strategy for metabolically driving a stem-like T cell program for improved tumor control</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Yapeng Su, PhD –<em> Fred Hutchinson Cancer Research Center</em></span></p> </td> </tr> <tr style="height: 40.4531px;"> <td style="width: 15.6337%; vertical-align: top; height: 40.4531px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>2:19 p.m.</strong></span></td> <td style="width: 84.3663%; vertical-align: top; height: 40.4531px;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0309"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(309) Engineering a novel switch receptor enhances CAR-T cell fitness in suppressive TGF-β-enriched solid tumors</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif;">Mengfei Qin – <em>Peter MacCallum Cancer Centre</em></span></p> </td> </tr> <tr style="height: 40.4531px;"> <td style="width: 15.6337%; vertical-align: top; height: 40.4531px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>2:34 p.m.</strong></span></td> <td style="width: 84.3663%; vertical-align: top; height: 40.4531px;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0368"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(368) Translational analyses reveal mechanisms of afami-cel’s anti-tumor activity in synovial sarcoma</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Mihaela Druta, MD – <em>Moffitt Cancer Center</em></span></p> </td> </tr> <tr style="height: 40.4531px;"> <td style="width: 15.6337%; vertical-align: top; height: 40.4531px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>2:49 p.m.</strong></span></td> <td style="width: 84.3663%; vertical-align: top; height: 40.4531px;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0579"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(579) Siglec-7/9 receptors suppress T cell immunity via trogocytosis and represent degradable targets for cancer immunotherapy</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Chao Wang, PhD – <em>The Scripps Research Institute</em></span></p> </td> </tr> <tr style="height: 40.4531px;"> <td style="width: 15.6337%; vertical-align: top; height: 40.4531px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>3:04 p.m.</strong></span></td> <td style="width: 84.3663%; vertical-align: top; height: 40.4531px;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0687"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(687) ACTengine IMA203 TCR-T targeting PRAME shows deep and durable anti-tumor activity in heavily pretreated solid cancer patients</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Martin Wermke, MD –<em> Uniklinik Dresden</em></span></p> </td> </tr> <tr style="height: 40.4531px;"> <td style="width: 15.6337%; vertical-align: top; height: 40.4531px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>3:19 p.m.</strong></span></td> <td style="width: 84.3663%; vertical-align: top; height: 40.4531px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Conclusion</strong></span></td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>Session Description</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p>Selected abstracts will be presented in 10-15 minute oral presentations. </p></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-1 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section37"><div class="ContentItemHtml"> <div class="HtmlContent"><div class="schedule-anchor" id="session-106d"></div> <hr style="height: 2px; border-width: 0; color: #f4d301; background-color: #f4d301; max-width: 255px; margin-left: 0px;"> <h3><strong>Concurrent Session 106d: Biotech Breakthroughs - Solid Tumor IO at the Tipping Point<br></strong></h3> <h4>1:45–3:20 p.m. CST | George R. Brown Convention Center - Level 3 - Grand Ballroom B</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-4 section38"><div class="ContentItemHtml"> <div class="HtmlContent"><h4><strong>Co-Chairs: </strong></h4> <p><strong>Kristen Hege, MD<br></strong></p> <p><strong>Zhen Su, MD, MBA<br></strong><em>Marengo Theraputics</em></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-8 section39"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>View Full Session Schedule</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 483.133px; width: 100%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 62.4667px;"> <td style="width: 15.6337%; height: 62.4667px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>1:45 p.m.</strong></span></td> <td style="width: 84.3663%; height: 62.4667px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Intro: Highlight FDA Approvals <br></strong><em>Co-Chair</em></span></td> </tr> <tr style="height: 63.1333px;"> <td style="width: 15.6337%; height: 63.1333px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>1:50 p.m.</strong></span></td> <td style="width: 84.3663%; height: 63.1333px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Lifileucel a Transformational Approach for Solid Cancer: First FDA Approved TIL Therapy for Advanced Melanoma<br></strong>Raj Puri, MD, PhD<em> - Iovance Biotherapeutics</em></span></td> </tr> <tr style="height: 63.1333px;"> <td style="width: 15.6337%; height: 63.1333px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>2:05 p.m.</strong></span></td> <td style="width: 84.3663%; height: 63.1333px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Delivering on the Promise of Cell Therapies for Solid Tumors: T-cell Therapy for Synovial Sarcoma<br></strong><span style="color: rgb(0, 0, 0); font-family: Calibri;" fontscheme="2">Jo Brewer, PhD - </span><em fontscheme="2" style="color: rgb(0, 0, 0); font-family: Calibri;">Adaptimmune</em><br><em></em></span></td> </tr> <tr style="height: 63.1333px;"> <td style="width: 15.6337%; height: 63.1333px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>2:20 p.m.</strong></span></td> <td style="width: 84.3663%; height: 63.1333px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Tarlatamab: a Bispecific T-cell Engager Immunotherapy Paving the Way for Small Cell Lung Cancer and Solid Tumors</strong><strong><br></strong>Pablo Martinez, MD, PhD<em> - Amgen</em><em></em></span></td> </tr> <tr style="height: 82px;"> <td style="width: 15.6337%; height: 82px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>2:35 p.m.</strong></span></td> <td style="width: 84.3663%; height: 82px; vertical-align: top;"> <p style="padding: 5px; text-align: left;"><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0991"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(991) ST101, an inhibitor of the transcription factor C/EBPß, promotes an immune-active tumor microenvironment in a window of opportunity (WoO) study of patients with glioblastoma (GBM)</strong></span></a></p> <p style="padding: 5px; text-align: left;"><span style="font-family: calibri, arial, helvetica, sans-serif;">Jim Rotolo, PhD – <em>Sapience Therapeutics</em></span></p> </td> </tr> <tr style="height: 63.1333px;"> <td style="width: 15.6337%; height: 63.1333px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>2:45 p.m.</strong></span></td> <td style="width: 84.3663%; height: 63.1333px; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.1472"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(1472) A phase 1/2 study evaluating the safety and efficacy of autologous TAC T cells in subjects with<br>claudin 18.2+ advanced solid tumors</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif;">Ecaterina E. Dumbrava, MD – <em>The University of Texas MD Anderson Cancer Center</em></span></p> </td> </tr> <tr style="height: 63.1333px;"> <td style="width: 15.6337%; height: 63.1333px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>2:55 p.m.</strong></span></td> <td style="width: 84.3663%; height: 63.1333px; vertical-align: top;"> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Panel Discussion:<span style="font-family: calibri, arial, helvetica, sans-serif;"> </span></strong></span><span style="font-family: calibri, arial, helvetica, sans-serif;"><strong>IO for Solid Tumors Beyond Checkpoint Inhibitors – Future Directions</strong></span></p> <div class="ewa-rteLine"><span style="color: rgb(0, 0, 0); font-family: Calibri; font-size: 12pt;" fontscheme="2">Kristen Hege, MD</span></div> <div class="ewa-rteLine"><span style="color: rgb(0, 0, 0); font-family: Calibri; font-size: 12pt;" fontscheme="2">Zhen Su, MD, MBA - <em>Marengo Therapeutics</em></span></div> <div class="ewa-rteLine"><span style="font-size: 12pt;"><span style="color: rgb(0, 0, 0); font-family: Calibri;" fontscheme="2">Raj Puri, MD, PhD -</span><em fontscheme="2" style="color: rgb(0, 0, 0); font-family: Calibri;"> Iovance Biotherapeutics</em><em fontscheme="2" style="color: rgb(0, 0, 0); font-family: Calibri;"><span style="color: rgb(0, 0, 0); font-family: Calibri;" fontscheme="2"></span></em></span></div> <div class="ewa-rteLine"><span style="font-size: 12pt;"><span style="color: rgb(0, 0, 0); font-family: Calibri;"><span style="color: rgb(0, 0, 0); font-family: Calibri;" fontscheme="2">Jo Brewer, PhD </span></span><em fontscheme="2" style="color: rgb(0, 0, 0); font-family: Calibri;"><span style="color: rgb(0, 0, 0); font-family: Calibri;" fontscheme="2">- </span>Adaptimmune </em></span></div> <div class="ewa-rteLine"> <div class="ewa-rteLine"><span style="font-size: 12pt;"><span style="color: rgb(0, 0, 0); font-family: Calibri;" fontscheme="2">Pablo Martinez, MD PhD - </span><em fontscheme="2" style="color: rgb(0, 0, 0); font-family: Calibri;">Amgen</em></span></div> <div class="ewa-rteLine"><span style="font-size: 12pt;"><span style="color: rgb(0, 0, 0); font-family: Calibri;"><span style="font-family: calibri, arial, helvetica, sans-serif;">William Grossman,</span></span><span style="color: rgb(0, 0, 0); font-family: Calibri;"><span style="font-family: calibri, arial, helvetica, sans-serif;"> PhD, MD</span></span><em fontscheme="2" style="color: rgb(0, 0, 0); font-family: Calibri;"><span style="font-family: calibri, arial, helvetica, sans-serif;"><em> - Gilead</em></span></em></span></div> <div class="ewa-rteLine"><span style="font-size: 12pt;"><span style="color: rgb(0, 0, 0); font-family: Calibri;"><span style="font-family: calibri, arial, helvetica, sans-serif;">Brad Loncar,</span></span><span style="color: rgb(0, 0, 0); font-family: Calibri;"><span style="font-family: calibri, arial, helvetica, sans-serif;"> BBA</span></span><em fontscheme="2" style="color: rgb(0, 0, 0); font-family: Calibri;"><span style="font-family: calibri, arial, helvetica, sans-serif;"><em> - BiotechTV</em></span></em></span></div> <div class="ewa-rteLine"><span style="font-size: 12pt;"><span style="color: rgb(0, 0, 0); font-family: Calibri;"><span style="font-family: calibri, arial, helvetica, sans-serif;"><span style="color: rgb(0, 0, 0); font-family: Calibri;">Allison Betof Warner, MD, PhD</span></span></span><em fontscheme="2" style="color: rgb(0, 0, 0); font-family: Calibri;"><span style="font-family: calibri, arial, helvetica, sans-serif;"><em><span style="color: rgb(0, 0, 0); font-family: Calibri;"> - </span><em style="color: rgb(0, 0, 0); font-family: Calibri;">Stanford University School of Medicine</em></em></span></em></span></div> </div> <div class="ewa-rteLine"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"></span></div> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><em></em></span></p> </td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>Session Description</strong><o:p></o:p></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p>Cancer immunotherapy has transformed cancer care over the past decade with more than 25 FDA approved medicines in the clinic. Immune activation focused novel modalities have demonstrated compelling efficacy and achieved regulatory approvals in hematologic malignancies over the past decade. Beyond the first wave T cell checkpoint blockade, developing next wave novel IO therapeutics in solid tumor have been challenging, but the tide has turned. 2024 is a breakthrough year for new and pending FDA approvals of both cell therapies and complex biologics in multiple solid tumor indications focusing on reinvigorating the anti-tumor immune response. In this session you will learn about the development and commercial launch of these exciting new immuno-oncology products including tumor infiltrating lymphocytes, T cell receptor engineered T cells, T cell engaging bispecific antibodies, next generation cytokines and more.</p></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-1 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section40"><div class="ContentItemHtml"> <div class="HtmlContent"><hr style="height: 2px; border-width: 0; color: #f4d301; background-color: #f4d301; max-width: 255px; margin-left: 0px;"> <h3><strong>Concurrent Session 106e: Commonalities and Site-Specific Factors for Immune Microenvironments across and between Tumor Types<br></strong></h3> <h4>1:45–3:20 p.m. CST | George R. Brown Convention Center - Level 3 - Grand Ballroom C</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-3 section41"><div class="ContentItemHtml"> <div class="HtmlContent"><h4><strong>Co-Chairs: </strong></h4> <p><strong>F. Stephen Hodi Jr., MD<br></strong><em>Dana-Faber Cancer Institute</em></p> <p><strong>Mario Sznol, MD<br></strong><em>Yale School of Medicine </em></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-9 section42"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>View Full Session Schedule</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 483.133px; width: 100%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 62.4667px;"> <td style="width: 15.6337%; height: 62.4667px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>1:45 p.m.</strong></span></td> <td style="width: 84.3663%; height: 62.4667px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>From the Clinic to the Lab: Investigating Mechanisms of Response and Resistance to Immune Checkpoint Therapy <br></strong>Padmanee Sharma, MD, PhD -<em> The University of Texas MD Anderson Cancer Center<br></em></span></td> </tr> <tr style="height: 63.1333px;"> <td style="width: 15.6337%; height: 63.1333px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>2:05 p.m.</strong></span></td> <td style="width: 84.3663%; height: 63.1333px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Defining and Using Immune Archetypes Classify and Treat Cancer<br></strong></span> <div class="ewa-rteLine"><span style="font-size: 12pt;"><span style="color: rgb(0, 0, 0); font-family: Calibri;">Alexis Combes, PhD - </span><em style="color: rgb(0, 0, 0); font-family: Calibri;">University of California, San Francisco</em></span></div> </td> </tr> <tr style="height: 63.1333px;"> <td style="width: 15.6337%; height: 63.1333px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>2:25 p.m.</strong></span></td> <td style="width: 84.3663%; height: 63.1333px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>High-Resolution Profiling of the Tumor Microenvironment with Spatial Ecotypes<br></strong>Aaron Newman, PhD -<em> Stanford University</em><em></em></span></td> </tr> <tr style="height: 63.1333px;"> <td style="width: 15.6337%; height: 63.1333px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>2:45 p.m.</strong></span></td> <td style="width: 84.3663%; height: 63.1333px; vertical-align: top;"> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Tumor Cell Heterogeneity Governs Spatial Organisation of the Tumor Microenvironment</strong></span></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Wolf H. Fridman, MD, PHD -<em> Cordeliers Research Centre</em><em></em></span></p> </td> </tr> <tr style="height: 82px;"> <td style="width: 15.6337%; height: 82px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>3:05 p.m.</strong></span></td> <td style="width: 84.3663%; height: 82px; vertical-align: top;"> <p style="padding: 5px; text-align: left;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong></strong><strong>ImmunoProfile: A Prospective Biomarker Trial Reveals that High Numbers of Intratumoral CD8+ and PD-1+ Lymphocytes Predict Favorable Survival Across Major Cancer Types Independent of Stage and Therapies<br></strong>Scott Rodig, MD, PhD -<em> Harvard Medical School</em><em></em></span></p> </td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>Session Description</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p>In humans, the immune component of the tumor microenvironment is likely shaped over many years. Tumor genetics and epigenetics, host genetics, and a lifetime of acute and chronic environmental exposures likely contribute to the immune composition of the tumor. These factors influence the natural history of the malignancy and its response to all forms of therapy including immune modulation. Recent data suggest that tumor immune microenvironments can be grouped into a limited number of phenotypes which could provide insights into pathogenesis and approaches to treatment. In this session, speakers will describe the spectrum of tumor immune microenvironments as revealed by analyses of histopathology, sequencing, and immune monitoring, characterizing commonalities and site-specific differences as they relate to the primary tumor site and/or site of metastases.</p></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-1 tab-content bg-gray-shadow "><div class="col-md-12 section43"><div class="ContentItemHtml"> <div class="HtmlContent"><h3 style="text-align: center;"><strong>Break</strong></h3> <h4 style="text-align: center;">3:20–3:50 p.m. CST </h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix page-1 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section44"><div class="ContentItemHtml"> <div class="HtmlContent"><div class="schedule-anchor" id="session-107a"></div> <hr style="height: 2px; border-width: 0; color: #f4d301; background-color: #f4d301; max-width: 255px; margin-left: 0px;"> <h3><strong>Concurrent Session 107a: Cellular Therapies/Regulatory/Manufacturing<br></strong></h3> <h4>3:50–5:25 p.m. CST | George R. Brown Convention Center - Level 3 - Hall A3</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-4 section45"><div class="ContentItemHtml"> <div class="HtmlContent"><h4><strong>Co-Chairs: </strong></h4> <p><strong>Chantale Bernatchez, PhD</strong><br><em>Cell Therapy Manufacturing Center </em><span style="font-size: 12pt;"></span></p> <p><span style="font-size: 12pt;"><strong>Patrick Hanley, PhD</strong><em><br>Children's National Hospital<br></em></span></p> <p><span style="font-size: 12pt;"><strong>Raj Puri, MD, PhD</strong><em><br>Iovance Biotheraputics</em></span></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-8 section46"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>View Full Session Schedule</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 416.4px; width: 100%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 71.2px;"> <td style="width: 15.5941%; height: 71.2px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>3:50 p.m.</strong></span></td> <td style="width: 84.4059%; height: 71.2px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Introduction<br></strong>Co-Chair <em> <br></em></span></td> </tr> <tr style="height: 90.4px;"> <td style="width: 15.5941%; height: 90.4px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>3:55 p.m.</strong></span></td> <td style="width: 84.4059%; height: 90.4px; vertical-align: top;"> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>The SITC Release Criteria Summit: Learnings from the Past Decade of Cell Therapy and Insights for a Path Forward</strong></span></p> <div class="ewa-rteLine"><span style="color: rgb(0, 0, 0); font-family: Calibri; font-size: 11pt;">Michael Kalos, PhD - </span><em><span style="font-family: calibri, arial, helvetica, sans-serif;">Next Pillar Consulting</span></em></div> </td> </tr> <tr style="height: 72.2px;"> <td style="width: 15.5941%; height: 72.2px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>4:20 p.m.</strong></span></td> <td style="width: 84.4059%; height: 72.2px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong></strong><strong>Point of Care Manufacturing - You Can Do It, But Do You Want To?<br></strong>Yongping Wang, MD, PhD - <em>Children's Hospital of Philadelphia</em><br><em></em></span></td> </tr> <tr style="height: 71.2px;"> <td style="width: 15.5941%; height: 71.2px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>4:40 p.m.</strong></span></td> <td style="width: 84.4059%; height: 71.2px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Lessons Learned from Successful Development, Manufacturing, and Regulatory Approval of TIL Therapy (AmtagviTM [lifileucel])</strong></span> <div class="ewa-rteLine"><span style="font-size: 12pt;"><span style="color: rgb(0, 0, 0); font-family: Calibri;">Arvind Natarajan, PhD - </span><em style="color: rgb(0, 0, 0); font-family: Calibri;">Iovance Biotherapeutics</em></span></div> <span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><br><em></em></span></td> </tr> <tr style="height: 111.4px;"> <td style="width: 15.5941%; height: 111.4px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>5 p.m.</strong></span></td> <td style="width: 84.4059%; height: 111.4px; vertical-align: top;"> <p style="padding-top: 5px; padding-right: 5px; padding-bottom: 5px; text-align: left;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Panel Discussion</strong></span></p> <div class="ewa-rteLine"> <div class="ewa-rteLine"> <div class="ewa-rteLine"><span style="color: rgb(0, 0, 0); font-family: Calibri; font-size: 12pt;">Chantale Bernatchez, PhD - <em>Cell Therapy Manufacturing Center</em></span></div> <div class="ewa-rteLine"><span style="color: rgb(0, 0, 0); font-family: Calibri; font-size: 12pt;">Patrick Hanley, PhD - <em>Children's National Hospital</em></span></div> <div class="ewa-rteLine"><span style="color: rgb(0, 0, 0); font-family: Calibri; font-size: 12pt;">Raj Puri, MD, PhD -<em> Iovance Biotherapeutics</em></span></div> <span style="font-size: 12pt;"><span style="color: rgb(0, 0, 0); font-family: Calibri;" fontscheme="2">Michael Kalos, PhD - </span><em><span style="font-family: calibri, arial, helvetica, sans-serif;">Next Pillar Consulting</span></em></span></div> <div class="ewa-rteLine"> <div class="ewa-rteLine"><span style="font-size: 12pt;"><span style="color: rgb(0, 0, 0); font-family: Calibri;" fontscheme="2">Yongping Wang, MD, PhD - </span><em fontscheme="2" style="color: rgb(0, 0, 0); font-family: Calibri;">Childrens Hospital of Philadelphia</em><span fontscheme="2" style="color: rgb(0, 0, 0); font-family: Calibri;"> </span></span></div> <div class="ewa-rteLine"> <div class="ewa-rteLine"><span style="font-size: 12pt;"><span style="color: rgb(0, 0, 0); font-family: Calibri;" fontscheme="2">Arvind Natarajan, PhD - </span><em fontscheme="2" style="color: rgb(0, 0, 0); font-family: Calibri;">Iovance Biotherapeutics</em></span></div> </div> </div> <span style="font-size: 12pt;"><span style="color: rgb(0, 0, 0); font-family: Calibri;">Agnes Yeboah, PhD - </span><em style="color: rgb(0, 0, 0); font-family: Calibri;">Bristol Myers Squibb</em></span></div> <div class="ewa-rteLine"> <div class="ewa-rteLine"><span style="font-size: 12pt;"><span style="color: rgb(0, 0, 0); font-family: Calibri;">Mathew Klinker, PhD - </span><em style="color: rgb(0, 0, 0); font-family: Calibri;">U.S. Food and Drug Administration</em></span></div> </div> </td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>Session Description</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p class="paragraph" style="vertical-align: baseline; margin: 0in 0in 8.0pt 0in;"><span class="normaltextrun"><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">Cellular therapies offer great promise as a cancer therapy. They are living biological drugs, and often personalized, which gives them unique properties, characteristics, and great variability. These factors have made adhering to existing regulatory requirements challenging and requires significant collaboration and interactions with the FDA and other health authorities. Commercializing approved cellular therapies requires novel strategies for adoption, patient access, and cost. Though in early stages, new paradigms for manufacturing and delivery of autologous cell therapies, namely point of care manufacturing, have emerged that may reduce cost to manufacture and increase patient access. Collaboration with health authorities is critical for point of care manufacturing to have regulatory success. This session will first provide an update on SITC’s Release Criteria Summit. During the one-day virtual summit, topics include stakeholder feedback, summaries, current state, and future directions identified during the one-day virtual summit. The session will then expand upon some of the concepts discussed during the release criteria summit and we will hear about Iovance Biotherapeutics’s experience with regulatory approval of the first and only FDA-approved T cell therapy for a solid tumor indication. Finally, we will hear about how new manufacturing strategies are being developed to reduce costs and increase access for patients and discussion on regulatory perspectives.</span></span><span data-ccp-props="{"201341983":0,"335559739":160,"335559740":259}"><span class="eop"><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;"> </span></span></span><o:p></o:p></p></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-1 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section47"><div class="ContentItemHtml"> <div class="HtmlContent"><hr style="height: 2px; border-width: 0; color: #f4d301; background-color: #f4d301; max-width: 255px; margin-left: 0px;"> <h3><strong>Concurrent Session 107b: Protein and Cellular Engineering Strategies<br></strong></h3> <h4>3:50–5:25 p.m. CST | George R. Brown Convention Center - Level 3 - General Assembly Theater</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-4 section48"><div class="ContentItemHtml"> <div class="HtmlContent"><h4><strong>Co-Chairs: </strong></h4> <p><span style="font-size: 12pt;"><strong>Marion Alcantara, MD, PhD</strong><br><em>Institut Curie, Paris</em></span><br><span style="font-size: 12pt;"></span></p> <p><span style="font-size: 12pt;"><strong>Cristina Puig-Saus, PhD</strong><br><em>UCLA <br></em></span></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-8 section49"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>View Full Session Schedule</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 383px; width: 99.6381%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 62.8px;"> <td style="width: 15.5797%; height: 62.8px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>3:50p.m.</strong></span></td> <td style="width: 84.4203%; height: 62.8px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Introduction <br></strong>Session Co-Chair <br></span></td> </tr> <tr style="height: 62.8px;"> <td style="width: 15.5797%; height: 62.8px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>3:55 p.m.</strong></span></td> <td style="width: 84.4203%; height: 62.8px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Ex vivo and In vivo CRISPR editing to program T cell function<br></strong>Justin Eyquem, PhD<em> - University of California, San Francisco<br></em></span></td> </tr> <tr style="height: 63.8px;"> <td style="width: 15.5797%; height: 63.8px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>4:15 p.m.</strong></span></td> <td style="width: 84.4203%; height: 63.8px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Cellular Engineering <br></strong>Marcela Maus, MD, PhD - <em>Massachusetts General Hospital</em><br></span></td> </tr> <tr style="height: 62.8px;"> <td style="width: 15.5797%; height: 62.8px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>4:35 p.m.</strong></span></td> <td style="width: 84.4203%; height: 62.8px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Multi-Pronged CAR-T Cell Therapy for Cancer<br></strong>Yvonne Chen, PhD<em> - University of California, Los Angeles<br></em></span></td> </tr> <tr style="height: 83px;"> <td style="width: 15.5797%; height: 83px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>4:55 p.m.</strong></span></td> <td style="width: 84.4203%; height: 83px; vertical-align: top;"> <p style="padding-top: 5px; padding-right: 5px; padding-bottom: 5px; text-align: left;"><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.1369"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(1369) Engineering approaches to exploit MHC-II presentation on lung cancer cells</strong></span></a></p> <p style="padding-top: 5px; padding-right: 5px; padding-bottom: 5px; text-align: left;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Alex M. Jaeger, PhD – <em>Moffitt Cancer Center</em></span></p> </td> </tr> <tr style="height: 52.8px;"> <td style="width: 15.5797%; height: 52.8px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>5:10 p.m.</strong></span></td> <td style="width: 84.4203%; height: 52.8px; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.1125"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(1125) Preclinical development of MT-303, a novel LNP-Formulated GPC3-Specific CAR mRNA, for in vivo programming of monocytes to treat hepatocellular carcinoma</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif;">Matt Maurer, MD – <em>Myeloid Therapeutics</em></span></p> </td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>Session Description</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p>Cell and gene therapies have made a great breakthrough in the immuno-oncology field. Technological advances have created opportunities for genetically engineered immune cells to be “redirected” against tumor cells. As such, chimeric antigen receptor (CAR)-T cells are now part of the routine clinical care for many hematological malignancies, but improvements are still needed. A better understanding of the mechanisms of action and the progress in molecular interventions are paving the way for the development of new generations of cellular immunotherapies. Innovative engineering methods will certainly lead to next-generation cell therapies with enhanced efficacy and/or reduced toxicity, notably for targeting low antigen-expressing tumors and solid cancers. This session will focus on genome and protein engineering strategies to optimize cell therapies for hematological and solid tumors.</p></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-1 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section50"><div class="ContentItemHtml"> <div class="HtmlContent"><hr style="height: 2px; border-width: 0; color: #f4d301; background-color: #f4d301; max-width: 255px; margin-left: 0px;"> <h3><strong>Concurrent Session 107c: Timing and Combination of Systemic Therapies in Solid Cancers<br></strong></h3> <h4>3:50–5:25 p.m. CST | George R. Brown Convention Center - Level 3 - Grand Ballroom A</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-4 section51"><div class="ContentItemHtml"> <div class="HtmlContent"><h4><strong>Co-Chairs: </strong></h4> <p><span style="font-size: 12pt;"><strong>Diwakar Davar, MD</strong><em><br>UPMC Hillman Cancer Center<br><br></em><strong>Sherene Loi, MD, PhD</strong><em><br>Peter MacCallum Cancer Centre<br></em></span></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-8 section52"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>View Full Session Schedule</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 68px; width: 100%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 68px;"> <td style="width: 15.5797%; height: 68px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>3:50 p.m.</strong></span></td> <td style="width: 84.4203%; height: 68px; vertical-align: top;"> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong></strong></span></p> <span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Introduction<br></strong>Co-Chair<em><br></em></span></td> </tr> <tr> <td style="width: 15.5797%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>3:55 p.m.</strong></span></td> <td style="width: 84.4203%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>A Personalized Approach: Neoantigen Vaccines for the Treatment of Solid Tumors<br></strong></span><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Janice M. Mehnert, MD - <em>Perlmutter Cancer Center of NYU Langone Health</em></span></td> </tr> <tr> <td style="width: 15.5797%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>4:15 p.m.</strong></span></td> <td style="width: 84.4203%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Applying Lessons Learned from Melanoma to the Treatment of RCC<br></strong>Mike Atkins, MD, FAIO - <em>Georgetown Lombardi Comprehensive Cancer Center</em></span></td> </tr> <tr> <td style="width: 15.5797%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>4:35 p.m.</strong></span></td> <td style="width: 84.4203%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Framework for Novel Combination Immunotherapy Development Informed by the TME<br></strong>Jason Luke, MD, FACP<em> - UPMC Hillman Cancer Center<br></em></span></td> </tr> <tr> <td style="width: 15.5797%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>4:55 p.m.</strong></span></td> <td style="width: 84.4203%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0603"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(603) Dual TIGIT and PD-1 blockade with domvanalimab plus zimberelimab in hepatocellular carcinoma refractory to anti-PD-1 therapies</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif;">David Hsieh – <em>University of Texas Southwestern</em></span></p> </td> </tr> <tr> <td style="width: 15.5797%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>5:10 p.m.</strong></span></td> <td style="width: 84.4203%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0607"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(607) CONSORTIUM-IO: A phase 1 study evaluating a combination of an 11-strain bacterial consortium (VE800) and nivolumab in treatment of select refractory or metastatic cancers</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif;">Carolina Lyon De Ana, PhD – <em>Vedanta Biosciences</em></span></p> </td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>Session Description</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p>This Session will explore how the underlying biology of combination therapies in solid tumors and how those combinations may change and overcome specific mechanisms of resistance to immune therapy in a spectrum of malignancies. The Session also aims to discuss provocative questions concerning novel combination immunotherapeutic development armed with a deeper biological understanding of how rational combinations and sequences of therapies can overcome specific resistance mechanisms, attendees will be equipped to design effective clinical trials leading to better patient outcomes.</p></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-1 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section53"><div class="ContentItemHtml"> <div class="HtmlContent"><div class="schedule-anchor" id="session-106c"></div> <hr style="height: 2px; border-width: 0; color: #f4d301; background-color: #f4d301; max-width: 255px; margin-left: 0px;"> <h3><strong>Concurrent Session 107d: NK Cells and Innate Immunity<br></strong></h3> <h4>3:50–5:25 p.m. CST | George R. Brown Convention Center - Level 3 - Grand Ballroom B</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-4 section54"><div class="ContentItemHtml"> <div class="HtmlContent"><h4><strong>Co-Chairs: </strong></h4> <p><span style="font-size: 12pt;"><strong>Katy Rezvani, MD, PhD</strong><em><br>The University of Texas MD Anderson Cancer Center<br></em></span></p> <p><span style="font-size: 12pt;"><strong>Eric Vivier, DVM, PhD</strong><em><br>Aix Marseille University<br></em></span></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-8 section55"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>View Full Session Schedule</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 442.265px; width: 100%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 62.9062px;"> <td style="width: 15.6337%; height: 62.9062px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>3:50 p.m.</strong></span></td> <td style="width: 84.3663%; height: 62.9062px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Introduction<br></strong>Co-Chair<em><br></em></span></td> </tr> <tr style="height: 63.4062px;"> <td style="width: 15.6337%; height: 63.4062px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>3:51 p.m.</strong></span></td> <td style="width: 84.3663%; height: 63.4062px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong></strong></span><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Harnessing Innate Immune Receptors in Cancer Immunotherapy<br></strong>Marco Colonna, MD<em> - Washington University School of Medicine, St. Louis </em></span><em><span style="font-family: calibri, arial, helvetica, sans-serif;"><span style="font-size: 16px;"></span></span></em></td> </tr> <tr style="height: 63.4062px;"> <td style="width: 15.6337%; height: 63.4062px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>4:13 p.m.</strong></span></td> <td style="width: 84.3663%; height: 63.4062px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong></strong></span><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>NK Cells: Next Generation Cell Therapies for Cancer<br></strong>Katy Rezvani<span color-m="#000000" font-m="Calibri" size-m="11pt">, MD, PhD –<em> </em></span><span style="font-size: 12pt;"><em>The University of Texas MD Anderson Cancer Center</em></span></span></td> </tr> <tr style="height: 63.4062px;"> <td style="width: 15.6337%; height: 63.4062px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>4:35 p.m.</strong></span></td> <td style="width: 84.3663%; height: 63.4062px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong></strong></span><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Harnessing NK Cells in Cancer Therapies <br></strong>Eric Vivier,<em> </em><span style="font-size: 12pt;"><em>DVM, PhD – Aix Marseille University</em></span></span><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><em> </em></span><em><span style="font-family: calibri, arial, helvetica, sans-serif;"><span style="font-size: 16px;"></span></span></em></td> </tr> <tr style="height: 83.5px;"> <td style="width: 15.6337%; height: 83.5px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif;"><span style="font-size: 16px;"><b>4:57 p.m.</b></span></span></td> <td style="width: 84.3663%; height: 83.5px; vertical-align: top;"> <p style="padding-top: 5px; padding-right: 5px; padding-bottom: 5px; text-align: left;"><span style="font-size: 12pt;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Next-Gen Cytokine Therapies - Systemic Cytokine Drugs that Decouple Tumor Activity from Peripheral Activity</strong></span></span></p> <p style="padding-top: 5px; padding-right: 5px; padding-bottom: 5px; text-align: left;"><span style="font-size: 12pt;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><em>Nicholas Huntington, PhD – Monash University</em></span><em><span style="font-family: calibri, arial, helvetica, sans-serif;"></span></em></span></p> </td> </tr> <tr style="height: 65.1875px;"> <td style="width: 15.6337%; height: 65.1875px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>5:10 p.m.</strong></span></td> <td style="width: 84.3663%; height: 65.1875px; vertical-align: top;"><span style="font-size: 12pt;"><strong style="font-family: calibri, arial, helvetica, sans-serif;">Panel Discussion</strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong></strong><em> </em></span><em><span style="font-family: calibri, arial, helvetica, sans-serif;"></span></em></span></td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>Session Description</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p>Natural Killer (NK) cells and Type 1 Innate Lymphoid Cells (ILCs) play a critical role in the innate immune response by detecting and destroying neoplastic cells independently of prior antigen exposure. Their therapeutic modulation represents an emerging frontier in cancer immunotherapy.</p> <p>In this session at the SITC conference Dr. Marco Colonna will provide a detailed overview of ILCs, highlighting their potential in cancer immunotherapy. Dr. Rezvani will present on the engineering of NK cells, discussing the latest strategies and preclinical evidence that underscore the translation of this strategy to the clinic. Dr. Eric Vivier will present on the application of NK cell multi-specific engagers, focusing on their design, mechanism of action, and their evolving role in the targeted treatment of cancer. Each presentation aims not only to educate but also to encourage dialogue on how these innovations can be best integrated and optimized within current clinical frameworks.</p></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-1 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section56"><div class="ContentItemHtml"> <div class="HtmlContent"><hr style="height: 2px; border-width: 0; color: #f4d301; background-color: #f4d301; max-width: 255px; margin-left: 0px;"> <h3><strong>Concurrent Session 107e: Immune Exclusion<br></strong></h3> <h4>3:50–5:25 p.m. CST | George R. Brown Convention Center - Level 3 - Grand Ballroom C</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-4 section57"><div class="ContentItemHtml"> <div class="HtmlContent"><h4><strong>Co-Chairs: </strong></h4> <p><span style="font-size: 12pt;"><strong>Christine Moussion, PhD</strong><em><br>Genentech<br><br></em><strong>Sara Pai, MD, PhD</strong><em><br>Yale University School of Medicine<br></em></span></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-8 section58"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>View Full Session Schedule</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 278.7px; width: 100%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 62.8px;"> <td style="width: 15.6337%; height: 62.8px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>3:50 p.m.</strong></span></td> <td style="width: 84.3663%; height: 62.8px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Introduction<br></strong><em>Session Co-Chair</em></span></td> </tr> <tr style="height: 23px;"> <td style="width: 15.6337%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>3:55 p.m.</strong></span></td> <td style="width: 84.3663%; height: 23px; vertical-align: top;"> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Debate: Defining Immune Exclusion - Physical v. Functional<br></strong><strong>Physical: </strong>Ellen Pure, PhD - <em>University of Pennsylvania: </em>Argument for Physical Barrier <em><br></em></span></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Functional:</strong> <span style="color: rgb(0, 0, 0); font-family: Calibri;">G. Travis Clifton, MD –</span><em style="color: rgb(0, 0, 0); font-family: Calibri;"> Incendia Therapeutics</em><span style="color: rgb(0, 0, 0); font-family: Calibri;">: Argument for Functional Barrier </span></span></p> </td> </tr> <tr style="height: 40.9px;"> <td style="width: 15.6337%; height: 40.9px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>4:20 p.m.</strong></span></td> <td style="width: 84.3663%; height: 40.9px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Identifying Immunotherapy Targets Using Perturb-map CRISPR Screens<br></strong>Brian Brown, PhD<em> - Mount Sinai</em></span></td> </tr> <tr style="height: 23px;"> <td style="width: 15.6337%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>4:35 p.m.</strong></span></td> <td style="width: 84.3663%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Targeting Cancer-Associated Myofibroblasts to Overcome Anti-Tumor Immune Suppression<br></strong>Akshay Krishnamurty, PhD<em> - Genentech<br></em></span></td> </tr> <tr style="height: 60px;"> <td style="width: 15.6337%; height: 60px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>4:50 p.m.</strong></span></td> <td style="width: 84.3663%; height: 60px; vertical-align: top;"> <p style="padding-top: 5px; padding-right: 5px; padding-bottom: 5px; text-align: left;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.1280"><strong>(1280) Therapeutic administration of an engineered sphingosine-1 phosphate lyase improves CD8 T cell trafficking to tumors and enhances antitumor response</strong></a><em></em></span></p> <p style="padding-top: 5px; padding-right: 5px; padding-bottom: 5px; text-align: left;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Alessandra M. Araujo, PhD – <em>University of Texas at Austin</em></span></p> </td> </tr> <tr> <td style="width: 15.6337%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>5:00 p.m.</strong></span></td> <td style="width: 84.3663%; vertical-align: top;"> <p style="padding-top: 5px; padding-right: 5px; padding-bottom: 5px; text-align: left;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Panel Discussion<br></strong></span></p> </td> </tr> <tr style="height: 23px;"> <td style="width: 15.6337%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>5:20 p.m.</strong></span></td> <td style="width: 84.3663%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Conclusion<br></strong>Session Co-Chair</span></td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>Session Description</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p>The tumor immune microenvironment is a crucial predictor of response to immunotherapy. Tumors infiltrated by activated T cells, a cancer immune phenotype referred to as “immune-inflamed,” are most likely to respond to immune checkpoint blockade. However, approximately one-third of cancer patients have tumors that spatially compartmentalize T cells to the periphery of the tumor, referred to as the “immune-excluded” phenotype, and these tumors have a poor response rate to immunotherapy. The research we will discuss today has the potential to impact the future of immunotherapy, offering novel approaches for improved treatments and outcomes.</p> <p>This session will highlight the latest research defining the cellular and molecular mechanisms of immune exclusion. It will feature an active debate on whether the physical versus the functional barrier prevents immune cell infiltration into the tumors. It will also explore the relevant crosstalk between stromal cells, myeloid cells, and lymphocytes that contributes to the immune-excluded immunophenotype. Based on the identified immune cell crosstalk, novel approaches to overcome immune exclusion will be discussed. The session will combine the perspectives of clinicians, pathologists, and basic science researchers from academia and industry to take a multi-prong approach to overcoming the challenges of immune exclusion.</p></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-1 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section59"><div class="ContentItemHtml"> <div class="HtmlContent"><hr style="height: 2px; border-width: 0; color: #f4d301; background-color: #f4d301; max-width: 255px; margin-left: 0px;"> <h3><strong>Concurrent Session 107f: Focus on Latin American Immuno-Oncology<br></strong></h3> <h4>3:50–5:25 p.m. CST | George R. Brown Convention Center - Level 3 - Meeting Room 332 | <span style="text-decoration: underline;"><span style="color: rgb(100, 167, 11); text-decoration: underline;"><a href="//higherlogicdownload.s3.amazonaws.com/SITCANCER/e16ea3ed-ca86-452e-b5e9-18d717c3857f/UploadedImages/Latin_American_Flyer_-_Early.pdf" title="Latin America Flyer" style="color: rgb(100, 167, 11); text-decoration: underline;">Download Flyer</a></span></span></h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-3 section60"><div class="ContentItemHtml"> <div class="HtmlContent"><h4><strong>Co-Chairs: </strong></h4> <p><span style="font-size: 12pt;"><strong>Nora Sobrevilla, MD</strong><em><br>Instituto Nacional de Cancerologia<br></em><em><strong>Ana Anderson, PhD</strong><br>Harvard Medical School<br></em></span></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-9 section61"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>View Full Session Schedule</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 569.156px; width: 100%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 70.4219px;"> <td style="width: 15.5797%; height: 70.4219px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>3:50 p.m.</strong></span></td> <td style="width: 84.4203%; height: 70.4219px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Introduction<br></strong>Session Chair <br></span></td> </tr> <tr style="height: 71.0938px;"> <td style="width: 15.5797%; height: 71.0938px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>3:53 p.m.</strong></span></td> <td style="width: 84.4203%; height: 71.0938px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Advanced Cancer Immunotherapy: The Center of Molecular Immunology Approach<br></strong>Tania Crombet, MD, PhD<em> - Centre of Molecular Immunology of Havana, Cuba</em></span><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><em><br></em></span></td> </tr> <tr style="height: 75.4219px;"> <td style="width: 15.5797%; vertical-align: top; height: 75.4219px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>4:13 p.m.</strong></span></td> <td style="width: 84.4203%; vertical-align: top; height: 75.4219px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Nuanced Role for Dendritic Cell Intrinsic IRE1 RNase in the Regulation of Antitumor Adaptive Immunity</strong></span> <div class="ewa-rteLine"><span style="color: rgb(0, 0, 0); font-family: Calibri; font-size: 12pt;">Fabiola Osorio, PhD -</span><em style="color: rgb(0, 0, 0); font-family: Calibri; font-size: 12pt;"> University of Chile</em><span style="color: rgb(0, 0, 0); font-family: Calibri; font-size: 12pt;"></span></div> </td> </tr> <tr style="height: 71.0938px;"> <td style="width: 15.5797%; vertical-align: top; height: 71.0938px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>4:33 p.m.</strong></span></td> <td style="width: 84.4203%; vertical-align: top; height: 71.0938px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Neoantigen Identification and Cancer Vaccines<br></strong></span> <div class="ewa-rteLine"><span style="color: rgb(0, 0, 0); font-family: Calibri; font-size: 12pt;">Carlos Alberto Parra-Lopez, MD, PhD -<em> National University of Colombia</em></span></div> </td> </tr> <tr style="height: 64px;"> <td style="width: 15.5797%; height: 64px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>4:53 p.m.</strong></span></td> <td style="width: 84.4203%; height: 64px; vertical-align: top;"> <div class="ewa-rteLine"> <div class="ewa-rteLine"><span style="font-family: calibri, arial, helvetica, sans-serif;"><span style="font-size: 16px;"><b>Networking Break</b></span></span></div> </div> </td> </tr> <tr style="height: 90.312px;"> <td style="width: 15.5797%; vertical-align: top; height: 90.312px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>5:03 p.m.</strong></span></td> <td style="width: 84.4203%; vertical-align: top; height: 90.312px;"> <div class="ewa-rteLine"> <div class="ewa-rteLine"><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.1190"><strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">(1190) Neuromuscular immune-related adverse events and diaphragmatic insufficiency as mortality predictors in immune checkpoint therapy associated myocarditis</span></strong></a></div> <div class="ewa-rteLine"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Keila C. Ostos-Mendoza – <em>The University of Texas MD Anderson Cancer Center</em></span></div> <div class="ewa-rteLine"><span style="color: rgb(255, 255, 255);">s</span></div> </div> </td> </tr> <tr style="height: 63.4062px;"> <td style="width: 15.5797%; vertical-align: top; height: 63.4062px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>5:13 p.m.</strong></span></td> <td style="width: 84.4203%; vertical-align: top; height: 63.4062px;"> <div class="ewa-rteLine"> <div class="ewa-rteLine"><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0947"><strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">(947) Soluble hIL-15/IL-15Rα complex enhances human NK and CD8 cytotoxicity and promotes killing of human melanoma in mice bearing a functional human immune system</span></strong></a></div> <div class="ewa-rteLine"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Flavia M. Ishikawa – <em>District Institute of Science, Biotechnology and Innovation in Health (IDCBIS)</em></span></div> <div class="ewa-rteLine"><span style="font-family: calibri, arial, helvetica, sans-serif;"><span style="font-size: 16px;"><b><span style="font-family: calibri, arial, helvetica, sans-serif;"></span></b></span></span><span style="color: rgb(255, 255, 255);">s</span></div> </div> </td> </tr> <tr style="height: 63.4062px;"> <td style="width: 15.5797%; vertical-align: top; height: 63.4062px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>5:23 p.m.</strong></span></td> <td style="width: 84.4203%; vertical-align: top; height: 63.4062px;"> <div class="ewa-rteLine"> <div class="ewa-rteLine"><span style="font-family: calibri, arial, helvetica, sans-serif;"><span style="font-size: 16px;"><b><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Conclusion<br></strong></span></b><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Session Chair </span></span></span></div> </div> </td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>Session Description</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p>This session will highlight some of the great basic and clinical research in Immuno-Oncology being done by Latin American scientists. One of SITC’s strategic goals is to extend the reach of the Society beyond North America, Europe, and Australia and integrate Latin American clinicians and researchers into our community. This session will feature talks from senior scientists doing basic and clinical research on cancer vaccines, including neoantigen discovery, vaccine development, and combinations with checkpoint inhibitors. The session will also feature short presentations of outstanding selected abstracts.</p></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-1 tab-content bg-gray-shadow "><div class="col-md-12 section62"><div class="ContentItemHtml"> <div class="HtmlContent"><h3 style="text-align: center;"><strong>Poster Reception </strong></h3> <h4 style="text-align: center;">5:30-7 p.m. CST | George R. Brown Convention Center - Level 1 -Exhibit Halls AB</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix page-2 tab-content bg-white-shadow "><div class="col-md-12 section63"><div class="ContentItemHtml"> <div class="HtmlContent"><h2 style="text-align: center;"><strong>Saturday, Nov. 9, 2024</strong></h2> <h3 style="text-align: center;">39<sup>th</sup> Annual Meeting | George R. Brown Convention Center | 7:15 a.m.–8:30 p.m. CST</h3> <p style="text-align: center;"><em>Exhibit Hall open from 9 a.m.–8:30 p.m. Times and program schedules subject to change.</em></p></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix page-2 tab-content session-200 bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section64"><div class="ContentItemHtml"> <div class="HtmlContent"><hr style="height: 2px; border-width: 0; color: #fba61c; background-color: #fba61c; max-width: 130px; margin-left: 0px;"> <h3><strong>Session 200: Business Meeting </strong></h3> <h4>7:15–7:45 a.m. CST | George R. Brown Convention Center - Level 3 - Hall A3</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-4 section65"><div class="ContentItemHtml"> <div class="HtmlContent"><h4><strong>Chair: </strong></h4> <p><strong>Leisha Emens, MD, PhD<br></strong><span style="font-size: 12pt;"><em><span style="font-family: Calibri, sans-serif;">Kaiser Permanente</span></em></span><br><span style="font-size: 12pt;"></span></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-8 section66"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>Session Description</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p class="MsoNormal"><span style="font-size: 12pt; font-family: calibri, arial, helvetica, sans-serif;">Join<strong> </strong>SITC President Leisha Emens, MD, PhD, and SITC Executive Director,<strong> </strong>Mary Dean, JD, CAE, for this annual briefing on Saturday, Nov. 9 from 7:15–7:45 a.m. CST. Dr. Emens and her guests Daniel S. Chen, MD, PhD and Stefani Spranger, PhD, will update you about the strategic direction of the society, including <b>SITC’s Immuno-Engineering Strategic Plan: Engineering a path to 100 novel IO agents</b>. All SITC members are invited to attend!</span><o:p></o:p></p> <p class="MsoNormal"><span style="font-family: 'Calibri', sans-serif; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255);"> </span></p></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-2 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section67"><div class="ContentItemHtml"> <div class="HtmlContent"><hr style="height: 2px; border-width: 0; color: #fba61c; background-color: #fba61c; max-width: 130px; margin-left: 0px;"> <h3><strong>Session 201: Organizer Welcome</strong></h3> <h4>8–8:05 a.m. CT | George R. Brown Convention Center - Level 3 - Hall A3</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-4 section68"><div class="ContentItemHtml"> <div class="HtmlContent"><h4><strong>Chair: </strong></h4> <p><strong>Harriet Kluger, MD<br></strong><em>Yale University</em><br><span style="font-size: 12pt;"><br></span></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-8 section69"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>View Full Session Schedule</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 79px; width: 96.247%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 23px;"> <td style="width: 15.6364%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>8 a.m.</strong></span></td> <td style="width: 84.3636%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Organizer Welcome<br></strong>Harriet Kluger, MD <em>– Yale University<br><br></em></span></td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>Session Description</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p>The official start of the second full day begins with a welcome from one of the Organizers behind the Annual Meeting programming. </p></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-2 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section70"><div class="ContentItemHtml"> <div class="HtmlContent"><div class="schedule-anchor" id="session-202"></div> <hr style="height: 2px; border-width: 0; color: #fba61c; background-color: #fba61c; max-width: 130px; margin-left: 0px;"> <h3><strong>Session 202: Richard V. Smalley Memorial Award and Lectureship<br></strong></h3> <h4>8:05–8:55 a.m. CST | George R. Brown Convention Center - Level 3 - Hall A3</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-4 section71"><div class="ContentItemHtml"> <div class="HtmlContent"><div id="session-203"></div> <h4><strong>Chair: </strong></h4> <p><strong>Leisha Emens, MD, PhD<br></strong><span style="font-size: 12pt;"><em><span style="font-family: Calibri, sans-serif;">Kaiser Permanente</span></em></span><br><span style="font-size: 12pt;"></span></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-8 section72"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>View Full Session Schedule</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 70.016px; width: 100%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 70.016px;"> <td style="width: 15.6337%; height: 70.016px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>8:05 a.m.</strong></span></td> <td style="width: 84.3663%; height: 70.016px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Introduction<br></strong>TBA<br></span></td> </tr> <tr> <td style="width: 15.6337%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>8:10 a.m.</strong></span></td> <td style="width: 84.3663%; vertical-align: top;"> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>The Era of Cancer Vaccines Has Arrived</strong></span></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Elizabeth M. Jaffee, MD, FAIO, FAACR, FACP, FAAAS - <em>Sidney Kimmel Cancer Center at Johns Hopkins </em><br></span></p> </td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>Session Description</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p class="MsoNormal"><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;"><span style="font-family: calibri, arial, helvetica, sans-serif;">Established in 2005, the Richard V. Smalley Memorial Award is presented each year to a luminary in the field that has significantly contributed to the advancement of cancer immunotherapy research. It is the society’s most prestigious award and serves to honor those that have been pioneers in their work and made a notable impact worthy of high regard and recognition by their peers.</span><o:p></o:p></span></p></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-2 tab-content bg-gray-shadow "><div class="col-md-12 section73"><div class="ContentItemHtml"> <div class="HtmlContent"><h3 style="text-align: center;"><strong>Break</strong></h3> <h4 style="text-align: center;">8:55–9:25 a.m. CST </h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix page-2 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section74"><div class="ContentItemHtml"> <div class="HtmlContent"><hr style="height: 2px; border-width: 0; color: #fba61c; background-color: #fba61c; max-width: 130px; margin-left: 0px;"> <div class="schedule-anchor" id="session-203"></div> <h3><strong>Session 203: Genomic Instability: How it Mediates Immunity and Immune Evasion<br></strong></h3> <h4>9:25–11:30 a.m. CST | George R. Brown Convention Center - Level 3 - Hall A3</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-4 section75"><div class="ContentItemHtml"> <div class="HtmlContent"><h4><strong>Co-Chairs: </strong></h4> <p><strong>David A. Braun, MD, PhD</strong><br><em>Yale School of Medicine </em><br><span style="font-size: 12pt;"></span></p> <p><span style="font-size: 12pt;"><strong>Stefani Spranger, PhD </strong><br><em>Koch Institute for Integrative Cancer Research at MIT<br></em></span></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-8 section76"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>View Full Session Schedule</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p></p> <table style="height: 540.4px; width: 100%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 62.8px;"> <td style="width: 15.6337%; height: 62.8px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>9:25 a.m.</strong></span></td> <td style="width: 84.3663%; height: 62.8px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Introduction </strong><br></span></td> </tr> <tr style="height: 62.8px;"> <td style="width: 15.6337%; height: 62.8px; vertical-align: top;"><strong><span style="font-size: 12pt; font-family: calibri, arial, helvetica, sans-serif;">9:30 a.m.</span></strong></td> <td style="width: 84.3663%; height: 62.8px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Immune Evasion Through Suppression of cGAS/STING in Renal Cell Cancer<br></strong>Samra Turajlic, MBBS, PhD - <em>Francis Crick Institute</em><br></span></td> </tr> <tr style="height: 63.8px;"> <td style="width: 15.6337%; height: 63.8px; vertical-align: top;"><strong><span style="font-size: 12pt; font-family: calibri, arial, helvetica, sans-serif;">9:50 a.m.</span></strong></td> <td style="width: 84.3663%; height: 63.8px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.1202">(1202) An NGS-based workflow to estimate allele-specific HLA loss of heterozygosity </a><br></strong>Jieming Chen, PhD – <em>Genentech</em><br></span></td> </tr> <tr style="height: 62.8px;"> <td style="width: 15.6337%; height: 62.8px; vertical-align: top;"><strong><span style="font-size: 12pt; font-family: calibri, arial, helvetica, sans-serif;">10:02 a.m.</span></strong></td> <td style="width: 84.3663%; height: 62.8px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Q&A</strong><em><br></em></span></td> </tr> <tr style="height: 63.8px;"> <td style="width: 15.6337%; height: 63.8px; vertical-align: top;"><strong><span style="font-size: 12pt; font-family: calibri, arial, helvetica, sans-serif;">10:10 a.m.</span></strong></td> <td style="width: 84.3663%; height: 63.8px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Chromosomal Instability as a Mechanism of Immune Evasion </strong></span><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong><br></strong>Samuel Bakhoum, MD, PhD -<em> Volastra Therapeutics<br></em></span></td> </tr> <tr style="height: 62.8px;"> <td style="width: 15.6337%; height: 62.8px; vertical-align: top;"><strong><span style="font-size: 12pt; font-family: calibri, arial, helvetica, sans-serif;">10:30 a.m.</span></strong></td> <td style="width: 84.3663%; height: 62.8px; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0821"><strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">(821) Immune-mediated mechanisms of PARP inhibitor (PARPi) resistance in BRCA1-associated triple negative breast cancer are overcome by addition of CSF-1R inhibition and immune checkpoint blockade</span></strong></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Adam Nelson, PhD –<em> Brigham and Women’s Hospital</em></span></p> </td> </tr> <tr style="height: 40.9px;"> <td style="width: 15.6337%; vertical-align: top; height: 40.9px;"><strong><span style="font-size: 12pt; font-family: calibri, arial, helvetica, sans-serif;">10:42 a.m.</span></strong></td> <td style="width: 84.3663%; vertical-align: top; height: 40.9px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Q&A</strong><br></span></td> </tr> <tr style="height: 39.9px;"> <td style="width: 15.6337%; vertical-align: top; height: 39.9px;"><strong><span style="font-size: 12pt; font-family: calibri, arial, helvetica, sans-serif;">10:50 a.m.</span></strong></td> <td style="width: 84.3663%; vertical-align: top; height: 39.9px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Targeting Chronic Interferon and Inflammatory Memory in Cancer Immunotherapy Resistance<br></strong>Andy Minn, MD, PhD - <em>University of Pennsylvania</em><br></span></td> </tr> <tr style="height: 40.9px;"> <td style="width: 15.6337%; vertical-align: top; height: 40.9px;"><strong><span style="font-size: 12pt; font-family: calibri, arial, helvetica, sans-serif;">11:10 a.m.</span></strong></td> <td style="width: 84.3663%; vertical-align: top; height: 40.9px;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0824"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(824) Defining the determinants of immune response in DNA homologous recombination deficient tumors</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif;">Natalie Vaninov, BA – <em>Icahn School of Medicine at Mount Sinai</em></span></p> </td> </tr> <tr style="height: 39.9px;"> <td style="width: 15.6337%; vertical-align: top; height: 39.9px;"><strong><span style="font-size: 12pt; font-family: calibri, arial, helvetica, sans-serif;">11:22 a.m.</span></strong></td> <td style="width: 84.3663%; vertical-align: top; height: 39.9px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Q&A</strong><br></span></td> </tr> </tbody> </table> <p></p></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>Session Description</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p>Genomic instability is a core feature of cancer evolution, but beyond tumor-intrinsic effects, it can also contribute to pro- or anti-tumor immune responses. Genomic instability leading to DNA damage and mutations increase the potential neoantigen burden and may therefore contribute positively to anti-tumor immunity. By contrast, chromosomal instability may lead to chronic activation of innate and adaptive immune pathways, ultimately mediating immune evasion by tumor cells. This session will focus on the role of understanding chromosomal instability in cancer evolution in the clinic, and then dive into the mechanistic underpinnings of how chromosomal instability and chronic interferon signaling may facilitate immune evasion and resistance to current immunotherapies. </p></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-2 tab-content bg-gray-shadow "><div class="col-md-12 section77"><div class="ContentItemHtml"> <div class="HtmlContent"><h3 style="text-align: center;"><strong>Break</strong></h3> <h4 style="text-align: center;">11:30–11:45 a.m. CST </h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix page-2 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section78"><div class="ContentItemHtml"> <div class="HtmlContent"><div class="schedule-anchor" id="session-204"></div> <hr style="height: 2px; border-width: 0; color: #fba61c; background-color: #fba61c; max-width: 130px; margin-left: 0px;"> <h3><strong>Session 204: <span data-olk-copy-source="MessageBody">Clinical</span> Late-Breaking Abstract Session </strong></h3> <p><span style="font-family: helvetica;"><strong><span style="font-size: 11pt;">The LBA Session will feature Late-Breaking Abstracts- Clinical Only (LBAs) for</span><span style="font-size: 11pt;"> <span lang="EN-GB">abstracts with late-breaking data from interventional clinical trials in humans. For more information about LBAs, click <a href="https://www.sitcancer.org/2024/abstracts/abstract-submission/abstract-lba">here</a>.</span></span></strong></span></p> <h4>11:45 a.m.–12:15 p.m. CST | George R. Brown Convention Center - Level 3 - Hall A3</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-4 section79"><div class="ContentItemHtml"> <div class="HtmlContent"><h4><strong>Chair: </strong></h4> <p><strong>Aurélien Marabelle, MD, PhD <br></strong><em>Gustave Roussy</em></p> <p><strong></strong><span style="font-size: 12pt;"><br></span></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-8 section80"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>View Full Session Schedule</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 79px; width: 96.247%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 23px;"> <td style="width: 15.6364%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>11:45 a.m.</strong></span></td> <td style="width: 84.3636%; height: 23px; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.1470"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(1470) START001: A Phase 1/2 study of Invikafusp alfa (STAR0602), a first-in-class TCR β chain-targeted bispecific antibody, as monotherapy in patients with antigen-rich solid tumors resistant to anti-PD(L)1</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif;">James Gulley, MD, PhD – <em>National Cancer Institute</em></span></p> </td> </tr> <tr> <td style="width: 15.6364%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>12 p.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.1504"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(1504) Primary analysis of the registration-intended cohort of patients with anti–PD-1–failed melanoma from the IGNYTE trial of RP1 plus nivolumab, including clinical subgroup and initial biomarker data</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Michael Wong, MD, PhD, FRCPC – <em>The University of Texas MD Anderson Cancer Center</em></span></p> </td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>Session Description</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p>This 30-minute session will highlight two selected Late-breaking Abstracts who will each showcase their work in a 15-minute oral presentation. </p></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-2 tab-content bg-gray-shadow "><div class="col-md-12 section81"><div class="ContentItemHtml"> <div class="HtmlContent"><h3 style="text-align: center;"><strong>Lunch and Poster Viewing </strong></h3> <h4 style="text-align: center;">12:15–1:45 p.m. CST | George R. Brown Convention Center - Level 1 - Exhibit Halls AB</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix page-2 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section82"><div class="ContentItemHtml"> <div class="HtmlContent"><hr style="height: 2px; border-width: 0; color: #fba61c; background-color: #fba61c; max-width: 130px; margin-left: 0px;"> <h3><strong>Session 205a: Rapid Oral Abstract-Basic </strong></h3> <h4>12:30–1:30 p.m. CST | George R. Brown Convention Center - Level 3 - Grand Ballroom B</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-4 section83"><div class="ContentItemHtml"> <div class="HtmlContent"><h4><strong>Co-Chairs: </strong></h4> <p><strong><span style="font-size: 12pt;">Nicole Scharping, PhD</span></strong><em><span style="font-size: 12pt;"><strong><br></strong>University of California, San Diego<br></span></em></p> <p><span style="font-size: 12pt;"><strong><br>Aleksei Tikhonov, PhD<br></strong><em>Gustave Roussy</em></span></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-8 section84"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>View Full Session Schedule</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 79px; width: 96.247%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 23px;"> <td style="width: 15.6364%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>12:30 p.m.</strong></span></td> <td style="width: 84.3636%; height: 23px; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0896"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(896) VCAM-1+ tumor associated macrophages form perivascular tumor niches and drive resistance to anti-CTLA-4 therapy</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif;">Mehdi Chaib – <em>The University of Texas MD Anderson Cancer Center</em></span></p> </td> </tr> <tr> <td style="width: 15.6364%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>12:38 p.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0259"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(259) Dual-targeted CAR T cells boost antitumor immunity against solid tumors</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Amanda V. Finck, BS –<em> University of Pennsylvania</em></span></p> </td> </tr> <tr> <td style="width: 15.6364%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>12:46 p.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0269"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(269) Preferential targeting of HER2-expressing cancer cells by FT825/ONO-8250, an off-the-shelf iPSCderived CAR-T cell incorporating novel synthetic mechanisms for enhanced solid tumor activity </strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Martin Hosking, PhD – <em>Fate Therapeutics, Inc.</em></span></p> </td> </tr> <tr> <td style="width: 15.6364%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>12:54 p.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Q&A</strong></span></td> </tr> <tr> <td style="width: 15.6364%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>1 p.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0293"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(293) Programming human CAR T cell phenotypes by perturbing key regulators of gene networks</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Sean McCutcheon, PhD –<em> Duke University</em></span></p> </td> </tr> <tr> <td style="width: 15.6364%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>1:08 p.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0826"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(826) A TROP2/Claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer </strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Bogang Wu, PhD – <em>Massachusetts General Hospital</em></span></p> </td> </tr> <tr> <td style="width: 15.6364%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>1:16 p.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.1018"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(1018) Leveraging innate immune sensors to generate durable anti-glioma adaptive immune responses</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Spencer T. Lea – <em>University of Texas MDACC UTHealth GSBS</em></span></p> </td> </tr> <tr> <td style="width: 15.6364%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>1:24 p.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Q&A</strong></span></td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>Session Description</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p>This fast-paced session will feature six oral presentations from select basic science abstracts with time for Q&A. </p></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-2 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section85"><div class="ContentItemHtml"> <div class="HtmlContent"><hr style="height: 2px; border-width: 0; color: #fba61c; background-color: #fba61c; max-width: 130px; margin-left: 0px;"> <h3><strong>Session 205b: Rapid Oral Abstract-Clinical </strong></h3> <h4>12:30–1:30 p.m. CST | George R. Brown Convention Center - Level 3 - Grand Ballroom C</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-4 section86"><div class="ContentItemHtml"> <div class="HtmlContent"><h4><strong>Co-Chairs: </strong></h4> <p><strong><span style="font-size: 12pt;">Golnaz Morad, DDS, PhD</span></strong><em><span style="font-size: 12pt;"><strong><br></strong>The University of Texas MD Anderson Cancer Center<br></span></em></p> <p><span style="font-size: 12pt;"><strong><br>Tanya Keenan, MD, MPH<br></strong><em>Merck</em></span></p> <p></p> <p><span style="font-size: 12pt;"> </span></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-8 section87"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>View Full Session Schedule</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 67px; width: 100%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 67px;"> <td style="width: 15.5941%; height: 67px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>12:30 p.m.</strong></span></td> <td style="width: 84.4059%; height: 67px; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0758"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(758) GLIMMER-01: Phase 1/2 trial of a first-in-class bi-sialidase (E-602) in combination with cemiplimab in patients with PD-(L)1-resistant solid tumors</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif;">Manish R. Sharma, MD – <em>START Center for Cancer Research</em></span></p> </td> </tr> <tr> <td style="width: 15.5941%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>12:38 p.m.</strong></span></td> <td style="width: 84.4059%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0560"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(560) Identification and therapeutic target of myeloid-mediated mechanisms of immunotherapy resistance in prostate cancer</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Aram Lyu, PhD – <em>University of California, San Francisco</em></span></p> </td> </tr> <tr> <td style="width: 15.5941%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>12:46 p.m.</strong></span></td> <td style="width: 84.4059%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0596"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(596) Oncolytic virotherapy combined with Nivolumab elicits complete responses in muscle-invasive bladder cancer in association with the formation of tertiary lymphoid structures</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Roger Li, MD – <em>H. Lee Moffitt Cancer Center</em></span></p> </td> </tr> <tr> <td style="width: 15.5941%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>12:54 p.m.</strong></span></td> <td style="width: 84.4059%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Q&A</strong></span></td> </tr> <tr> <td style="width: 15.5941%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>1 p.m.</strong></span></td> <td style="width: 84.4059%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0661"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(661) Enhanced pharmacology data of next-generation IMA203CD8 TCR-T monotherapy targeting PRAME</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Martin Wermke, MD – Uniklinik Dresden</span></p> </td> </tr> <tr> <td style="width: 15.5941%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>1:08 p.m.</strong></span></td> <td style="width: 84.4059%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.1207"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(1207) Artificial Intelligence-powered assessment of tumor microenvironment in pre-treatment and ontreatment biopsies informs treatment outcomes to pembrolizumab in patients with rare tumors</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Mohamed H. Derbala, MD –<em> The University of Texas MD Anderson Cancer Center</em></span></p> </td> </tr> <tr> <td style="width: 15.5941%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>1:16 p.m.</strong></span></td> <td style="width: 84.4059%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.1242"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(1242) Integrative machine learning for identifying treatment-specific impacts and biomarkers applied to multi-platform data from non-small-cell lung cancer treated with neoadjuvant chemoimmunotherapies</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Stephanie T. Schmidt, PhD – <em>The University of Texas MD Anderson Cancer Center</em></span></p> </td> </tr> <tr> <td style="width: 15.5941%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>1:24 p.m.</strong></span></td> <td style="width: 84.4059%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Q&A</strong></span></td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>Session Description</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p>This fast-paced session will feature six oral presentations from select clinical abstracts with time for Q&A. </p></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-2 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section88"><div class="ContentItemHtml"> <div class="HtmlContent"><div class="schedule-anchor" id="session-206"></div> <hr style="height: 2px; border-width: 0; color: #fba61c; background-color: #fba61c; max-width: 130px; margin-left: 0px;"> <h3><strong>Session 206: Presidential Session </strong></h3> <h4>1:45–3:10 p.m. CST | George R. Brown Convention Center - Level 3 - Hall A3</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-3 section89"><div class="ContentItemHtml"> <div class="HtmlContent"><h4><strong>Chair: </strong></h4> <p><strong>Leisha Emens, MD, PhD<br></strong><span style="font-size: 12pt;"><em><span style="font-family: Calibri, sans-serif;">Kaiser Permanente</span></em></span><strong><br></strong><br><br><span style="font-size: 12pt;"></span></p> <p><span style="font-size: 12pt;"> </span></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-9 section90"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>View Full Session Schedule</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 79px; width: 100%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 79px;"> <td style="width: 15.5941%; height: 79px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>1:45 p.m.</strong></span></td> <td style="width: 84.4059%; height: 79px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Introduction<br></strong>Leisha A. Emens, MD, PhD<br></span></td> </tr> <tr> <td style="width: 15.5941%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>1:50 p.m.</strong></span></td> <td style="width: 84.4059%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0855"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(855) LRIG1 engages ligand VISTA to impede T cell activation and enable tumor immune evasion</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Hieu M. Ta, PhD – <em>Cleveland Clinic Foundation</em></span></p> </td> </tr> <tr> <td style="width: 15.5941%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>2:05 p.m.</strong></span></td> <td style="width: 84.4059%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.1175"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(1175) Deciphering immunotherapy’s challenges: A novel mouse model for immune related adverse events </strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Dipyaman Patra, PhD – <em>University of Pittsburgh</em></span></p> </td> </tr> <tr> <td style="width: 15.5941%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>2:20 p.m.</strong></span></td> <td style="width: 84.4059%; vertical-align: top;"> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Expert Discussant</strong></span></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Thomas F. Gajewski, MD, PhD – <em>University of Chicago</em></span></p> </td> </tr> <tr> <td style="width: 15.5941%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>2:30 p.m.</strong></span></td> <td style="width: 84.4059%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.1253"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(1253) Exercise-induced microbiota vitamin B9 metabolite enhances CD8 T cell antitumor immunity and promotes immunotherapy efficacy</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Catherine Phelps, MS – <em>University of Pittsburgh School of Medicine</em></span></p> </td> </tr> <tr> <td style="width: 15.5941%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>2:45 p.m.</strong></span></td> <td style="width: 84.4059%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.1099"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(1099) Harnessing lymph nodes for polyclonal multipotent T cell therapy in solid tumors</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Tatiana Delgado Cruz, MD – <em>Weill Cornell Medical College</em></span></p> </td> </tr> <tr> <td style="width: 15.5941%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>3 p.m.</strong></span></td> <td style="width: 84.4059%; vertical-align: top;"> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Expert Discussant</strong></span></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Ira Mellman, PhD – <em>Genentech</em></span></p> </td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>Session Description</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p>Join SITC President Leisha Emens, MD, PhD for oral presentations from the top four scoring Young Investigator Award abstract authors. The Presidential Award recipient will be selected following the session and will be announced at the Awards Ceremony that evening at 6:40–7:10 p.m. CT. </p></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-2 tab-content bg-gray-shadow "><div class="col-md-12 section91"><div class="ContentItemHtml"> <div class="HtmlContent"><h3 style="text-align: center;"><strong>Break</strong></h3> <h4 style="text-align: center;">3:10–3:25 p.m. CST </h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix page-2 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section92"><div class="ContentItemHtml"> <div class="HtmlContent"><div class="schedule-anchor" id="session-207a"></div> <hr style="height: 2px; border-width: 0; color: #fba61c; background-color: #fba61c; max-width: 130px; margin-left: 0px;"> <h3><strong>Session 207a: CD4 & Tregs<br></strong></h3> <h4>3:25–4:45 p.m. CST | George R. Brown Convention Center - Level 3 - Hall A3</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-4 section93"><div class="ContentItemHtml"> <div class="HtmlContent"><h4><strong>Co-Chairs: </strong></h4> <p><strong>Lawrence Fong, MD <br></strong><em>Fred Hutchinson Cancer Center</em><br><span style="font-size: 12pt;"><br><strong>Sergio A. Quezada, PhD <br></strong><em>University College London</em><br></span></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-8 section94"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>View Full Session Schedule</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 79px; width: 96.247%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 23px;"> <td style="width: 15.6364%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>3:25 p.m.</strong></span></td> <td style="width: 84.3636%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Role of CD4 T Cells in Tumor Immunology<br></strong>Session Co-Chair<br></span></td> </tr> <tr> <td style="width: 15.6364%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>3:30 p.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Human Neoantigen-Specific CD4 T Cells in the Native Setting and Following Cancer Vaccination<br></strong><span style="color: rgb(0, 0, 0); font-family: Calibri;" fontscheme="2">Cathy Wu, MD - </span><em fontscheme="2" style="color: rgb(0, 0, 0); font-family: Calibri;">Dana-Farber Cancer Institute</em></span></td> </tr> <tr> <td style="width: 15.6364%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>3:50 p.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Targeting Intratumoral Tumor-Specific Regulatory CD4 T Cells</strong><br></span> <div class="ewa-rteLine"><span style="font-size: 12pt;"><span style="color: rgb(0, 0, 0); font-family: Calibri;" fontscheme="2">Aurélien Marabelle, MD, PhD – </span><em fontscheme="2" style="color: rgb(0, 0, 0); font-family: Calibri;">Gustave Roussy </em></span></div> </td> </tr> <tr> <td style="width: 15.6364%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>4:10 p.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Guiding Principles of Clinical Efficacy in Chimeric Antigen Receptor-Redirected Autologous T Cells for Cancer Treatment<br></strong>Joseph Melenhorst, PhD - Cleveland Clinic<br></span></td> </tr> <tr> <td style="width: 15.6364%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>4:30 p.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0493"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(493) Distinct correlative signatures of CD4+ helper and regulatory T cells associate with response to different neoadjuvant immune checkpoint inhibitor combinations in HNSCC</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif;">Matthias Brand, MD – <em>University of Pittsburgh</em></span></p> </td> </tr> </tbody> </table> <p></p></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>Session Description</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p><span style="font-size: 11pt;">Explore the different roles CD4+ T cells play in tumor immunity. Topics will include antigen recognition, regulatory T cells, and the importance of CD4+ CAR T cells.</span></p></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-2 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section95"><div class="ContentItemHtml"> <div class="HtmlContent"><div class="schedule-anchor" id="session-207b"></div> <hr style="height: 2px; border-width: 0; color: #fba61c; background-color: #fba61c; max-width: 130px; margin-left: 0px;"> <h3><strong>Session 207b: Everything but the Cell: Priming Patients for T Cell Administration <br></strong></h3> <h4>3:25-4:45 p.m. CST | George R. Brown Convention Center - Level 3 - General Assembly Theater</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-4 section96"><div class="ContentItemHtml"> <div class="HtmlContent"><h4><strong>Co-Chairs: </strong></h4> <p><strong>Stephanie Goff, MD, FACS <br></strong><em>National Cancer Institute</em><strong> </strong><br><span style="font-size: 12pt;"><strong><br>Marco Ruella, MD<br></strong><em>University of Pennsylvania</em><br></span></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-8 section97"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>View Full Session Schedule</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 261.15px; width: 96.247%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 62.8px;"> <td style="width: 15.6364%; height: 62.8px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>3:25 p.m.</strong></span></td> <td style="width: 84.3636%; height: 62.8px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Countdown to Cells: Lymphodepletion for TIL<br></strong>Stephanie Goff, MD, FACS - <em>National Cancer Institute</em><br></span></td> </tr> <tr style="height: 71.75px;"> <td style="width: 15.6364%; vertical-align: top; height: 71.75px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>3:45 p.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top; height: 71.75px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>The Critical Role of Lymphodepletion before Adoptive CAR T-Cell Immunotherapies</strong></span> <div class="ewa-rteLine"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Marco Ruella, MD - <em>University of Pennsylvania<br></em></span></div> </td> </tr> <tr style="height: 63.8px;"> <td style="width: 15.6364%; vertical-align: top; height: 63.8px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>4:05 p.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top; height: 63.8px;"> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Efficacy of Lymphodepletion in Enhancing Adoptive Cancer Immunotherapy</strong></span></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Chrystal Paulos, PhD - <em>Winship Cancer Institute at Emory University </em></span></p> </td> </tr> <tr style="height: 62.8px;"> <td style="width: 15.6364%; vertical-align: top; height: 62.8px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>4:25 p.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top; height: 62.8px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Novel, Future Strategies for Safer and Effective Lymphodepletion <br></strong>Q&A; Panel Discussion<br></span></td> </tr> </tbody> </table> <p></p></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>Session Description</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p><span style="font-size: 11.0pt; line-height: 107%; font-family: 'Segoe UI',sans-serif; mso-fareast-font-family: Aptos; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;">This session delves into the critical role of lymphodepletion as a preparatory step in adoptive T-cell therapies. The speakers will explore the foundations, current practices, and future directions of lymphodepletion strategies to optimize the efficacy of T-cell administration in cancer treatment. Dr. Goff will provide an insightful overview of lymphodepletion, sharing her extensive experience with tumor-infiltrating lymphocytes (TILs) and early CAR-T. This talk will highlight key clinical outcomes and lessons learned from pioneering treatments at the National Cancer Institute. Dr. Ruella will discuss the specific applications of lymphodepletion in CAR-T and TCR-engineered T-cell therapies. His presentation will cover the practical aspects of patient preparation, focusing on optimizing treatment efficacy and patient safety. Dr. Paulos will delve into the mechanistic insights and the importance of preclinical models in understanding lymphodepletion. Her talk aims to bridge the gap between laboratory findings and clinical applications, providing a robust scientific foundation. Lastly, the panel discussion will explore emerging strategies and innovations designed to enhance the safety and effectiveness of lymphodepletion. The session will examine potential advancements that could revolutionize how patients are prepared for adoptive T-cell therapies. Attendees will gain a comprehensive understanding of the various facets of lymphodepletion, including current techniques, challenges, and innovative approaches on the horizon. This session is designed for clinicians, researchers, and healthcare professionals involved in the field of cancer immunotherapy, offering critical insights that could shape future treatment protocols.</span></p></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-2 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section98"><div class="ContentItemHtml"> <div class="HtmlContent"><hr style="height: 2px; border-width: 0; color: #fba61c; background-color: #fba61c; max-width: 130px; margin-left: 0px;"> <h3><strong>Session 207c: Biomarkers Guiding Design of T Cell Therapies <br></strong></h3> <h4>3:25–4:45 p.m. CST | George R. Brown Convention Center - Level 3 - Grand Ballroom A</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-4 section99"><div class="ContentItemHtml"> <div class="HtmlContent"><h4><strong>Co-Chairs: </strong></h4> <p><strong>James Yang, MD<br></strong><em>The National Cancer Institute</em><strong><br><br>Simon Turcotte, MD, MSc, FRCSC<br></strong><em>Universite de Montreal</em><strong><br></strong><span style="font-size: 12pt;"><br></span></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-8 section100"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>View Full Session Schedule</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 382.578px; width: 96.247%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 62.9062px;"> <td style="width: 15.6364%; height: 62.9062px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>3:25 p.m.</strong></span></td> <td style="width: 84.3636%; height: 62.9062px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Parameters for Success of TIL Therapy<br></strong>George Coukos, MD, PhD<em> - Ludwig Cancer Research Lausanne Branch<br></em></span></td> </tr> <tr style="height: 63.4062px;"> <td style="width: 15.6364%; vertical-align: top; height: 63.4062px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong> 3:45 p.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top; height: 63.4062px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Tumor neoantigen reactivity-selected TIL for the treatment of metastatic gastrointestinal cancers<br></strong><span style="color: rgb(0, 0, 0); font-family: Calibri; font-size: 11pt;" fontscheme="2">Frank Lowery, PhD – </span><em fontscheme="2" style="color: rgb(0, 0, 0); font-family: Calibri; font-size: 11pt;">National Cancer Institute</em><br></span></td> </tr> <tr style="height: 63.4062px;"> <td style="width: 15.6364%; vertical-align: top; height: 63.4062px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong> 4:05 p.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top; height: 63.4062px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Circulating Tumor DNA as an Early Endpoint of Immunotherapy Response <br></strong><em>Valsamo Anagnostou, MD, PhD - Johns Hopkins University</em></span></td> </tr> <tr style="height: 86.3594px;"> <td style="width: 15.6364%; vertical-align: top; height: 86.3594px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong> 4:25 p.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top; height: 86.3594px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0067">(67) <span style="font-size: 12pt; font-family: Calibri, sans-serif;">A 12-chemokine gene expression signature identifies melanomas with heightened tumor infiltrating lymphocytes: A retrospective analysis</span></a><br></strong><span>Daniel Abate-Daga, PhD </span> <span style="font-family: calibri, arial, helvetica, sans-serif;">–</span><em><span style="font-family: calibri, arial, helvetica, sans-serif;"> </span>H. Lee Moffitt Cancer Center & Research Institute</em></span></td> </tr> <tr style="height: 106.5px;"> <td style="width: 15.6364%; vertical-align: top; height: 106.5px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong> 4:35 p.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top; height: 106.5px;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0447"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(447) Clinical factors associated with growth and reactivity of tumor infiltrating lymphocytes for adoptive cell transfer in patients with metastatic epithelial cancers</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif;">Alexandra Gustafson, MD – <em>National Cancer Institute</em></span></p> </td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>Session Description</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p class="MsoNormal"><i>Due to their complexity, designing cell-based immunotherapy trials to integrate with other therapies, be efficiently implemented and then be quickly evaluated for efficacy is difficult. New technologies can assist in these goals. This session looks at how some of those methods can accelerate the identification of tumor from which tumor-reactive T cells can be expanded ex-vivo, the selection of patients more likely to respond, and then provide early endpoints of treatment efficacy. Because the common epithelial cancers result in the vast majority of cancer deaths, the application of these approaches towards tumor infiltrating lymphocyte therapy for these cancers will be highlighted.</i><o:p></o:p></p></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-2 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section101"><div class="ContentItemHtml"> <div class="HtmlContent"><div class="schedule-anchor" id="session-207d"></div> <hr style="height: 2px; border-width: 0; color: #fba61c; background-color: #fba61c; max-width: 130px; margin-left: 0px;"> <h3><strong>Session 207d: Oral Abstract Session </strong></h3> <h4>3:25–4:45 p.m. CST | George R. Brown Convention Center - Level 3 - Grand Ballroom B</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-4 section102"><div class="ContentItemHtml"> <div class="HtmlContent"><h4><strong>Co-Chairs: </strong></h4> <p><strong>Katie Campbell, PhD<br></strong><em>University of California, Los Angeles</em><strong><em><br></em></strong></p> <p><strong>Mathieu Rouanne, MD, PhD<br></strong><em>Columbia University</em><strong><br></strong><br><strong></strong></p> <p></p> <p><span style="font-size: 12pt;"> </span></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-8 section103"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>View Full Session Schedule</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 79px; width: 96.247%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 23px;"> <td style="width: 15.6364%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>3:25 p.m.</strong></span></td> <td style="width: 84.3636%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Introduction<br></strong><br></span></td> </tr> <tr> <td style="width: 15.6364%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>3:29 p.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0591"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(591) In-situ vaccination by tumor treating fields and anti-PD-1 immunotherapy in patients with large residual GBM results in robust T cell selection and expansion, high response rate, and extended survival</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif;">David D. Tran – <em>University of Southern California</em></span></p> </td> </tr> <tr> <td style="width: 15.6364%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>3:44 p.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0620"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(620) HBI-8000, a class I histone deacetylase (HDAC) inhibitor, in combination with nivolumab for treatment of anti-PD(L)1-naive advanced melanoma: final analysis of Study HBI-8000-302</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif;">Nikhil I. Khushalani, MD – <em>Moffitt Cancer Center</em></span></p> </td> </tr> <tr> <td style="width: 15.6364%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>3:59 p.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0780"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(780) Targeting myeloid cells with BO-112 engages T cell immunity in combination with radiotherapy and checkpoint blockade in preclinical models and a phase 1 neoadjuvant clinical trial</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Jie Deng, MD, PhD – <em>University of California, Los Angeles</em></span></p> </td> </tr> <tr> <td style="width: 15.6364%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>4:14 p.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0298"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(298) Therapeutic potential of IMPT-601, a Claudin18.2/TGF-β bispecific CAR, against gastric cancer</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif;">Melanie Munguia – <em>Immpact Bio</em></span></p> </td> </tr> <tr> <td style="width: 15.6364%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>4:29 p.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.1270"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(1270) Sucralose supports microbial dysbiosis and ablates immunotherapy response</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Kristin Morder, MS – <em>University of Pittsburgh</em></span></p> </td> </tr> <tr> <td style="width: 15.6364%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>4:44 p.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Conclusion</strong></span></td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>Session Description</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p>Selected abstracts will be presented in 10-15 minute oral presentations. </p></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-2 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section104"><div class="ContentItemHtml"> <div class="HtmlContent"><hr style="height: 2px; border-width: 0; color: #fba61c; background-color: #fba61c; max-width: 130px; margin-left: 0px;"> <h3><strong>Session 207e: Modulating the Tumor Vasculature to Improve Immunotherapy<br></strong></h3> <h4>3:25–4:45 p.m. CST | George R. Brown Convention Center - Level 3 -Grand Ballroom C</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-3 section105"><div class="ContentItemHtml"> <div class="HtmlContent"><h4><strong>Co-Chairs: </strong></h4> <p><strong>Edda Sciutto, PhD<br></strong><em>Instituto de Investigaciones Biomedicas, Universidad Nacional Autonoma de Mexico</em><strong><br><br>Sabina Signoretti, MD<br></strong><em>Brigham and Women's Hospital</em><strong></strong></p> <p><br><span style="font-size: 12pt;"><br></span></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-9 section106"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>View Full Session Schedule</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 79px; width: 96.247%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 23px;"> <td style="width: 15.6364%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>3:25 p.m.</strong></span></td> <td style="width: 84.3636%; height: 23px; vertical-align: top;"> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Normalizing Lymphatic Vessels to Uncouple Metastasis and Tumor Immune Surveillance</strong></span></p> Amanda Lund, PhD - <em>NYU Grossman School of Medicine</em></td> </tr> <tr> <td style="width: 15.6364%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>3:45 p.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top;"> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Targeting VEGF to Improve Immunotherapy</strong></span></p> <span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Mahrukh Huseni, PhD <strong>- </strong><em>Consultant</em><strong><br></strong></span></td> </tr> <tr> <td style="width: 15.6364%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>4:05 p.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top;"> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Tailoring Vascular Function to Promote Anti-tumor Immunity in Glioma</strong></span></p> <span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Anna Dimberg, MSc, PhD <strong>- </strong><em>Uppsala University</em><strong><br></strong></span></td> </tr> <tr> <td style="width: 15.6364%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>4:25 p.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.1112"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(1112) Sticky T-cells: Engineered T-cells targeting biglycan on tumor endothelial cells enhance infiltration into metastatic tumors</strong></span></a></p> <span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Monish Kumar, PhD – <em>University of Houston</em></span></td> </tr> <tr> <td style="width: 15.6364%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>4:35 p.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0900"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(900) An iron-rich subset of macrophages promotes tumor growth through a Bach1-Ednrb axis</strong></span></a></p> <span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Ian W. Folkert, MD, PhD – <em>The University of Texas MD Anderson Cancer Center</em></span></td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>Session Description</strong><span data-contrast="auto" style="font-size: 11pt; line-height: 17px; font-family: Arial, 'Arial_EmbeddedFont', 'Arial_MSFontService', sans-serif;" xml:lang="EN" lang="EN" class="TextRun SCXW108032399 BCX2"><span class="NormalTextRun SCXW108032399 BCX2" data-ccp-parastyle="HTML Preformatted"></span></span></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><div class="OutlineElement Ltr SCXW108032399 BCX2" style="direction: ltr;"></div> <div class="OutlineElement Ltr SCXW108032399 BCX2" style="direction: ltr;"></div> <div class="OutlineElement Ltr SCXW108032399 BCX2" style="direction: ltr;"> <p class="Paragraph SCXW108032399 BCX2" style="font-weight: normal; font-style: normal; vertical-align: baseline; background-color: transparent; color: windowtext; text-align: left; margin: 0px 0px 10.6667px; padding-left: 0px; padding-right: 0px; text-indent: 0px;" paraid="158146661" paraeid="{61b1d6d6-c82c-4607-b2ea-3a3c90785144}{184}"><span data-contrast="auto" style="font-size: 11pt; line-height: 19.6917px; font-family: Arial, 'Arial_EmbeddedFont', 'Arial_MSFontService', sans-serif;" xml:lang="EN-US" lang="EN-US" class="TextRun SCXW108032399 BCX2"><span class="NormalTextRun SCXW108032399 BCX2">Blood </span><span class="NormalTextRun SCXW108032399 BCX2">and lymphatic </span><span class="NormalTextRun SCXW108032399 BCX2">vessels are essential for </span><span class="NormalTextRun SCXW108032399 BCX2">ox</span><span class="NormalTextRun SCXW108032399 BCX2">y</span><span class="NormalTextRun SCXW108032399 BCX2">gen and nutrient </span><span class="NormalTextRun SCXW108032399 BCX2">delivery</span><span class="NormalTextRun SCXW108032399 BCX2">,</span><span class="NormalTextRun SCXW108032399 BCX2"> </span><span class="NormalTextRun SCXW108032399 BCX2">remov</span><span class="NormalTextRun SCXW108032399 BCX2">al</span><span class="NormalTextRun SCXW108032399 BCX2"> </span><span class="NormalTextRun SCXW108032399 BCX2">of </span><span class="NormalTextRun SCXW108032399 BCX2">waste products</span><span class="NormalTextRun SCXW108032399 BCX2">, and </span><span class="NormalTextRun SCXW108032399 BCX2">control</span><span class="NormalTextRun SCXW108032399 BCX2"> of </span><span class="NormalTextRun SCXW108032399 BCX2">immune responses</span><span class="NormalTextRun SCXW108032399 BCX2"> </span><span class="NormalTextRun SCXW108032399 BCX2">to </span><span class="NormalTextRun SCXW108032399 BCX2">maintain</span><span class="NormalTextRun SCXW108032399 BCX2"> normal tissu</span><span class="NormalTextRun SCXW108032399 BCX2">e</span><span class="NormalTextRun SCXW108032399 BCX2"> homeostasis. The rapid formation of tumor tissues requires </span><span class="NormalTextRun SCXW108032399 BCX2">an</span><span class="NormalTextRun SCXW108032399 BCX2"> accelerated vascularization process that </span><span class="NormalTextRun SCXW108032399 BCX2">leads to </span><span class="NormalTextRun SCXW108032399 BCX2">a dysfunctional blood </span><span class="NormalTextRun SCXW108032399 BCX2">and lymphatic </span><span class="NormalTextRun SCXW108032399 BCX2">vessel network</span><span class="NormalTextRun SCXW108032399 BCX2">. </span><span class="NormalTextRun AdvancedProofingIssueV2Themed SCXW108032399 BCX2">This abnormal tumor vasculature</span><span class="NormalTextRun AdvancedProofingIssueV2Themed SCXW108032399 BCX2"> </span><span class="NormalTextRun AdvancedProofingIssueV2Themed SCXW108032399 BCX2">contributes to the creation of a</span><span class="NormalTextRun AdvancedProofingIssueV2Themed SCXW108032399 BCX2"> </span><span class="NormalTextRun AdvancedProofingIssueV2Themed SCXW108032399 BCX2">hypoxi</span><span class="NormalTextRun AdvancedProofingIssueV2Themed SCXW108032399 BCX2">c</span><span class="NormalTextRun AdvancedProofingIssueV2Themed SCXW108032399 BCX2"> and acid</span><span class="NormalTextRun AdvancedProofingIssueV2Themed SCXW108032399 BCX2">ic </span><span class="NormalTextRun AdvancedProofingIssueV2Themed SCXW108032399 BCX2">tumor microenvironment</span><span class="NormalTextRun AdvancedProofingIssueV2Themed SCXW108032399 BCX2">,</span><span class="NormalTextRun AdvancedProofingIssueV2Themed SCXW108032399 BCX2"> </span><span class="NormalTextRun AdvancedProofingIssueV2Themed SCXW108032399 BCX2">which </span><span class="NormalTextRun AdvancedProofingIssueV2Themed SCXW108032399 BCX2">facilitates</span><span class="NormalTextRun AdvancedProofingIssueV2Themed SCXW108032399 BCX2"> cancer cells</span><span class="NormalTextRun AdvancedProofingIssueV2Themed SCXW108032399 BCX2"> </span><span class="NormalTextRun AdvancedProofingIssueV2Themed SCXW108032399 BCX2">growth </span><span class="NormalTextRun AdvancedProofingIssueV2Themed SCXW108032399 BCX2">and </span><span class="NormalTextRun AdvancedProofingIssueV2Themed SCXW108032399 BCX2">m</span><span class="NormalTextRun AdvancedProofingIssueV2Themed SCXW108032399 BCX2">etasta</span><span class="NormalTextRun AdvancedProofingIssueV2Themed SCXW108032399 BCX2">tic</span><span class="NormalTextRun AdvancedProofingIssueV2Themed SCXW108032399 BCX2"> dissemi</span><span class="NormalTextRun AdvancedProofingIssueV2Themed SCXW108032399 BCX2">nation</span><span class="NormalTextRun AdvancedProofingIssueV2Themed SCXW108032399 BCX2">,</span><span class="NormalTextRun AdvancedProofingIssueV2Themed SCXW108032399 BCX2"> </span><span class="NormalTextRun AdvancedProofingIssueV2Themed SCXW108032399 BCX2">and</span><span class="NormalTextRun AdvancedProofingIssueV2Themed SCXW108032399 BCX2"> also</span><span class="NormalTextRun AdvancedProofingIssueV2Themed SCXW108032399 BCX2"> </span><span class="NormalTextRun AdvancedProofingIssueV2Themed SCXW108032399 BCX2">limits the infiltration of immune cells and their </span><span class="NormalTextRun AdvancedProofingIssueV2Themed SCXW108032399 BCX2">anti-tumor </span><span class="NormalTextRun AdvancedProofingIssueV2Themed SCXW108032399 BCX2">activity</span><span class="NormalTextRun AdvancedProofingIssueV2Themed SCXW108032399 BCX2">.</span><span class="NormalTextRun SCXW108032399 BCX2"> </span></span><span class="EOP SCXW108032399 BCX2" style="font-size: 11pt; line-height: 19.6917px; font-family: Arial, 'Arial_EmbeddedFont', 'Arial_MSFontService', sans-serif;" data-ccp-props="{"201341983":0,"335559739":160,"335559740":278}"> </span></p> </div> <div class="OutlineElement Ltr SCXW108032399 BCX2" style="direction: ltr;"> <p class="Paragraph SCXW108032399 BCX2" style="font-weight: normal; font-style: normal; vertical-align: baseline; background-color: transparent; color: windowtext; text-align: left; margin: 0px 0px 10.6667px; padding-left: 0px; padding-right: 0px; text-indent: 0px;" paraid="500555996" paraeid="{e36403c1-e475-4819-a9dd-6ecd03111437}{53}"><span data-contrast="auto" style="font-size: 11pt; line-height: 19.6917px; font-family: Arial, 'Arial_EmbeddedFont', 'Arial_MSFontService', sans-serif;" xml:lang="EN-US" lang="EN-US" class="TextRun SCXW108032399 BCX2"><span class="NormalTextRun SCXW108032399 BCX2">New approaches</span><span class="NormalTextRun SCXW108032399 BCX2"> aimed at </span><span class="NormalTextRun SCXW108032399 BCX2">modulating</span><span class="NormalTextRun SCXW108032399 BCX2"> the</span><span class="NormalTextRun SCXW108032399 BCX2"> tumor vasculature </span><span class="NormalTextRun SCXW108032399 BCX2">represent </span><span class="NormalTextRun SCXW108032399 BCX2">a promising </span><span class="NormalTextRun SCXW108032399 BCX2">strategy </span><span class="NormalTextRun SCXW108032399 BCX2">to maximize patient response to </span><span class="NormalTextRun SCXW108032399 BCX2">cancer treatment</span><span class="NormalTextRun SCXW108032399 BCX2">s</span><span class="NormalTextRun SCXW108032399 BCX2">. </span><span class="NormalTextRun SCXW108032399 BCX2">This session will </span><span class="NormalTextRun SCXW108032399 BCX2">focus</span><span class="NormalTextRun SCXW108032399 BCX2"> on </span><span class="NormalTextRun SCXW108032399 BCX2">exciting </span><span class="NormalTextRun SCXW108032399 BCX2">findings obtained</span><span class="NormalTextRun SCXW108032399 BCX2"> </span><span class="NormalTextRun SCXW108032399 BCX2">by</span><span class="NormalTextRun SCXW108032399 BCX2"> targeting blood and lymphatic vessels </span><span class="NormalTextRun SCXW108032399 BCX2">to increase the </span><span class="NormalTextRun SCXW108032399 BCX2">efficacy </span><span class="NormalTextRun SCXW108032399 BCX2">of </span><span class="NormalTextRun SCXW108032399 BCX2">immunotherapy in various cancer types</span><span class="NormalTextRun SCXW108032399 BCX2">. </span></span><span class="EOP SCXW108032399 BCX2" style="font-size: 11pt; line-height: 19.6917px; font-family: Arial, 'Arial_EmbeddedFont', 'Arial_MSFontService', sans-serif;" data-ccp-props="{"201341983":0,"335559739":160,"335559740":278}"> </span></p> </div></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-2 tab-content bg-gray-shadow "><div class="col-md-12 section107"><div class="ContentItemHtml"> <div class="HtmlContent"><h3 style="text-align: center;"><strong>Break</strong></h3> <h4 style="text-align: center;">4:45–5:15 p.m. CST </h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix page-2 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section108"><div class="ContentItemHtml"> <div class="HtmlContent"><div class="schedule-anchor" id="session-208a"></div> <hr style="height: 2px; border-width: 0; color: #fba61c; background-color: #fba61c; max-width: 130px; margin-left: 0px;"> <h3><strong>Session 208a: The Yin and Yang of Myeloid Cells<br></strong></h3> <p><strong>This session is co-organized by the Society for Immunotherapy of Cancer (SITC) and The Myeloid Network.</strong></p> <h4>5:15–6:35 p.m. CST | George R. Brown Convention Center - Level 3 - Hall A3</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-4 section109"><div class="ContentItemHtml"> <div class="HtmlContent"><h4><strong>Co-Chairs: </strong></h4> <p><span style="font-size: 12pt;"><strong>Jennifer Guerriero, PhD </strong></span><em><span style="font-size: 12pt;"><strong><br></strong>Brigham and Women's Hospital<br></span></em></p> <p><span style="font-size: 12pt;"><strong><br>Alberto Mantovani, MD <br></strong><em>Instituto Clinico Humanitas<br></em></span></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-8 section110"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>View Full Session Schedule</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 314px; width: 100%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 61.4667px;"> <td style="width: 15.5941%; height: 61.4667px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">5:15 p.m.</span></td> <td style="width: 84.4059%; height: 61.4667px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Molecular and Spatial Control of Tumor-Associated Macrophages</strong><br>Renato Ostuni, PhD - <em>Vita-Salute San Raffaele University</em><br></span></td> </tr> <tr style="height: 63.1333px;"> <td style="width: 15.5941%; vertical-align: top; height: 63.1333px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">5:35 p.m.</span></td> <td style="width: 84.4059%; vertical-align: top; height: 63.1333px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Targeting Pathogenic Myelopoiesis in Cancer</strong><br>Miriam Merad, MD, PhD, FAIO - <em> Icahn School of Medicine at Mount Sinai</em><br></span></td> </tr> <tr style="height: 63.1333px;"> <td style="width: 15.5941%; vertical-align: top; height: 63.1333px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">5:55 p.m.</span></td> <td style="width: 84.4059%; vertical-align: top; height: 63.1333px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Neutrophils: The Power Of Many</strong><br>Lai Guan Ng, PhD -<em> Shanghai Immune Therapy Institute</em><br></span></td> </tr> <tr style="height: 63.1333px;"> <td style="width: 15.5941%; vertical-align: top; height: 63.1333px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">6:15 p.m.</span></td> <td style="width: 84.4059%; vertical-align: top; height: 63.1333px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0893"><strong>(893) Spatiotemporal mapping of melanoma-draining lymph nodes reveals a protective innate alarm system ahead of metastasis</strong></a><br>Katherine Ventre – <em>NYU Langone Health</em><br></span></td> </tr> <tr style="height: 63.1333px;"> <td style="width: 15.5941%; vertical-align: top; height: 63.1333px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">6:25 p.m.</span></td> <td style="width: 84.4059%; vertical-align: top; height: 63.1333px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0902"><strong>(902) Hematopoietic aging promotes cancer by fueling IL-1α-driven emergency myelopoiesis</strong></a><br>Matthew D. Park, PhD – <em>Icahn School of Medicine at Mount Sinai</em><br></span></td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>Session Description</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p>Myeloid cells are a major component of the tumor microenvironment (TME) and can promote tumor progression and resistance to immunotherapy; conversely, they can also contribute to anti-tumor responses. This program will explore the opposing roles (ie the Yin and Yang) of myeloid cells. This program will explore the recent advances in the field including underlying biology and diversity of myeloid cells, myeloid signaling pathways, regulation of myeloid cells and therapeutic approaches to target myeloid cells in immuno-oncology. The session aims to bring the field together to educate and promote myeloid cell targeting with the overall goal of making the TME more permissive and expanding tumor specific T cells. This session is relevant to basic, translational, and clinical researchers and physicians and will provide an overview of the diversity, functions and therapeutic targeting of myeloid cells in cancer. </p></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-2 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section111"><div class="ContentItemHtml"> <div class="HtmlContent"><hr style="height: 2px; border-width: 0; color: #fba61c; background-color: #fba61c; max-width: 130px; margin-left: 0px;"> <h3 id="208b"><strong>Session 208b: Cellular Therapies - Financial Toxicities, Access to Care <br></strong></h3> <h4>5:15–6:35 p.m. CST | George R. Brown Convention Center - Level 3 - Grand Ballroom B</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-4 section112"><div class="ContentItemHtml"> <div class="HtmlContent"><h4><strong>Co-Chairs: </strong></h4> <p><strong>Nirav Shah, MD, MSHP <br></strong><em>Medical College of Wisconsin</em><br><span style="font-size: 12pt;"><br><strong>Anna Sureda, MD, PhD<br></strong><em>Barcelona Hematology Institute<br></em></span></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-8 section113"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>View Full Session Schedule</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 313.531px; width: 101.112%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 59.9062px;"> <td style="width: 15.6888%; height: 59.9062px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>5:15 p.m.</strong></span></td> <td style="width: 84.3594%; height: 59.9062px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Financial Toxicity of CART Cell Therapies-A Threat to Access and Quality of Care<br></strong><span style="line-height: 107%; font-family: Calibri, sans-serif;"><span style="font-family: calibri, arial, helvetica, sans-serif;">Nandita Khera, MD, M.P.H</span></span><em><span style="line-height: 107%; font-family: Calibri, sans-serif;"><span style="font-family: calibri, arial, helvetica, sans-serif;"> - Mayo Clinic</span></span> <br></em></span></td> </tr> <tr style="height: 63.4062px;"> <td style="width: 15.6888%; vertical-align: top; height: 63.4062px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>5:35 p.m.</strong></span></td> <td style="width: 84.3594%; vertical-align: top; height: 63.4062px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong><span style="font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-font-kerning: 0pt; mso-ligatures: none; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Improving Accessibility of CAR-T Cell Therapy through Alternative Manufacturing Models<br></span></span></strong><span style="font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-font-kerning: 0pt; mso-ligatures: none; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><span style="line-height: 107%; font-family: Calibri, sans-serif;"><span style="font-family: calibri, arial, helvetica, sans-serif;">Nirav Shah, MD -<em> Medical College of Wisconsin</em></span></span></span></span><strong><span style="font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-font-kerning: 0pt; mso-ligatures: none; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><em> </em></span></span></strong></span></td> </tr> <tr style="height: 63.4062px;"> <td style="width: 15.6888%; vertical-align: top; height: 63.4062px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>5:55 p.m.</strong></span></td> <td style="width: 84.3594%; vertical-align: top; height: 63.4062px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong><span style="line-height: 107%; font-family: Calibri, sans-serif;"><span style="font-family: calibri, arial, helvetica, sans-serif;"><span style="line-height: 107%; font-family: Calibri, sans-serif;"></span></span></span></strong><strong>Disparities in Access to CAR T-Cell Therapies<br></strong><span style="line-height: 107%; font-family: Calibri, sans-serif;"><span style="font-family: calibri, arial, helvetica, sans-serif;">Anurekha Hall, MD, MS </span></span><em><span style="line-height: 107%; font-family: Calibri, sans-serif;"><span style="font-family: calibri, arial, helvetica, sans-serif;">– Seattle Childrens </span></span> </em><span style="line-height: 107%; font-family: Calibri, sans-serif;"><span style="font-family: calibri, arial, helvetica, sans-serif;"><span style="line-height: 107%; font-family: Calibri, sans-serif;"><span style="font-family: calibri, arial, helvetica, sans-serif;"><em></em></span></span></span></span></span></td> </tr> <tr style="height: 63.4062px;"> <td style="width: 15.6888%; vertical-align: top; height: 63.4062px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>6:15 p.m.</strong></span></td> <td style="width: 84.3594%; vertical-align: top; height: 63.4062px;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0589"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(589) BASECAMP-1 is an efficient pre-screening study that identifies patients with HLA LOH and provides mutational, RNA-Seq, and microbiome data for precision logic-gated CAR T therapeutic trials</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif;">Julian R. Molina, MD, PhD – <em>Mayo Clinic</em></span></p> </td> </tr> <tr style="height: 63.4062px;"> <td style="width: 15.6888%; vertical-align: top; height: 63.4062px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>6:25 p.m.</strong></span></td> <td style="width: 84.3594%; vertical-align: top; height: 63.4062px;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.1352"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(1352) Impact of timing of real-world CT imaging on cost-effectiveness of a molecular biomarker for treatment response monitoring of immunotherapy</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Zachary Rivers, PharmD, PhD – <em>Tempus AI</em></span></p> </td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>Session Description</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p class="MsoNormal">This session will explore various aspects of CAR-T and their impact on patients. First we will evaluate the financial toxicities to the patients and its potential harms with cellular therapies. Next we will discuss alternative models of cell therapy manufacturing and how it may increase accessibility to these products to different populations and its global implications. Lastly, we will review the role of disparities and how they impact access to care.<o:p></o:p></p></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-2 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section114"><div class="ContentItemHtml"> <div class="HtmlContent"><hr style="height: 2px; border-width: 0; color: #fba61c; background-color: #fba61c; max-width: 130px; margin-left: 0px;"> <h3><strong>Session 208c: Evolution of Predictive Biomarkers in Immunotherapy: From Current State to Future Frontiers <br></strong></h3> <h4>5:15–6:35 p.m. CST | George R. Brown Convention Center - Level 3 - Grand Ballroom C</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-4 section115"><div class="ContentItemHtml"> <div class="HtmlContent"><h4><strong>Co-Chairs: </strong></h4> <p><strong>Alessio Cortellini, MD, PhD<br></strong><span style="font-family: helvetica;"><em><span style="font-size: 12pt;"><span style="color: rgb(0, 0, 0);">Fondazione Policlinico Campus Bio-Medico & Campus Bio-Medico University & Department of Surgery and Cancer, Imperial College London</span> </span></em> </span> <strong> </strong><br><span style="font-size: 12pt;"><br></span></p> <p><span style="font-size: 12pt;"><strong>Kerry L. Reynolds, MD<br></strong><em>Massachusetts General Hospital </em><br></span></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-8 section116"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>View Full Session Schedule</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 79px; width: 96.247%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 23px;"> <td style="width: 15.6364%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>5:15 p.m.</strong></span></td> <td style="width: 84.3636%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Biomarkers for Immunotherapy: Where Are We Now?<br></strong>Douglas Johnson, MD, MSCI – <em>Vanderbilt University Medical Center</em><br></span></td> </tr> <tr> <td style="width: 15.6364%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>5:27 p.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Leveraging Novel Omics Approaches for Immuno Oncology Biomarkers to Optimize Patient Selection <br></strong><span style="line-height: 107%; font-family: Calibri, sans-serif;"><span style="font-family: calibri, arial, helvetica, sans-serif;">Abdul Rafeh Naqash, MD </span></span><em><span style="line-height: 107%; font-family: Calibri, sans-serif;"><span style="font-family: calibri, arial, helvetica, sans-serif;">- </span></span>University of Oklahoma Medical Center</em><strong><br></strong></span></td> </tr> <tr> <td style="width: 15.6364%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>5:39 p.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong> Germline Status as Biomarkers for irAEs<br></strong><span style="line-height: 107%; font-family: Calibri, sans-serif;"><span style="font-family: calibri, arial, helvetica, sans-serif;">Pauline Funchain, MD </span></span><em><span style="line-height: 107%; font-family: Calibri, sans-serif;"><span style="font-family: calibri, arial, helvetica, sans-serif;">- Stanford</span></span></em><strong><em> </em></strong><em>University</em><strong><em><br></em></strong></span></td> </tr> <tr> <td style="width: 15.6364%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>5:51 p.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong> Advancing Immunotherapy: Model Systems in Drug Development<br></strong><span style="line-height: 107%; font-family: Calibri, sans-serif;"><span style="font-family: calibri, arial, helvetica, sans-serif;">Russel Jenkins, MD, PhD</span></span><em><span style="line-height: 107%; font-family: Calibri, sans-serif;"><span style="font-family: calibri, arial, helvetica, sans-serif;"> - Massachusetts General Hospital</span></span></em></span></td> </tr> <tr> <td style="width: 15.6364%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>6:03 p.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0030"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(30) Key learnings from BDC-1001 phase 1 FIH dose escalation trial inform next-generation ISACs</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif;">Jason Ptacek, PhD – <em>Bolt Biotherapeutics</em></span></p> </td> </tr> <tr> <td style="width: 15.6364%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>6:13 p.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0476"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(476) The skin microbiome in immune-related cutaneous adverse events (ircAE) differs from that of patients without ircAE</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif;">Lukas Kraehenbuehl, MD – <em>University Hospital Zurich</em></span></p> </td> </tr> <tr> <td style="width: 15.6364%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>6:23 p.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top;"> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong> Panel Discussion - Q&A<br></strong><br></span></p> </td> </tr> </tbody> </table> <p></p></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>Session Description</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p>This session will provide a comprehensive overview of the evolving role of predictive biomarkers in immunotherapy, focusing on both current advancements and future directions. The discussion will begin with an exploration of the integration of predictive biomarkers in immuno-oncology, covering the latest state-of-the-art developments and their clinical implications. Following this, the session will delve into the use of novel omics biomarkers to enhance patient selection, including insights into cutting-edge techniques such as spatial transcriptomics. The session will also address the critical issue of biomarkers for immune-related adverse events, examining their current state and the potential impplications for clinical practice. Finally, the session will explore how model systems in drug development can drive advancements in immunotherapy. Through these discussions, attendees will gain a deeper understanding of the dynamic landscape of predictive biomarkers in immunotherapy, equipping them with the knowledge to address current challenges and seize future opportunities.</p></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-2 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section117"><div class="ContentItemHtml"> <div class="HtmlContent"><div class="schedule-anchor" id="session-208d"></div> <hr style="height: 2px; border-width: 0; color: #fba61c; background-color: #fba61c; max-width: 130px; margin-left: 0px;"> <h3><strong>Session 208d: CAR-T cells vs T-cell engaging bispecifics in Hematological Malignancies<br></strong></h3> <p><strong>This session is co-organized by the Society for Immunotherapy of Cancer (SITC) and American Society of Hematology (ASH).</strong></p> <h4>5:15–6:35 p.m. CST | George R. Brown Convention Center - Level 3 - Grand Ballroom A</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-3 section118"><div class="ContentItemHtml"> <div class="HtmlContent"><h4><strong>Co-Chairs: </strong></h4> <p><strong>Natalie Grover, MD<br></strong><em>University of North Carolina</em><strong> </strong></p> <p><strong> </strong><br><strong><span style="font-size: 12pt;">Aurélien Marabelle, MD, PhD<br></span></strong><em><span style="font-size: 12pt;">Gustave Roussy, France</span></em></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-9 section119"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>View Full Session Schedule</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 79px; width: 96.247%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 23px;"> <td style="width: 15.6858%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>5:15 p.m.</strong></span></td> <td style="width: 84.3268%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Evaluating Infection Risk with CART Cell Therapy and Bispecific Antibodies for Myeloma <br></strong><span style="line-height: 107%; font-family: Calibri, sans-serif;"><span style="font-family: calibri, arial, helvetica, sans-serif;">Meera Mohan, MD, MS, FACP</span></span><em><span style="line-height: 107%; font-family: Calibri, sans-serif;"><span style="font-family: calibri, arial, helvetica, sans-serif;"> - Medical College of Wisconsin</span></span> </em><br></span></td> </tr> <tr> <td style="width: 15.6858%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>5:35 p.m.</strong></span></td> <td style="width: 84.3268%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0267"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(267) Strategic optimization of BCMA and GPRC5D dual-targeted CAR T cells for heterogeneous multiple myeloma </strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Sarah Johnson, PhD, MBA – <em>Oricell Therapeutics</em></span></p> </td> </tr> <tr> <td style="width: 15.6858%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>5:45 p.m.</strong></span></td> <td style="width: 84.3268%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0231"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(231) Infectious complications in patients with hematologic malignancies receiving CD19 vs. BCMA targeted CAR-T Therapy</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif;">Muhammad Bilal Abid, MD, MS, FACP – <em>UT Houston McGovern School of Medicine</em></span></p> </td> </tr> <tr> <td style="width: 15.6858%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>5:55 p.m.</strong></span></td> <td style="width: 84.3268%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>CAR T vs Bispecifics: Clinical Implications and Future Directions<br></strong><span style="line-height: 107%; font-family: Calibri, sans-serif;"><span style="font-family: calibri, arial, helvetica, sans-serif;">Jason Westin, MD</span></span><em><span style="line-height: 107%; font-family: Calibri, sans-serif;"><span style="font-family: calibri, arial, helvetica, sans-serif;"> – The University of Texas MD Anderson Cancer Center</span></span></em></span></td> </tr> <tr> <td style="width: 15.6858%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>6:15 p.m.</strong></span></td> <td style="width: 84.3268%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0244"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(244) A Phase 1 study of novel transposon-Based BAFF CAR-T cells (LMY-920) for treatment of relapsed or refractory non-hodgkin lymphoma (NHL) </strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif;">Matthew A. Spear, MD – <span style="color: rgb(0, 0, 0); font-family: Calibri; font-size: 11pt;" fontscheme="2"></span><span style="font-size: 12pt;"><em fontscheme="2" style="color: rgb(0, 0, 0); font-family: Calibri;">Luminary Therapeutics</em></span></span></p> </td> </tr> <tr> <td style="width: 15.6858%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>6:25 p.m.</strong></span></td> <td style="width: 84.3268%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.1137"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(1137) EVOLVE205, a highly potent 2:1 CD20-targeted CD2 co-stimulatory T cell engager engineered for the treatment of B cell malignancies and B cell autoimmune diseases </strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif;">Afsana Sabrin, PhD – <em>EvolveImmune Therapeutics</em></span></p> </td> </tr> </tbody> </table> <p></p></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>Session Description</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p>Join our session to explore the latest advancements in CAR-T cells and bispecific T-cell engagers for the treatment of hematological malignancies. Discover the unique advantages, challenges, and opportunities of these novel therapies in revolutionizing patient outcomes. Learn about the current innovation in cell therapy and drug design but also the specific adverse events of such constructs. Don't miss this opportunity to gain insights from leading experts in the field and to access the latest advances from selected SITC abstracts.</p></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-2 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section120"><div class="ContentItemHtml"> <div class="HtmlContent"><div class="schedule-anchor" id="session-208e"></div> <hr style="height: 2px; border-width: 0; color: #fba61c; background-color: #fba61c; max-width: 130px; margin-left: 0px;"> <h3><strong>Session 208e: Oral Abstract Session </strong></h3> <h4>5:15–6:35 p.m. CST | George R. Brown Convention Center - Level 3 -General Assembly Theater</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-4 section121"><div class="ContentItemHtml"> <div class="HtmlContent"><h4><strong>Co-Chairs: </strong></h4> <p><strong>Sandra Susanibar, MD<br></strong><em>University of Pennsylvania</em><strong> </strong></p> <p><strong> </strong><br><strong>Anusha Kalbasi, MD<br></strong><em>Stanford</em></p> <p><br><span style="font-size: 12pt;"><br></span></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-8 section122"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>View Full Session Schedule</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 79px; width: 96.247%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 23px;"> <td style="width: 15.6364%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>5:15 p.m.</strong></span></td> <td style="width: 84.3636%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Introduction<br></strong><br></span></td> </tr> <tr> <td style="width: 15.6364%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>5:19 p.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.1096"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(1096) Microbial metabolite-derived oral prodrug reprograms T cell metabolism and improves cancer immunotherapy </strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Youngseok Cho, PharmD, PhD –<em> University of Michigan</em></span></p> </td> </tr> <tr> <td style="width: 15.6364%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>5:34 p.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.1127"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(1127) Virus nanoparticle intratumoral vaccines for HER2+ malignancies </strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Miguel A. Moreno-Gonzalez – <em>University of California, San Diego</em></span></p> </td> </tr> <tr> <td style="width: 15.6364%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>5:49 p.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.1156"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(1156) Small circular RNA vaccines for combination cancer immunotherapy</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Guizhi Zhu, PhD – <em>University of Michigan</em></span></p> </td> </tr> <tr> <td style="width: 15.6364%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>6:04 p.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.1232"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(1232) Decoding the immunologic networks of the AML marrow microenvironment using CODEX </strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Cameron Park, MS –<em> Columbia University</em></span></p> </td> </tr> <tr> <td style="width: 15.6364%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>6:19 p.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.1419"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(1419) An anti-CXCL1/2/3/5 antibody breaks cancer-stroma paracrine network links and improve microenvironment beneficial for tumor growth </strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Akiko Yoshioka, MS –<em> Chiome Bioscience Inc.</em></span></p> </td> </tr> <tr> <td style="width: 15.6364%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>6:34 p.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Conclusion</strong></span></td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>Session Description</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p>Selected abstracts will be presented in 10-15 minute oral presentations. </p></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-2 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section123"><div class="ContentItemHtml"> <div class="HtmlContent"><hr style="height: 2px; border-width: 0; color: #fba61c; background-color: #fba61c; max-width: 130px; margin-left: 0px;"> <h3><strong>Session 209: Awards Ceremony</strong></h3> <h4>6:40–7:10 p.m. CST | George R. Brown Convention Center - Level 3 - Hall A3</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-3 section124"><div class="ContentItemHtml"> <div class="HtmlContent"><h4><strong>Chair: </strong></h4> <p><strong>Leisha Emens, MD, PhD<br></strong><span style="font-size: 12pt;"><em><span style="font-family: Calibri, sans-serif;">Kaiser Permanente</span></em></span><strong><br></strong><br><br><span style="font-size: 12pt;"></span></p> <p><span style="font-size: 12pt;"> </span></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-9 section125"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>View Full Session Schedule</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 122px; width: 100%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 62.8px;"> <td style="width: 15.5941%; height: 62.8px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>6:40 p.m.</strong></span></td> <td style="width: 84.4059%; height: 62.8px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Introduction<br></strong>Leisha Emens, MD, PhD <br></span></td> </tr> <tr style="height: 59.2px;"> <td style="width: 15.5941%; vertical-align: top; height: 59.2px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>6:45 p.m.</strong></span></td> <td style="width: 84.4059%; vertical-align: top; height: 59.2px;"> <p><strong><span style="font-family: calibri, arial, helvetica, sans-serif;">Award Recognition</span></strong></p> <p><strong><span style="font-family: calibri, arial, helvetica, sans-serif;">• Connect-a-Colleague Top Referrer </span></strong></p> <p><strong><span style="font-family: calibri, arial, helvetica, sans-serif;">• JITC Best Paper Awards </span></strong></p> <p><strong><span style="font-family: calibri, arial, helvetica, sans-serif;">• JITC Peer Review Mentorship Program Class of 2024 Graduates </span></strong></p> <p><strong><span style="font-family: calibri, arial, helvetica, sans-serif;">• Young Investigator Awards </span></strong></p> <p><strong><span style="font-family: calibri, arial, helvetica, sans-serif;">• Martin "Mac" Cheever Excellence in Clinical Trial Design - Travel Award </span></strong></p> <p><strong><span style="font-family: calibri, arial, helvetica, sans-serif;">• SITC Fellowship Recipients </span></strong></p> <p><strong><span style="font-family: calibri, arial, helvetica, sans-serif;">• Sparkathon Class of 2024 Recognition </span></strong></p> <p><strong><span style="font-family: calibri, arial, helvetica, sans-serif;">• Presidential Travel Awards </span></strong></p> <p><strong><span style="font-family: calibri, arial, helvetica, sans-serif;">• Presidential Award </span></strong></p> </td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>Session Description</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p>TBA</p></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-2 tab-content bg-gray-shadow "><div class="col-md-12 section126"><div class="ContentItemHtml"> <div class="HtmlContent"><h3 style="text-align: center;"><strong>Poster Reception </strong></h3> <h4 style="text-align: center;">7:10-8:30 p.m. CST | George R. Brown Convention Center - Level 1 - Exhibit Halls AB</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix page-2 tab-content bg-gray-shadow "><div class="col-md-12 section127"><div class="ContentItemHtml"> <div class="HtmlContent"><h3 style="text-align: center;"><strong>The CheckPoints Party </strong></h3> <h4 style="text-align: center;">8:30 p.m.-Midnight CST | Marriott Marquis - Level 2 - Houston Ballroom</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix page-3 tab-content bg-white-shadow "><div class="col-md-12 section128"><div class="ContentItemHtml"> <div class="HtmlContent"><h2 style="text-align: center;"><strong>Sunday, Nov. 10, 2024</strong></h2> <h3 style="text-align: center;">39<sup>th</sup> Annual Meeting | George R. Brown Convention Center | <span style="background-color: rgb(255, 255, 255);"> 8:15 a.m.–12:35 p.m. CST</span></h3> <p style="text-align: center;"><em>Times and program schedules subject to change.</em></p></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix page-3 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section129"><div class="ContentItemHtml"> <div class="HtmlContent"><hr style="height: 2px; border-width: 0; color: #fba61c; background-color: #fba61c; max-width: 130px; margin-left: 0px;"> <h3><strong>Session 300: Organizer Welcome </strong></h3> <h4>8:15–8:20 a.m. CST | George R. Brown Convention Center - Level 3 - Hall A3</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-4 section130"><div class="ContentItemHtml"> <div class="HtmlContent"><h4><strong>Chair: </strong></h4> <p><strong>Miriam Merad, MD, PhD<br></strong><em>Icahn School of Medicine at Mount Sinai</em><br><span style="font-size: 12pt;"><br></span></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-8 section131"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>View Full Session Schedule</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 79px; width: 96.247%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 23px;"> <td style="width: 15.6364%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>8:15 a.m.</strong></span></td> <td style="width: 84.3636%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Organizer Welcome<br></strong>Miriam Merad, MD, PhD -<em> Icahn School of Medicine at Mount Sinai</em><br></span></td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>Session Description</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p>The official start of the last day begins with a welcome from one of the Organizers behind the Annual Meeting programming</p></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-3 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section132"><div class="ContentItemHtml"> <div class="HtmlContent"><div class="schedule-anchor" id="session-301"></div> <hr style="height: 2px; border-width: 0; color: #fba61c; background-color: #fba61c; max-width: 130px; margin-left: 0px;"> <h3><strong>Session 301: Thomas Waldmann Memorial Plenary Session: Understanding Response and Resistance – Lessons from Patient Samples<br></strong></h3> <h4>8:20–10:30 a.m. CST | George R. Brown Convention Center - Level 3 - Hall A3</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-4 section133"><div class="ContentItemHtml"> <div class="HtmlContent"><h4><strong>Co-Chairs: </strong></h4> <p><strong>Antoni Ribas, MD, PhD<br></strong><em>University of California, Los Angeles</em><br><span style="font-size: 12pt;"><br><strong>Catherine Wu, MD<br></strong><em>Dana-Farber Cancer Institute</em><br><br></span></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-8 section134"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>View Full Session Schedule</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 440.7px; width: 96.247%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 60.9px;"> <td style="width: 15.6364%; height: 60.9px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>8:20 a.m.</strong></span></td> <td style="width: 84.3636%; height: 60.9px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Introduction<br></strong>Co-Chair<br></span></td> </tr> <tr style="height: 62.8px;"> <td style="width: 15.6364%; vertical-align: top; height: 62.8px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>8:25 a.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top; height: 62.8px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong></strong><strong>Spatially Organized Immune Hubs in Colon Cancer<br></strong>Karin Pelka, PhD – <em>Gladstone Institutes </em><br></span></td> </tr> <tr style="height: 63.8px;"> <td style="width: 15.6364%; vertical-align: top; height: 63.8px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>8:55 a.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top; height: 63.8px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong></strong><strong>Contextualizing Tumor Biomarkers in the Anti-PD-1-Refractory Setting<br></strong>Katie Campbell, PhD - <em>University of California, Los Angeles</em><br><em></em></span></td> </tr> <tr style="height: 62.8px;"> <td style="width: 15.6364%; vertical-align: top; height: 62.8px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>9:25 a.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top; height: 62.8px;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0077"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(77) Predicting the tumor microenvironment molecular composition to assess immunotherapy efficacy in non-small cell lung cancer from digital histopathology images</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif;">Alex Chen, MS – <em>National Cancer Institute</em></span></p> </td> </tr> <tr style="height: 63.8px;"> <td style="width: 15.6364%; vertical-align: top; height: 63.8px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>9:40 a.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top; height: 63.8px;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0209"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(209) Spatial multi-omics reveal humoral immunity niches associated with tertiary lymphoid structures in pancreatic cancer pathologic responders to neoadjuvant immunotherapy</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif;">Dimitrios N. Sidiropoulos, PhD –<em> Johns Hopkins</em></span></p> </td> </tr> <tr style="height: 62.8px;"> <td style="width: 15.6364%; vertical-align: top; height: 62.8px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>9:55 a.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top; height: 62.8px;"> <p><a href="https://dx.doi.org/10.1136/jitc-2024-SITC2024.0543"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(543) Integrated single-cell and spatial analysis of immune cell interactions in response to immune checkpoint blockade</strong></span></a></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif;">Athena Golfinos-Owens, BS –<em> University of Wisconsin-Madison</em></span></p> </td> </tr> <tr style="height: 63.8px;"> <td style="width: 15.6364%; vertical-align: top; height: 63.8px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>10:10 a.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top; height: 63.8px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong><span style="font-size: 12pt;"><strong style="font-family: calibri, arial, helvetica, sans-serif;"></strong></span></strong><strong>Discussion<br></strong>Antoni Ribas, MD, PhD - <em>University of California, Los Angeles</em><br><span style="font-size: 12pt;"><span style="font-family: calibri, arial, helvetica, sans-serif;"><em></em></span></span></span></td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>Session Description</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p style="margin: 0in;"><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">New single cell spatial pathology technologies are enabling a better understanding of the tumor microenvironment and how immune cells interact with cancer cells in response or resistance to cancer immunotherapies. The analysis of patient biopsy samples at unprecedented multidimensionality and resolution uncovers new biology and better understanding of how the immune system can treat cancer. In this session, two invited speakers that are at the forefront of the field will present analyses of patient biopsies, and three proffered speakers will be invited from the submitted abstracts that are thematically aligned with the session, followed by an expert discussion of the three oral presentations.<o:p></o:p></span></p></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix page-3 tab-content bg-gray-shadow "><div class="col-md-12 section135"><div class="ContentItemHtml"> <div class="HtmlContent"><h3 style="text-align: center;"><strong>Break </strong></h3> <h4 style="text-align: center;">10:30-11 a.m. CST</h4></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-3 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section136"><div class="ContentItemHtml"> <div class="HtmlContent"><div class="schedule-anchor" id="session-302"></div> <hr style="height: 2px; border-width: 0; color: #fba61c; background-color: #fba61c; max-width: 130px; margin-left: 0px;"> <h3><a id="session-303"></a><b>Session 302: Hot Topic Symposium: AI in Discovery<br></b></h3> <h4>11 a.m.–12:35 p.m. CST | George R. Brown Convention Center - Level 3 - Hall A3</h4></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-4 section137"><div class="ContentItemHtml"> <div class="HtmlContent"><h4><strong>Co-Chairs: </strong></h4> <p><strong>Riyue Bao, PhD<br></strong><em>UPMC Hillman Cancer Center </em><br><span style="font-size: 12pt;"><br><strong>Ira Mellman, PhD<br></strong><em>Genentech </em><br><br></span></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-8 section138"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>View Full Session Schedule</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 299px; width: 96.247%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 45.8px;"> <td style="width: 15.6364%; height: 45.8px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>11:00 a.m.</strong></span></td> <td style="width: 84.3636%; height: 45.8px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Introduction<br></strong>Session Co-Chair<br></span></td> </tr> <tr style="height: 63.3px;"> <td style="width: 15.6364%; vertical-align: top; height: 63.3px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>11:05 a.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top; height: 63.3px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>IGSF8 is a Novel Immune Checkpoint and Cancer Immunotherapy Target<br></strong>X. Shirley Liu, PhD -<em> GV20Theraputics</em></span></td> </tr> <tr style="height: 63.3px;"> <td style="width: 15.6364%; vertical-align: top; height: 63.3px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>11:25 a.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top; height: 63.3px;"> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong><span>Foundational Pathology Models to Drive Personalized Immunotherapies</span></strong></span></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Carlo Bifulco, MD - <em>Providence Genomics</em></span><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><br></span></p> </td> </tr> <tr style="height: 63.3px;"> <td style="width: 15.6364%; vertical-align: top; height: 63.3px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>11:45 a.m.</strong></span></td> <td style="width: 84.3636%; vertical-align: top; height: 63.3px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Machine Learning for Decoding Tumor Microenvironments and Predicting Patient Outcomes<br></strong>Linghua Wang, MD, PhD<em> - The University of Texas MD Anderson Cancer Center</em></span></td> </tr> <tr style="height: 63.3px;"> <td style="width: 15.6364%; vertical-align: top; height: 63.3px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>12:05 p.m.<br></strong></span></td> <td style="width: 84.3636%; vertical-align: top; height: 63.3px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Panel Discussion<br></strong><br></span></td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3><strong>Session Description</strong></h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p><span style="font-size: 11.0pt; line-height: 107%; font-family: 'Aptos',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Aptos; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;">The integration of Artificial Intelligence (AI) into the field of immunotherapy has opened new avenues for research, diagnosis, and treatment. This session will explore cutting-edge AI-driven solutions and innovations to improve patient outcomes, streamline clinical workflows, and as a tool to assist in the discovery of new therapeutics. We will feature three invited talks from leading experts in academic biomedical centers and industry, followed by an in-depth panel discussion addressing critical challenges and propose solutions for implementing AI practices effectively and realistically, in the hope of shaping the future of immunotherapy.</span></p></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-12 section139"><div class="ContentUserControl"> <script charset="utf-8">let button = document.getElementById("button"); let makepdf = document.getElementById("MainCopy_ContentWrapper"); button.addEventListener("click", function () { let mywindow = window.open("", "PRINT", "height=400,width=600"); mywindow.document.write(MainCopy_ContentWrapper.innerHTML); mywindow.document.close(); mywindow.focus(); mywindow.print(); mywindow.close(); return true; });</script> </div></div></div> <div id="MainCopy_extraPanel"> </div> </div> </div>  </div> </div> <div id="MPOuterFooter" class="row siteFrame"> <div id="FOOTER" class="col-md-12"> <div class="row row-full footer-top "><div class="col-md-3 section1"><div class="ContentItemHtml footer-logo"> <div class="HtmlContent"><p><a href="https://www.sitcancer.org/2024/home"><img class="img-responsive" src="https://higherlogicdownload.s3.amazonaws.com/SITCANCER/e16ea3ed-ca86-452e-b5e9-18d717c3857f/UploadedImages/AMPCP_2024/SITC2024-logo-dates-rev_clr_300px.png" alt="footer-logo-big.png" data-mce-hlimagekey="67b5f853-bdcd-2be1-5090-160ad9540305" data-mce-hlselector="#TinyMceContent_2338b29b-686c-d08e-8f04-19a29db1b932-tinyMceHtml"></a></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-3 section2"><div class="ContentItemHtml footer-contact"> <div class="HtmlContent"><h4><span style="font-family: helvetica;">Contact Us</span></h4> <p><span style="font-family: calibri, arial, helvetica, sans-serif;">555 East Wells Street, Suite 1100</span></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif;">Milwaukee, WI 53202-3823</span></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif;">Email: <a href="mailto:info@sitcancer.org" target="_blank" rel="noopener">info@sitcancer.org</a></span></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif;">Phone: USA Tel: +1 414 271 2456</span></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif;">Fax: +1 414 276 3349</span></p> <p></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-3 section3"><div class="ContentItemHtml footer-links"> <div class="HtmlContent"><h4><span style="font-family: helvetica;">Quick Links</span></h4> <p><a href="https://www.sitcancer.org/2024/home">Home</a></p> <p><a href="https://www.sitcancer.org/2024/attendee-resources/registration">Register</a></p> <p><a href="https://www.sitcancer.org/2024/schedule/sitc24-annualmeeting">Schedule</a></p> <p><a href="https://www.sitcancer.org/2024/abstracts/abstract-submission">Abstracts</a></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-3 section4"><div class="ContentItemHtml footer-social"> <div class="HtmlContent"><p><a href="https://www.sitcancer.org/home" target="_blank" rel="noopener"><img class="img-responsive" src="https://higherlogicdownload.s3.amazonaws.com/SITCANCER/e16ea3ed-ca86-452e-b5e9-18d717c3857f/UploadedImages/Logos/SITC-rev-grn.png" alt="" data-mce-hlimagekey="8680bb71-e3a3-c9e1-5055-e08862e837dc" data-mce-hlselector="#TinyMceContent_510a025b-4442-1629-33bf-9157ceb40a82-tinyMceHtml" width="718" height="308"></a></p> <ul> <li><a href="https://www.facebook.com/sitcancer" target="_blank" rel="noopener noreferrer"> <i class="fab fa-facebook"></i></a></li> <li><a href="https://twitter.com/sitcancer" target="_blank" rel="noopener noreferrer"><i class="fa-brands fa-x-twitter"></i></a></li> <li><a href="https://www.linkedin.com/company/381116" target="_blank" rel="noopener noreferrer"><i class="fab fa-linkedin-in"></i></a></li> <li><a href="http://www.youtube.com/user/SITCancer?feature=watch" target="_blank" rel="noopener noreferrer"><i class="fab fa-youtube"></i> </a></li> </ul></div><div class="HtmlFooter"></div></div></div></div> <div id="MPFooter" class="row"> <div class="Footer col-md-12"> <div id="FooterContent"> </div> <div id="MPBottomMenu" class="MPBottomMenu" align="center"> </div> </div> </div> <div class="row"> <div id="MPCopyright" class="col-md-12"> </div> </div> <div class="row row-full footer-bottom "><div class="col-md-6 section1"><div class="ContentItemHtml copyright"> <div class="HtmlContent"><p><span style="font-family: calibri, arial, helvetica, sans-serif;">© 2024 Society for Immunotherapy of Cancer (SITC). All rights reserved.</span></p></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml"> <div class="HtmlContent"><p> <script type="text/javascript"> _linkedin_partner_id = "2569393"; window._linkedin_data_partner_ids = window._linkedin_data_partner_ids || []; window._linkedin_data_partner_ids.push(_linkedin_partner_id); </script> <script type="text/javascript"> (function(l) { if (!l){window.lintrk = function(a,b){window.lintrk.q.push([a,b])}; window.lintrk.q=[]} var s = document.getElementsByTagName("script")[0]; var b = document.createElement("script"); b.type = "text/javascript";b.async = true; b.src = "https://snap.licdn.com/li.lms-analytics/insight.min.js"; s.parentNode.insertBefore(b, s);})(window.lintrk); </script> </p> <noscript> <img height="1" width="1" style="display: none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2569393&fmt=gif" data-mce-src="https://px.ads.linkedin.com/collect/?pid=2569393&fmt=gif" data-mce-style="display: none;"> </noscript></div><div class="HtmlFooter"></div></div></div><div class="col-md-6 section2"><div class="ContentItemHtml attribution"> <div class="HtmlContent"></div><div class="HtmlFooter"></div></div></div></div> <div class="row"> <div class="col-md-12"></div> </div> </div> </div> <div id="MPFooterLink" class="row siteFrame"> <div class="col-md-12"> <div id="MPFooterLinkContent"> <a href="http://www.higherlogic.com" target="_blank">Powered by Higher Logic</a> </div> </div> </div> <div id="GlobalPopupContainer"> <div id="GlobalPopupContent" > <img ID="imgGlobalProcessing" alt="" src="https://d2x5ku95bkycr3.cloudfront.net/img/loading.gif" /> </div> </div> <script type="text/javascript"> //<![CDATA[ var _suppressGlobalPopupContainer = false; Sys.Application.add_load(GlobalApplicationLoadHandler); function GlobalApplicationLoadHandler(sender, args) { var prm = Sys.WebForms.PageRequestManager.getInstance(); if (!prm.get_isInAsyncPostBack()) { prm.add_initializeRequest(initRequest); prm.add_endRequest(endRequest); } } function initRequest(sender, args) { if (!_suppressGlobalPopupContainer) { hl_common_ui_blockUI(); } } function endRequest(sender, args) { hl_common_ui_unBlockUI(); }//]]> </script> </form> </div> <script> $(document).ready(function () { var path = window.location.pathname; var lastChar = path.substr(-1); // Selects the last character if (lastChar != '?' && lastChar != '/' && lastChar != ';') { // If the last character is not a slash path = path + '/'; // Append a slash to it. } $('ul.navbar-nav a').each(function () { var myHref = $(this).attr('href').split("?")[0]; var lastChar2 = myHref.substr(-1); // Selects the last character if (lastChar2 != '?' && lastChar2 != '/' && lastChar2 != ';') { // If the last character is not a slash myHref = myHref + '/'; // Append a slash to it. } if (path == myHref) { $(this).parents('li').last().addClass('active current-page'); $(this).parent('li').addClass('active current-page'); } }); $('#modalTags').on('tagAdded', function () { var oldCount = parseInt($('#litCommunityTagsCount').text()); $('#litCommunityTagsCount').text(oldCount + 1); }).on('tagRemoved', function () { var oldCount = parseInt($('#litCommunityTagsCount').text()); $('#litCommunityTagsCount').text(oldCount - 1); }); var isImpersonating = false; var padMPOuterHeader = function () { var headerHeight = $("#MPOuterHeader").height(); $("#MPOuter").css("padding-top", parseInt(headerHeight) + 5); }; $("#MPOuterHeader").addClass('stickyNav stickyNav-full'); padMPOuterHeader(); $(window).bind('resize', function () { padMPOuterHeader(); }); }); //var btn = $.fn.button.noConflict(); // reverts $.fn.button to jqueryui btn //$.fn.btn = btn; // assigns bootstrap button functionality to $.fn.btn </script> </body> </html>